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Resumo 
 
A terapêutica disponível para o melanoma apresenta elevada toxicidade e uma baixa 
eficácia. O desenvolvimento e a progressão do melanoma envolvem diferentes mecanismos 
e a combinação de fármacos permitirá obter tratamentos mais efetivos e com efeitos adversos 
menos acentuados. 
O antiestrogénio tamoxifeno (TAM) é amplamente prescrito para pacientes com 
carcinoma da mama, mas induz vários efeitos adversos e a sua eficácia é limitada pelo 
metabolismo interindividual ou pela coadministração de medicamentos que possam diminuir 
os níveis dos seus metabolitos ativos, o endoxifeno (EDX) e o 4-hidroxitamoxifeno 
(OHTAM). O TAM tem sido também usado no tratamento do melanoma, todavia a sua 
utilização e os mecanismos de acção nesta patologia permanecem controversos. Assim, dado 
que alguns dos efeitos adversos do TAM resultam de indução de disfunção mitocondrial, 
investigámos os efeitos do EDX em mitocôndrias de fígado, individualmente ou em 
combinação com o ácido trans-retinóico (RA) para clarificar se o EDX é uma alternativa 
menos tóxica; posteriormente, estudámos também os efeitos do EDX numa linha celular de 
melanoma, individualmente ou em combinação com o RA ou com o antagonista dos 
recetores do N-metil-D-aspartato (NMDA) MK-801, para avaliar a eficácia do EDX no 
melanoma relativamente ao TAM. Estudámos também a expressão e a função do recetor 
associado à proteína G 30 (GPR30) nas células de melanoma para clarificar o mecanismo de 
ação dos antiestrogénios. 
Os resultados obtidos demonstram que o EDX apenas afecta a função bioenergética 
mitocondrial em concentrações superiores às atingidas nos tecidos, induzindo uma ligeira 
alteração na integridade da membrana mitocondrial, contrariamente aos efeitos acentuados 
do TAM. O EDX também inibiu a permeabilidade transitória mitocondrial (MPT) induzida 
por cálcio e fosfato. 
O RA é um eficiente citostático cuja utilização clínica é limitada pelos seus efeitos 
adversos, incluindo hepatotoxicidade, que está possivelmente associada à indução da MPT. 
Uma vez que as combinações de RA com o TAM apresentam ação sinérgica em células do 
cancro da mama e que os nossos resultados demonstram que o EDX é menos tóxico para a 
mitocôndria, avaliámos os efeitos do RA em combinação com o EDX na bioenergética 
mitocondrial e na MPT. O EDX, assim como o TAM e o OHTAM, preveniu a MPT induzida 
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pelo RA, podendo contribuir para reduzir a sua hepatotoxicidade. Os efeitos do RA na 
bioenergética mitocondrial não foram potenciados pelo EDX. Deste modo, a combinação de 
EDX com o RA poderá apresentar vantagens na terapêutica do melanoma. Assim, e 
considerando que o RA e o TAM individualmente diminuem a proliferação e a migração das 
células de melanoma, estudámos os efeitos do EDX combinado com o RA nestas células. A 
combinação de RA com EDX potenciou significativamente a ação antiproliferativa de ambos 
os compostos, induzindo bloqueio do ciclo celular em G1, indicando que os seus 
mecanismos de ação convergem na regulação do ciclo celular. Contudo, verificámos que o 
TAM não potenciou os efeitos antiproliferativos do RA. A combinação do RA com EDX 
diminuiu ainda a migração das células de melanoma em concentrações que não afetaram a 
proliferação de células não-neoplásicas. 
Recentemente, foi demonstrado que o MK-801 diminui a proliferação de células do 
melanoma. Após testarmos os efeitos dos antagonistas dos recetores ionotrópicos do 
glutamato em células do melanoma, selecionámos o MK-801 para estudar em combinação 
com o TAM, OHTAM e EDX. Os antiestrogénios atuaram sinergicamente com o MK-801 
na diminuição da proliferação das células do melanoma, sendo as combinações com EDX e 
OHTAM as mais eficazes, bloqueando a progressão do ciclo celular em G1. 
O papel emergente do GPR30 no cancro levou-nos a investigar a sua expressão e 
função no melanoma, uma vez que este recetor é ativado pelo TAM e pelo OHTAM. 
Verificámos que a linha celular de melanoma expressa o GPR30 e que o seu agonista seletivo 
G-1 reduziu drasticamente a proliferação celular, sugerindo que o GPR30 poderá ser um 
novo alvo terapêutico no melanoma e, possivelmente, estar envolvido na ação 
antiproliferativa dos antiestrogénios nestas células. Estudámos ainda os efeitos dos 
antiestrogénios na via das cinases reguladas por sinal extracelular (ERK) e verificámos que 
nas condições experimentais utilizadas o EDX é mais potente do que o TAM na redução da 
fosforilação da ERK 1/2, podendo justificar a maior eficácia do EDX em relação ao TAM 
no melanoma, individualmente ou em combinação com o RA ou com o MK-801, que 
também modulam esta via de sinalização. 
Assim, os resultados obtidos indicam que o EDX poderá ser uma alternativa ao 
TAM no tratamento do cancro e mais eficaz no melanoma maligno, particularmente em 
associação com outros fármacos.  
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Abstract 
 
The available treatments for melanoma rely on aggressive strategies that fail to alter 
the history of the disease. The onset and progression of melanoma involves a complex 
molecular machinery and, therefore, the use of combinations of drugs is a rational approach 
to build more effective treatments and to minimize side effects. 
The antiestrogen tamoxifen (TAM) is widely prescribed for patients with breast 
carcinoma, but induces several adverse effects. Moreover, the efficacy of TAM is limited by 
the individual metabolism or by coadministered medication that may decrease the effective 
levels of TAM active metabolites, endoxifen (EDX) and 4-hydroxytamoxifen (OHTAM), 
which are responsible for the anticancer action of TAM. TAM is also used in the treatment 
of melanoma, but its inclusion in therapeutic regimens and its action mechanisms remain 
controversial.  
In the present work we had the following goals: as some of TAM adverse effects 
result from mitochondrial damage, we investigated the effects of EDX on liver mitochondrial 
function, either individually or in combination with all-trans-retinoic acid (RA), to clarify 
whether EDX is a less toxic drug; afterwards, we studied the effects of EDX on a melanoma 
cell line individually or in combination with RA or with the N-methyl-D-aspartate (NMDA) 
receptor antagonist MK-801, to assess the efficacy of EDX in melanoma in comparison with 
TAM. Finally, we evaluated the expression and role of the G protein-coupled estrogen 
receptor 30 (GPR30) in melanoma cells to characterize the action mechanisms of 
antiestrogens. 
Our results show that EDX compromised mitochondrial bioenergetics at 
concentrations higher than those reached in tissues and mildly affects mitochondrial 
membrane integrity in comparison with TAM, suggesting that the adverse effects related 
with mitochondrial damage can be minimized by using EDX instead of TAM. Furthermore, 
like TAM or OHTAM, EDX prevented the mitochondrial permeability transition (MPT) 
induced by Ca2+ and phosphate.  
RA is a powerful anticancer agent, but its clinical utilization is limited by its adverse 
effects, including the hepatotoxicity, which is probably related with MPT induction. Since 
the combinations of RA with TAM demonstrated a synergism of action in breast cancer cells 
and our results show that EDX is less toxic to mitochondria, we monitored the effects of RA 
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in combination with EDX on mitochondria. EDX, similarly to TAM or OHTAM, prevented 
RA-induced MPT. Moreover, RA compromised mitochondrial bioenergetics in a 
concentration-dependent manner, but its effects were not enhanced by EDX. Thus, the 
combination with EDX may contribute to reduce the hepatotoxicity of RA and low 
concentrations of both drugs might be given together with acceptable toxicity. 
Considering these promising results and that RA and TAM decrease the 
proliferation and migration of melanoma cells individually, we investigated the effects of 
EDX in combination with RA on melanoma cells. RA combined with EDX significantly 
enhanced the antiproliferative activity of the drugs alone by inducing cell cycle arrest in G1, 
indicating that their mechanisms of action converge in the regulation of the cell cycle. In 
contrast, TAM was unable to potentiate the actions of RA. The combination of RA with 
EDX also decreased melanoma cell migration at concentrations that do not affect the 
proliferation of non-neoplasic cells, suggesting that the combined treatment of RA and EDX 
may be devoid of significant toxicity. 
Recently, it was reported that MK-801 decreases melanoma cell proliferation. Thus, 
after investigating the effects of ionotropic glutamate receptor antagonists on melanoma 
cells, we chose MK-801 to combine with TAM, OHTAM and EDX. The antiestrogens acted 
synergistically with MK-801 to decrease melanoma cell proliferation and the combinations 
with EDX and OHTAM were more effective than the combinations with TAM, inducing 
cell cycle arrest in G1.  
The emerging role of GPR30 in cancer, which is activated by TAM and OHTAM, 
led us to investigate its expression and function in melanoma. The melanoma cell line used 
expressed GPR30 and its activation by the selective agonist G-1 markedly decreased cell 
proliferation, pointing out that the GPR30 is a new target in melanoma and it is possibly 
involved in the antiproliferative effect of antiestrogens on melanoma cells. We also 
addressed the effects of antiestrogens on the activation of the extracellular signal-regulated 
kinase (ERK) pathway and we found that, in our experimental setting, EDX was more 
effective than TAM in the reduction of ERK 1/2 phosphorylation, providing the first clues 
on the superior efficacy of EDX over TAM in melanoma, either individually or in 
combination with RA or MK-801, which also target this pathway. 
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Altogether, the data obtained support that EDX may be an alternative to TAM in 
cancer therapy and a more effective drug for the management of malignant melanoma, 
particularly in therapeutic association. 
 
Keywords: endoxifen; all-trans-retinoic acid; glutamate receptor antagonists; mitochondria; 
melanoma. 
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1.1 - Introduction 
 
Malignant melanoma is one of the most aggressive and treatment-resistant of 
human cancers. Melanoma incidence has increased by approximately 2.8 % annually since 
1981 (Fig. 1.1) and it is estimated that almost 2 % of Americans will receive a melanoma 
diagnosis during their lifetime (Jemal et al., 2010; Little and Eide, 2012). The incidence and 
the mortality of melanoma are generally greater in men than women (29.1 per 100 000 in 
males compared with 19 per 100 000 in women, in 2008) (Fig. 1.1) (Little and Eide, 2012). 
In fact, male gender was associated with a greater incidence of unfavorable primary tumor 
characteristics (Scoggins et al., 2006) and increased rate of metastasis, as well as a shorter 
long term survival after development of distant metastasis (Mervic, 2012). However, 
melanoma incidence in younger women is increasing, and this shift can possibly reflect 
recent trends in indoor tanning (Little and Eide, 2012). There are also differences related 
with race and ethnicity, and the lower incidence of melanoma in darker-skinned individuals 
has been associated with the protective effects of higher melanin densities (Little and Eide, 
2012). 
Exposure to ultraviolet radiation, personal history of melanoma, genetic 
predisposition, phenotypic characteristics (fair skin and blond or red hair) and the dysplastic 
nevus syndrome are known risk factors, although the molecular alterations underlying the 
development and progression of melanoma are still under investigation (Russo et al., 2009). 
Other factors, such as socioeconomic status and access to healthcare seem to be relevant to 
melanoma epidemiology (Little and Eide, 2012). 
If diagnosed early, melanoma can be removed by surgery and about 80 % of the 
cases are successfully dealt with in this way (Gray-Schopfer et al., 2007; Russo et al., 2009). 
On the contrary, the available treatments for patients with locally advanced or metastatic 
disease fail to clearly alter the natural history of the disease (Lutzky, 2010; Ko and Fisher, 
2011). The resistance of melanoma to most of the available therapies is possibly a 
consequence of the complex machinery in melanoma onset and progression (Palmieri et al., 
2009). Melanomas are highly heterogeneous malignancies, not only between patients, but 
also within the same tumor, as there are several disease variants, mostly characterized by 
differences in oncogene and tumor suppressor drivers (Herlyn, 2009). Moreover, within one  
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Fig. 1.1 - Age-adjusted melanoma incidence rates from 1975 to 2008 according to the US 
Surveillance, Epidemiology and End Results program (Little and Eide, 2012). 
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tumor there are subpopulations of cells that respond differently to therapy as well as multiple 
signaling pathways constitutively activated (Herlyn, 2009). 
Immunotherapy has been extensively evaluated in advanced melanoma with several 
agents tested over the years, but the only approved immunotherapy regimens were until 
recently interferon-α and high-dose of interleukin-2 (Lutzky, 2010). Interferon-α is the most 
widely used adjuvant immunotherapy for melanoma, but it presents limited efficacy in 
metastatic melanoma. Interferon-α has also been combined with chemotherapy, but without 
significant improvements in the clinical outcomes (Lutzky, 2010; Ko and Fisher, 2011). 
Interleukin-2 is approved for metastatic disease, but induces severe toxic effects, such as 
vascular leak syndrome, with symptoms of hypotension and oliguria, and it is not suitable 
for most patients, requiring staff expertise and often intensive support (Lutzky, 2010; Ko 
and Fisher, 2011; Curti and Urba, 2012; Ma and Armstrong, 2013). In 2011, the Food and 
Drug Administration (FDA) and the European Medicines Agency approved the human 
monoclonal antibody ipilimumab, which yields significant and durable response rates in 10 
% of the patients with metastatic melanoma (Hodi et al., 2010; Curti and Urba, 2012; 
Wolchok, 2012). However, ipilimumab reactivates immune responses that were silenced, 
leading to immune-related adverse events, such as rash, diarrhea, colitis with perforation, 
endocrinopathies, hepatocellular injury, fatigue and pyrexia (Curti and Urba, 2012; 
Eggermont and Robert, 2012; Ma and Armstrong, 2013).  
Systemic chemotherapy has been another therapy of choice for metastatic 
melanoma. The alkylating agent dacarbazine is the only cytotoxic agent approved by the 
FDA providing responses in approximately 5-10 % of patients (Lutzky, 2010; Ko and Fisher, 
2011). Temozolomide is an orally available analog of dacarbazine that it is preferred in 
patients with brain metastases due to its better central nervous system (CNS) penetration 
(Lutzky, 2010). Other chemotherapeutic agents, such as nitrosoureas, taxanes, cisplatin and 
carboplatin, have similar efficacy profiles in the metastatic setting (Lutzky, 2010; Ko and 
Fisher, 2011). Several clinical trials have investigated the combination of dacarbazine or 
temozolomide with other drugs without demonstrating clear benefits in clinically relevant 
endpoints over single agents (Lutzky, 2010). 
In the last years, cellular and molecular studies have significantly increased our 
knowledge regarding the initiation and progression of melanoma, paving the way for the 
development of new therapies. The identification of the Ras GTPase/RAF proto-oncogene 
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serine/threonine-protein kinase (Raf)/mitogen-activated protein kinase kinase (MEK)/ 
extracellular signal-regulated kinase (ERK) known as the mitogen-activated protein kinase 
(MAPK) pathway and the phosphoinositide-3-kinase (PI3K) as key signaling pathways in 
melanoma has provided the opportunity to develop new targeted therapies. 
The MAPK pathway is a signal transduction cascade relaying extracellular signals 
from plasma membrane to the nucleus by consecutive phosphorylation events. Upon cellular 
stimulation, for instance as consequence of growth factor-mediated activation of receptor 
tyrosine kinases (RTKs), Ras assumes an activated, guanosine triphosphate-bound state, 
leading to the recruitment of Raf from the cytosol to the cell membrane where it becomes 
activated, likely via a Src-family tyrosine kinase. Then, the activated Raf causes the 
phosphorylation and activation of MEK 1/2, which in turn phosphorylate and activate the 
ERK. The activated ERK translocates to the nucleus, where it phosphorylates several nuclear 
transcription factors, stimulating the cellular proliferation, differentiation, and survival.  
ERK is constitutively activated in up to 90 % of melanomas, most commonly due 
to mutations of the genes encoding the GTPase N-Ras (15-30 %) and especially the 
serine/threonine-protein kinase B-Raf (50-70 %) (Russo et al., 2009). Activating B-Raf 
mutations occur in approximately 60 % of melanomas and, therefore, are considered the 
most important target in melanoma (Davies, 2012). The most frequent B-Raf mutation, 
observed in approximately 90 % of melanomas with alteration of B-Raf, is the T1799A point 
mutation, in which a T → A transversion converts glutamic acid for valine at the codon 600 
in exon 15 (Val600Glu; B-RafV600E). This mutation introduces a conformational change in 
the protein structure, leading to its constitutive activation with a substantial increase in the 
basal kinase activity and, consequently, to the hyperactivity of the MAPK pathway (Russo 
et al., 2009; Ko and Fisher, 2011). However, the fact that both activating B-Raf and N-Ras 
mutations are found at high rates in benign nevi suggests that the activation of the MAPK 
pathway alone does not fully explain the pathogenesis of melanoma and that other pathways 
may play a critical role as well (Davies, 2012).  
Growing evidence implicates the aberrant expression and activity of the PI3K 
pathway in the onset and progression of melanoma, which frequently occurs with concurrent 
activation of MAPK signaling. In response to activated growth factor receptors, the PI3K 
phosphorylates phosphatidylinositol-4,5-biphosphate (PIP2) to phosphatidylinositol-3,4,5-
triphosphate (PIP3), activating the protein kinase B, also known as Akt (Russo et al., 2009; 
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Davies, 2012). Akt is a serine-threonine kinase that is usually present in the cytoplasm in an 
inactive conformation and has 3 highly homologous isoforms (Akt1, Akt2 and Akt3). Upon 
activation of PI3K, Akt is recruited to the cell membrane where it is phosphorylated to 
activate the catalytic activity of Akt (Davies, 2012). The activated Akt, which is one of the 
major effectors of the PI3K pathway, is then able to phosphorylate the downstream proteins 
(Russo et al., 2009). The mammalian target of rapamycin (mTOR) is a downstream effector 
of the PI3K/Akt pathway, that consists of 2 protein complexes mTORC1 and mTORC2 (Ko 
and Fisher, 2011; Pópulo et al., 2012). The activation of PI3K with subsequent activation of 
Akt allows mTORC1 to promote cell proliferation via downstream transduction of 
proliferative signals (LoRusso et al., 2013). Besides the activation by PI3K, mTOR can also 
be activated by the MAPK pathway, in order to regulate cell proliferation and survival (Ko 
and Fisher, 2011; Pópulo et al., 2012). The mTORC2 complex regulates the actin 
cytoskeleton and Akt signaling through phosphorylation (Ko and Fisher, 2011; Pópulo et al., 
2012).  
A study by Dai et al (2005) reported that phosphorylated Akt is expressed in 17 %, 
43 %, 49 % and 77 % of the biopsies of normal nevi, dysplastic nevi, primary melanoma and 
melanoma metastases, respectively, and that a strong phosphorylated Akt expression is 
inversely correlated with the overall survival of patients with primary melanoma. The 
predominant active isoform of Akt in melanoma is Akt3, which promotes cell survival and 
tumor development in 43 to 60 % of nonfamilial melanomas, and its activation increases 
during tumor progression (Stahl et al., 2004). The activated Akt3 can phosphorylate up to 9 
000 substrate proteins and this way regulates several cellular processes (Madhunapantula et 
al., 2011). Moreover, the inactivation, loss or decreased expression of the phosphatase and 
tensin homolog (PTEN), a crucial regulator of this pathway that acts through the 
dephosphorylation of PIP3, is frequently observed in melanoma cell lines and biopsies 
specimens, and the loss of PTEN was reported in approximately 20-30 % of melanomas 
(Guldberg et al., 1997; Tsao et al., 1998; Zhou et al., 2000; Madhunapantula et al., 2011). 
Therefore, considering the key role played by the MAPK and the PI3K pathways in 
melanoma, several inhibitors of these pathways have been developed. 
Vemurafenib is the first and most extensively investigated of selective B-Raf 
inhibitors (Fig. 1.2). The initial objective response rates to this B-Raf targeted agent are 
much higher than to any other treatments. In a phase III clinical trial, vemurafenib provided 
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major tumor responses shortly after the treatment initiation in 50 % of patients (Curti and 
Urba, 2012; Eggermont and Robert, 2012). However, side effects, including arthralgia, 
fatigue, and cutaneous manifestations are common in patients taking vemurafenib, and 
approximately 40 % of patients require a reduction in the recommended dose (Curti and 
Urba, 2012; Eggermont and Robert, 2012). On the other hand, the degree of tumor reduction 
varies widely, with less than 10 % of the patients achieving a complete tumor regression 
(Davies, 2012). Clinical response was only observed in patients whose levels of 
phosphorylated ERK were reduced in about 80 %, suggesting that an almost complete 
inhibition of MAPK pathway may be required to achieve a significant tumor response 
(Bollag et al., 2010). Importantly, the median duration of response is modest and essentially 
all patients relapse, reflecting the development of resistance, either by MAPK reactivation 
or by the activation of alternative survival pathways, such as the PI3K pathway (Nazarian et 
al., 2010; Paraiso et al., 2010; Eggermont and Robert, 2012). It was reported that the PI3K 
signaling is increased in B-Raf inhibitor-resistant melanoma cells, as well as in a post-relapse 
tumor sample, and that the simultaneous inhibition of the MAPK and PI3K pathways 
markedly induces cell death, overcoming the resistance to B-Raf inhibitors (Villanueva et 
al., 2010; Posch et al., 2013). Thus, the combination of B-Raf and MEK inhibitors or the 
dual targeting of the MAPK and PI3K pathways have been investigated as an attempt to 
abrogate drug resistance (Madhunapantula et al., 2011; Shi et al., 2011; Davies, 2012; 
Eggermont and Robert, 2012). 
Multiple inhibitors of PI3K pathway were also developed, including the Akt 
inhibitor perifosine and the mTOR inhibitors everolimus and temsirolimus (Fig. 1.2), which 
were tested in patients with metastatic melanoma without providing objective clinical 
responses (Ernst et al., 2005; Margolin et al., 2005). However, in any of the clinical trials 
performed to evaluate the benefits of perifosine in melanoma the expression or the activity 
of Akt was taken into consideration (Madhunapantula et al., 2011). On the other hand, the 
existence of compensatory signaling can limit the efficacy of PI3K pathway inhibitors, as 
the inhibition of mTOR by rapamycin or everolimus can lead to the hyperactivation of Akt 
(Wan et al., 2007; Madhunapantula et al., 2011).  
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Fig. 1.2 - Major pathways involved in melanoma pathogenesis and point-of-action of 
targeted therapies. The MAPK and the PI3K pathways are major signaling cascades involved 
in the development and progression of melanoma. The figure depicts a simplified scheme of 
both pathways as well as selected agents that target these pathways.  
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In fact, given the complexity of melanoma, it is unlikely that a single agent can 
yield a significant antitumor response. To deal effectively with the vast majority of 
melanomas, it is necessary to develop combinations of drugs that have a strong rationale for 
single agent therapy, in order to target all cells within a tumor (Herlyn, 2009; Palmieri et al., 
2009). Thus, considering the rising incidence of malignant melanoma and its poor prognosis, 
it is urgent to develop new combinations of drugs that through a synergism of action allow 
to obtain therapeutic efficacy with lower doses, this way minimizing the toxic effects typical 
of systemic chemotherapy, and also contributing to avoid the development of resistance to 
therapy.  
  
1.2 - Use of antiestrogens in malignant melanoma therapy 
  
Introduced in the clinical practice in 1977, the antiestrogen tamoxifen (TAM) 
remains the standard therapy for women with estrogen receptor (ER)-positive (ER+) breast 
carcinoma and it is estimated that the lives of half a million women were spared by adjuvant 
therapy with TAM (Jordan, 2008).  
It is widely accepted that the pharmacological action of TAM in breast cancer is 
mainly mediated by binding to ERα. However, the demonstration that some ER-negative 
(ER−) breast cancers also respond to TAM, raised the possibility of an antitumor mechanism 
independent of the ER (Croxtall et al., 1994; Charlier et al., 1995). Since then, the effects of 
TAM on ovarian cancer, malignant glioma, melanoma, as well as on hepatocellular, 
pancreatic, and renal cell carcinomas, were investigated in several clinical trials (Goldenberg 
and Froese, 1982; Gelmann, 1996, 1997).  
TAM inhibits melanoma cell proliferation (Gill et al., 1984; Piantelli et al., 1995; 
Lama et al., 1998; Kanter-Lewensohn et al., 2000), invasion and metastasis (Matsuoka et al., 
2009). The mechanisms underlying the antitumor activity of TAM in melanoma are not 
entirely clarified. Earlier investigations detected the presence of ER in more than 40 % of 
the patients with malignant melanoma, which had longer disease-free survival than the ER− 
patients (Fisher et al., 1976; Walker et al., 1987). However, further studies using ER-specific 
monoclonal antibodies demonstrated that usually melanoma cells do not express ER (Neifeld 
and Lippman, 1980; Flowers et al., 1987; Cohen et al., 1990; Lecavalier et al., 1990; Kanter-
Lewensohn et al., 2000). More recently, methylated ERα were detected in the tumor tissues 
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and sera of melanoma patients resulting in ERα gene silencing (Mori et al., 2006). These 
findings have implications not only for prognosis, since the presence of methylated ERα in 
serum was shown to be an unfavorable prognostic factor, but also for the identification of 
patients that would benefit from the inclusion of TAM in their therapeutic regimens and the 
patients for whom an alternative treatment should be sought (Mori et al., 2006; Tanemura et 
al., 2007).  
On the other hand, considerable attention has been given to ER-independent targets, 
often called nongenomic, because they do not require the interaction of TAM with ER and/or 
do not directly affect the transcriptional regulatory activities of ER, although these effects 
may also be important in ER+ tumors (Clarke et al., 2001). One of the primary mechanisms 
reported for TAM in ER− cancer cells is the inhibition of protein kinase C (PKC) signaling 
(Gundimeda et al., 1996; Gelmann, 1997; Luo et al., 1997). In melanoma cells, TAM inhibits 
cell migration, invasion and metastasis through the suppression of PKC/MEK/ERK and 
PKC/PI3K/Akt activation (Mastuoka et al., 2009). TAM also inactivates the insulin-like 
growth factor-1 receptor (IGF-1R) in melanoma cells (Kanter-Lewensohn et al., 2000). In 
addition, TAM stimulates the activity of natural killers, which can also contribute to control 
the tumor growth (Mandeville et al., 1984; Baral et al., 1995), and inhibits angiogenesis in 
part by inducing transforming growth factor-β (TGF-β) stimulation (Toma et al., 1999). 
Moreover, TAM and its active metabolite 4-hydroxytamoxifen (OHTAM) are highly 
hydrophobic molecules that strongly partition in biomembranes (Custódio et al., 1991) 
affecting the bilayer dynamics, which is another possible mechanism of the anticancer 
activity of both drugs (Custódio et al., 1993a, b). 
Although TAM individually has provided extremely poor response rates (less than 
10 %) in melanoma clinical trials (Rumke et al., 1992; Toma et al., 1999), the synergistic 
effects reported when TAM was combined with other agents, such as fotemustine (Fischel 
et al., 1994), cisplatin (McClay et al., 1993; Jones et al., 1997) and interferons (Lindner and 
Borden, 1997), have led to the investigation of the benefits of the inclusion of TAM in 
combination regimens. In fact, the initial trials performed in patients with metastatic 
melanoma provided encouraging results. The combination of TAM with dacarbazine 
improved the response rate and median survival in comparison with dacarbazine alone, 
particularly in women (Cocconi et al., 1992), whereas the addition of TAM to dacarbazin 
and cisplatin induced a small increase in the response rate (Flaherty et al., 1996). However, 
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subsequent trials failed to show significant improvements in clinically relevant endpoints 
when TAM was used in combination with several agents in patients with locally advanced 
and metastatic melanoma. In patients with advanced melanoma, the combination of TAM, 
carmustine, cisplatin and dacarbazine increased the overall response rate in comparison with 
dacarbazine alone, but the toxic effects were also enhanced by the combination and the 
impact on overall survival was very limited (Chiarion-Sileni et al., 2001). Moreover, the 
addition of TAM to dacarbazine or dacarbazine plus interferon-α or dacarbazine plus 
carboplatin did not improve the response rate or the overall survival of patients with 
metastatic melanoma (Falkson et al., 1998; Agarwala et al., 1999). In a phase II trial with 
patients with metastatic melanoma, the combination of TAM with paclitaxel provided an 
overall response rate of 24 %, but the contribution of TAM was unclear since plasma levels 
were not measured (Nathan et al., 2000).  
The Dartmouth regimen, which consists of quadruple drug therapy with 
dacarbazine, cisplatin, carmustine and TAM, has been a widely used combination 
chemotherapy regimen for metastatic melanoma, since this combination was reported to give 
an overall response rate of 47 % (McClay and McClay, 1994). However, the value of TAM 
in the Dartmouth regimen has been questioned and, while in a randomized trial no beneficial 
effect was reported (Rusthoven et al., 1996), other studies demonstrated advantage in 
patients treated with the TAM-containing regimen (McClay et al., 1989, 1992).  
In a systematic review and meta-analysis of six randomized controlled trials to 
assess the benefit of TAM addition to various chemotherapy and biochemotherapy regimens, 
TAM failed to improve the overall response rate, the complete response rate or the survival 
rate in metastatic disease (Lens, 2003). More recently, Beguerie et al (2010) performed a 
meta-analysis including nine randomized controlled trials. The inclusion of TAM in 
systemic chemotherapy improved the overall and the partial response of patients with 
advanced melanoma, with female patients being more likely to respond (Beguerie et al., 
2010). However, the incidence of hematologic toxicity was higher in the TAM group, and 
there was no improvement in 1-year mortality (Beguerie et al., 2010).  
Thus, the many clinical trials already performed up to now produced inconclusive 
results and the benefits of TAM in chemotherapy regimens for melanoma remain highly 
controversial. The clarification of the mechanisms underlying the effects of antiestrogens on 
melanoma would certainly shed new lights on the role of antiestrogens in melanoma therapy 
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and help to identify subgroups of patients who would benefit from an antiestrogen-
containing regimen. In fact, recent evidences raise new questions that may contribute to 
explain the contradictory results obtained in the clinical trials conducted so far. On the one 
hand, the establishment of an association between TAM metabolism and clinical outcome in 
breast cancer patients; on the other hand, the identification of a new estrogen receptor, the 
G protein-coupled receptor 30 (GPR30), also designated G protein coupled estrogen receptor 
1 (GPER1). 
 
1.2.1 - Importance of metabolism in the antiestrogenic activity of tamoxifen 
 
TAM is extensively metabolized in the liver by phase I and phase II enzymes, 
including cytochrome P450 (CYP), sulfotransferases and UDP-glucuronosyltransferases 
(Kiyotani et al., 2012). The N-demethylation of TAM, primarily catalyzed by CYP3A4 and 
CYP3A5, produces the major metabolite of TAM, N-desmethyltamoxifen, which presents 
steady-state plasma concentrations twice as high as that of its parent drug (Fig. 1.3) (Brauch 
et al., 2009; Kiyotani et al., 2012). This metabolite, per se is not relevant for the biological 
activity of TAM, as it shows weak affinity for the ERs. The CYP2D6-mediated 
hydroxylation of N-desmethyltamoxifen at the para position of the phenyl ring is required 
to produce the more active metabolite 4-hydroxy-N-desmethyltamoxifen, referred as 
endoxifen (EDX) (Brauch et al., 2009; Kiyotani et al., 2012). Likewise, the other active 
metabolite of TAM, OHTAM, is formed by CYP2D6-mediated hydroxylation of TAM, also 
at the para position of the phenyl ring of the parent drug (Brauch et al., 2009; Kiyotani et 
al., 2012). TAM metabolism by CYP enzymes produces other metabolites, but EDX and 
OHTAM remain the only TAM metabolites with relevant pharmacological activity 
identified so far (Brauch et al., 2009; Kiyotani et al., 2012). 
Since EDX and OHTAM have been considered responsible for the anticancer 
activity of TAM (Kiyotani et al., 2012), in the last years several studies were performed to 
clarify the impact of TAM metabolism in the clinical outcomes. The steady-state plasma 
concentrations of TAM, OHTAM and EDX in patients taking TAM (20 mg/day) are 72-160 
µg/L, 1.15-6.4 µg/L and 8.1-20.7 µg/L, respectively (Brauch et al., 2009), but the 
concentrations reached in tissues are 10- to 60-fold higher (Lien et al., 1991). The wide range  
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Fig. 1.3 - Major metabolic pathways of TAM in humans (Kiyotani et al., 2012). 
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of concentrations reported is thought to reflect genetic variants of CYP2D6 that lead to the 
production of enzymes with different functional activity. Individuals homozygous for alleles 
that produce enzymes with normal activity are named extensive metabolizers, whereas those 
carrying multiple copies of CYP2D6 alleles associated with high enzyme activity are termed 
ultrarapid metabolizers. Individuals with one or two variant alleles with reduced or null 
activity are designated intermediate or poor metabolizers, respectively (Higgins and Stearns, 
2010). Importantly, the available evidence suggests that women treated with TAM who carry 
nonfunctional or reduced-function CYP2D6 alleles have lower circulating levels of EDX 
and achieve worse clinical outcomes in comparison with those with normal enzyme activity 
(Schroth et al., 2009; Higgins and Stearns, 2010; Lammers et al., 2010; Thompson et al., 
2011). The incidence of single nucleotide polymorphisms in CYP2D6 varies by race and 
ethnicity and it estimated that approximately 7 % of caucasian women are homozygous for 
nonfunctional CYP2D6 alleles (Sachse et al., 1997; Mürdter et al., 2011). These observations 
may have implications not only in the treatment efficacy, but also in the selection of the 
optimal dose (Ingle, 2008; Irvin Jr et al., 2011).  
Besides the genetic polymorphisms, several drugs can also influence the enzymatic 
activity of CYP2D6 and this way the biological activity of TAM (Kelly et al., 2010; 
Lammers et al., 2010; Binkhorst et al., 2012). The simultaneous administration of TAM and 
CYP2D6 inhibitors was associated with reduced EDX concentrations proportional to the 
potency of the inhibitor (Jin et al., 2005). Accordingly, a review of medical records showed 
that breast cancer patients simultaneously treated with TAM and CYP2D6-inhibiting 
medication had increased risk of recurrence (Aubert et al., 2009).  
Considering that the CYP3A4/A5 and the CYP2D6 are involved in the metabolism 
of 37 % e 15 % of drugs, respectively (Zanger et al., 2008), the coadministration of 
CYP3A4/A5 and CYP2D6-inhibiting medication should be handled with care. Particularly 
relevant in the context of breast cancer therapy are the interactions with selective serotonin 
reuptake inhibitors, frequently prescribed to prevent the hot flushes experienced by up to 45 
% of patients taking TAM (Ahmad et al., 2010a; Kelly et al., 2010). 
The clinical utilization of TAM active metabolites may, therefore, present strong 
advantages relatively to the use of the prodrug TAM, as it avoids the intervariability in TAM 
metabolism, increasing the number of patients who would benefit from the treatment with 
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antiestrogens, and avoids drug interactions that can compromise the efficacy of the 
treatment. 
In breast cancer therapy, much attention has been given to EDX, which is 
considered the major active metabolite of TAM, as it presents higher steady-state 
concentrations than OHTAM (Brauch et al., 2009; Gjerde et al., 2012). EDX has 
demonstrated an antiestrogenic potency similar to OHTAM that is 30-100-fold more potent 
than TAM (Lim et al., 2005). Moreover, at concentrations achieved in CYP2D6-extensive 
metabolizers, EDX also targets ERα degradation by the proteasome in breast cancer cells 
(Wu et al., 2009). Additionally, EDX is a potent inhibitor of aromatase activity (Ki = 4.0 
µM), whereas high concentrations of TAM or OHTAM do not significantly affect the 
enzyme activity (Lu et al., 2012). These data suggest that EDX may present additional 
mechanisms of action in breast cancer therapy in comparison with TAM and OHTAM, and 
support the benefits of EDX over TAM. Furthermore, studies performed in healthy 
individuals demonstrated that EDX is safe and well tolerated and that the oral administration 
of 4 mg EDX/day allows achieving effective steady-state plasma concentrations (Ahmad et 
al., 2010b).  
In contrast, although relatively well tolerated compared with cytotoxic 
chemotherapy, TAM induces several adverse effects. TAM treatment is associated with an 
increased incidence of vaginal bleeding, endometrial polyps, endometrial thickening, and 
ovarian cysts (Baum, 2002). Moreover, according to several trials performed, hot flushes are 
reported by approximately 40 % of the women taking TAM (Baum, 2002). Less common is 
the long-term risk of endometrial cancer and thromboembolic disease (Braithwaite et al., 
2003). TAM has been associated with a decreased bone mineral density in premenopausal 
women, whereas an increase in postmenopausal women is observed (Ramaswamy and 
Shapiro, 2003). Several cases of hepatotoxicity during treatment with TAM (Labbe et al., 
2008), hypertriglyceridemia (Sakhri et al., 2010), as well as hemolytic anemia, which has 
been related with the disruption of membrane structure (Cruz Silva et al., 2000), were also 
reported. 
To our knowledge the studies performed in melanoma patients have not considered 
the possibility that the intervariability in TAM metabolism may also have an impact on the 
outcome of melanoma treatment and the pharmacological activity of TAM metabolites in 
melanoma has not been studied so far. These are matters deserving further investigation. 
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1.2.2 - GPR30: an emerging target in cancer therapy 
 
Emerging evidence suggests that G protein-coupled receptors (GPCRs) play a 
central role in cancer onset, progression, tumor-induced angiogenesis, and metastasis (Lee 
et al., 2008). Therefore, the interference with GPCRs and their downstream targets has been 
investigated as an opportunity for the development of mechanism-based strategies for cancer 
therapy (Lee et al., 2008). 
The GPR30 was identified in the late 1990s by four different groups (Owman et al., 
1996; Carmeci et al., 1997; Takada et al., 1997; O'Dowd et al., 1998). Following this 
discovery, other papers have supported the view that the GPR30 is a 17β-estradiol-binding 
protein, structurally distinct from the classical ERs, which led to a new designation in 2007 
– GPER1. 
The subcellular localization of GPR30 remains controversial, although it has been 
reported that it is localized in the plasma membranes (Thomas et al., 2005; Funakoshi et al., 
2006; Filardo et al., 2007) or in the endoplasmatic reticulum (Revankar et al., 2005). It has 
been suggested that the subcellular localization of GPR30 may vary according to the cell 
requirements, as different locations can possibly produce different biological activity 
(Prossnitz et al., 2008; Wang et al., 2010). However, according to more recent reports that 
describe the constitutive internalization of plasma membrane GPR30, the receptor 
localization seems to be predominantly intracellular (Cheng et al., 2011; Sandén et al., 2011). 
The identification of G-1 in 2006 as the first GPR30-selective agonist, which shows 
no significant activity at concentrations up to 10 µM on classic ERs or on other GPRCRs 
(Bologa et al., 2006), and the identification of GPR30-selective antagonists G-15 and G-36 
(Dennis et al., 2009, 2011) were a step further in the characterization of the GPR30-mediated 
signaling (Fig. 1.4). In addition to 17β-estradiol and G-1, TAM, OHTAM, fulvestrant and 
environmental estrogens, such as genistein and bisphenol A, were also found to bind to 
GPR30 (Fig. 1.4) (Wang et al., 2010). In contrast, estrone and estriol have very low binding 
affinities to GPR30, whereas 17α-estradiol and other steroid hormones cannot bind to 
GPR30 at all (Wang et al., 2010).  
It is widely accepted that the interaction of 17β-estradiol with the ERs leads to a 
configurational change that allows the binding to estrogen response elements (ERE) in the 
promoter regions of target genes and the recruitment of additional transcriptional 
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coregulators, resulting in the regulation of target protein products. These events usually take 
hours to days to produce the biological actions characteristic of estrogen, but it can also 
trigger a variety of rapid signaling events, which occur in seconds to minutes, including the 
mobilization of intracellular calcium and the activation of multiple intracellular kinase 
cascades, namely the MAPK, PI3K, protein kinase A (PKA) and PKC pathways (Chen et 
al., 2008; Wang et al., 2010). Although there is evidence that also relates classic ERs to these 
nongenomic events, the structure of ERs lacks functional motifs that promote second 
messenger signaling (Filardo et al., 2000, 2002; Prossnitz et al., 2007). Indeed, around one 
third of the genes in humans that are regulated by estrogen do not contain ERE-like 
sequences and are typically regulated via interactions with other transcription factors (Teng 
et al., 2008). The initiation of these rapid signaling events is commonly associated with the 
activation of GPCRs and it has led to the investigation of the role of the GPR30 in estrogen-
mediated signaling in breast cancer cells. It was reported that ligands, such as 17β-estradiol, 
TAM, fulvestrant and G-1, cross the plasma membrane and bind to GPR30. Then, through 
a Gβγ-subunit protein pathway, Src is activated and mediates matrix metalloproteinase 
(MMP)-dependent cleavage of pro-heparin-bound epidermal growth factor (HB-EGF); the 
free HB-EGF activates the epidermal growth factor receptor (EGFR), leading to downstream 
activation of ERK 1/2 (Fig. 1.5) (Prenzel et al., 1999; Filardo et al., 2000). On the other 
hand, via Gα subunit, 17β-estradiol, fulvestrant or TAM stimulate adenylate cyclase activity 
and induce cyclic adenosine monophosphate (cAMP)-dependent PKA-mediated suppression 
of the MAPK pathway, through Raf inactivation (Filardo et al., 2002). Thus, it was suggested 
that the activation of GPR30 can trigger opposing signaling mechanisms that regulate ERK 
1/2 activity (Filardo et al., 2002). On the other hand, 17β-estradiol-mediated activation of 
GPR30 also stimulates PI3K activation (Revankar et al., 2005) and intracellular calcium 
mobilization (Fig. 1.5) (Revankar et al., 2005; Ariazi et al., 2010). It is not clear what triggers 
the increase in calcium. It was proposed that the activated phospholipase C (PLC) produces 
inositol triphosphate that binds to its receptor and leads to intracellular calcium mobilization 
(Prossnitz et al., 2008; Wang et al., 2010), but according to Revankar et al (2005) PLC does 
not seem to be involved (Fig. 1.5). Through these rapid actions, GPR30 can also regulate 
transcriptional activity. The activation of MAPK and PI3K pathways results in the 
phosphorylation and activation of transcription factors, such as the serum response factor  
 
 ______________________________________________________________________ General Introduction 
27 
 
 
 
 
 
 
 
 
Fig. 1.4 - Agonists and antagonists of ER and GPR30. SERMs, selective estrogen receptors 
modulators; SERDs, selective estrogen receptors down-regulators (Modified from Barton, 
2012). 
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(SRF) and members of the E26 transformation specific (ETS) family, such as Elk-1, whereas 
the increase in cAMP elicited by GPR30 signaling could be expected to activate the cAMP-
responsive element-binding protein (CREB) (Fig. 1.5) (Prossnitz et al, 2008; Pandey et al., 
2009; Wang et al., 2010). These transcription factors then promote the expression of a second 
wave of transcription factors, as shown in figure 1.5 (Pandey et al. 2009). The gene most 
strongly induced by 17β-estradiol or OHTAM is the connective tissue growth factor (CTGF), 
which is involved in cell proliferation and in GPR30-induced stimulation of cell migration 
(Fig. 1.5) (Pandey et al., 2009).  
The GPR30-mediated signaling seems complex, as there may be a variety of cross-
talk pathways and both negative and positive feedback loops (Fig. 1.6). For instance, 
Albanito et al (2008) demonstrated that the epidermal growth factor (EGF) up-regulates 
GPR30 expression through the MAPK pathway and considering that the GPR30 signals 
through this pathway, it is plausible that the GPR30 itself is part of a positive feedback loop 
(Maggiolini and Picard, 2010). Moreover, an interplay between ER and GPR30 for the 
regulation of transcriptional effects was recently demonstrated. Notas et al (2012) showed 
that the majority of the transcription inhibited by G-15 is also inhibited by fulvestrant and 
only a small number of transcripts is exclusively inhibited by G-15, supporting the existence 
of specific GPR30 transcriptional activity. Thus, the cross-talk between ER and GPR30 is a 
matter deserving further investigaton. 
So far, the expression of GPR30 was detected in several tissues or cell lines, 
including heart, liver, lung, ovary, brain, breast, uterus, prostate, arteries and vessels 
(Mizukami, 2010; Wang et al., 2010) and has been shown to play a role in immunity, in the 
cardiovascular system and in glucose homeostasis (Wang et al., 2008; Haas et al., 2009; 
Martensson et al., 2009; Barton, 2012). Futhermore, the expression of GPR30 in osteocytes, 
osteoclasts, osteoblasts and chondrocytes and the bone preserving effects of 17β-estradiol, 
selective ER modulators and down-regulators, which act as GPR30 agonists, suggests that 
in addition to the classic ERs, this receptor may be involved in bone metabolism as well 
(Prossnitz and Barton, 2012). Emerging data also point to the involvement of GPR30, which 
is expressed throughout the CNS and peripheral nervous system of male and female rodents, 
in estradiol-mediated neurological functions (Prossnitz and Barton, 2012). 
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Fig. 1.5 - GPR30-mediated signaling. 17β-estradiol (E2), G-1 or OHTAM activate GPR30, 
leading to Src-mediated, MMP-dependent cleavage of pro-HB-EGF and release of HB-EGF 
that transactivates the EGFR, which in turn activates MAPK and PI3K pathways. GPR30 
activation also stimulates PKA activity via adenylate cyclase. The final result is the 
activation of transcription factors, such as SRF, Elk-1 and CREB, which promote the 
expression of a second wave of transcription factors. CTGF is the gene most strongly 
induced by E2 or OHTAM. GPR30 activation also induces calcium mobilization, but it is 
not yet clarified what triggers the increase in calcium. GPR30 is arbitrarily located in the 
plasma membrane (Modified from Maggiolini and Picard, 2010). 
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Fig. 1.6 - Interaction between ER- and GPR30-mediated signaling induced by estrogen. 
Estrogen can activate ERs and directly regulate transcription. Both ERs and GPR30 can 
activate cellular kinase pathways that can lead to the phosphorylation of ERs. The activation 
of MAPK and PI3K pathways also results in the phosphorylation and activation of 
transcription factors, such as Elk-1 and SRF, whereas cAMP production can induce CREB 
activation. CRE, cAMP response element; SRE, serum response element [Modified from 
Prossnitz et al (2008)].  
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The role played by GPR30 in cancer has only recently begun to be elucidated. The 
GPR30 is expressed in cancer cell lines and primary tumors of the breast (Filardo et al., 
2000, 2006), endometrium (He et al., 2009; Du et al., 2012), ovaries (Fujiwara et al., 2012), 
thyroid (Vivacqua et al., 2006a), lung (Jala et al., 2012), prostate (Chan et al., 2010) and 
testicular germ cells (Chevalier et al., 2012).  
As mentioned above, in ER− human breast cancer cells, the activation of GPR30 
by 17β-estradiol or by OHTAM leads to the secretion of CTGF, which promotes cell 
proliferation and migration (Pandey et al., 2009). Accordingly, 17β-estradiol and OHTAM 
induce the proliferation of triple-negative breast cancer cells (lack ERα, progesterone 
receptor and do not overexpress human epidermal growth factor receptor 2) and increase the 
transactivation of EGFR, which is prevented by knockdown of GPR30 expression (Girgert 
et al., 2012). GPR30 also mediates the increased migration of MCF-7 cells [ERα+/ERβ+/ G 
protein-coupled receptor 30-positive (GPR30+)] promoted by OHTAM (Li et al., 2013). In 
SkBr3 breast cancer cells (ERα−/ERβ−/GPR30+), the hypoxia-inducible factor-1α up-
regulates the GPR30 and its downstream target CTGF (Recchia et al., 2011). Moreover, it 
was shown that the apoptotic response to hypoxia is prevented by estrogens through GPR30, 
indicating that the GPR30 is involved in the adaptation of cells to a low oxygen 
microenvironment (Recchia et al., 2011). The GPR30 is also required for the proliferation 
and migration of cancer-associated fibroblasts induced by physiologic concentrations of 
17β-estradiol, indicating that the GPR30 has a functional role in the regulation of tumor 
microenvironment (Madeo and Maggiolini, 2010). 
The role of GPR30 in breast cancer response and resistance to hormonotherapy has 
also been investigated, given that the partial ER antagonists TAM and OHTAM behave as 
agonists for GPR30 (Wang et al., 2010). In fact, about 25 % of ER+ breast cancer patients 
do not respond to antiestrogen therapy, suggesting that such tumors remain estrogen 
responsive in spite of classic ER blockade through another pathway, and the development of 
resistance to TAM is frequent (Early Breast Cancer Trialists' Collaborative Group, 2005; 
Wang et al., 2010; Gigoux and Fourmy, 2013). Breast cancer TAM-resistant cells exhibit 
increased sensitivity to 17β-estradiol and G-1 when compared to the parental cells and in 
these cells TAM stimulates cell proliferation and MAPK phosphorylation (Ignatov et al., 
2010a). 17β-estradiol and fulvestrant inhibit the TGF-β signaling through the activation of 
the MAPK pathway via GPR30, which is another mechanism known to contribute to 
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resistance to antiestrogens (Kleuser et al., 2008). Moreover, EGF and transforming growth 
factor-α (TGF-α) up-regulate GPR30 expression in TAM-resistant breast cancer cells 
(Vivacqua et al., 2009). As EGFR overexpression is associated with TAM resistance, the 
activation of EGFR can contribute to explain the failure of TAM therapy by up-regulating 
GPR30, which facilitates the action of both 17β-estradiol and TAM (Vivacqua et al., 2009). 
However, the correlation between GPR30 expression and ER expression, tumor 
characteristics and aggressiveness remains largely controversial (Notas et al., 2012). 
While some reports point to a strong association between ER and GPR30 
expression in breast cancer (Filardo et al., 2006; Broselid et al., 2013), others reported a low 
negative correlation (Tu et al., 2009). It was shown that the GPR30 is expressed in 
approximately 50 % of all breast cancers and correlates with increased tumor size, 
metastasis, poor outcome (Filardo et al., 2006), and tumor recurrence (Liu et al., 2009). 
Likewise, Ignatov et al (2011) detected GPR30 expression in almost 60 % of the breast 
cancer specimens, which is associated with shorter relapse-free survival. Noteworthy, 
GPR30 expression negatively correlates with relapse-free survival only in patients treated 
with TAM (with or without chemotherapy), but tends to be a favorable factor in patients who 
did not receive TAM (Ignatov et al., 2011). These results suggest that treatment with 
antiestrogens might in fact stimulate rather than inhibit a subset of TAM-resistant tumors 
and therefore breast cancer patients with high GPR30 expression may not benefit from 
treatment with TAM alone (Ignatov et al., 2011). In contrast, it was reported that the levels 
of GPR30 mRNA are significantly down-regulated in cancer tissues in comparison with their 
matched normal tissues and that the expression of GPR30 mRNA is significantly lower in 
tumor tissues from patients who had lymph node metastasis than in lymph node metastasis-
negative patients (Poola et al., 2008). In agreement with these observations, GPR30 mRNA 
expression is down-regulated in infiltrating ductal carcinoma and a correlation with clinical 
parameters, including patient survival, was not established (Kuo et al., 2007). Accordingly, 
the study conducted by Tu et al (2009) did not support the existence of an association 
between GPR30 expression with the size and/or extent of the primary tumor, the spread to 
nearby lymph nodes or the presence of metastasis (TNM stage). Moreover, in inflammatory 
breast cancer, an aggressive and commonly hormone-independent form of breast cancer, 
GPR30 expression was not associated with overall or disease-free survival, but patients with 
GPR30 overexpression had prolonged disease-free survival although without statistical 
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significance (Arias-Pulido et al., 2010). In particular, tumors that expressed both GPR30 and 
ER showed a trend towards better overall or disease-free survival (Arias-Pulido et al., 2010). 
Moreover, the recent study conducted by Broselid et al (2013), supports that the GPR30 is a 
prognostic indicator of distant disease-free survival. Therefore, these conflicting reports 
represent a paradox to resolve in future studies, but considering the complexity of these 
cancers, it is likely that GPR30 may play a different role in different subsets of patients. 
More consentual is the possible role played by the GPR30 in the promotion of 
endometrial and ovarian cancers by 17β-estradiol and antiestrogens. Through the GPR30, 
TAM, OHTAM, 17β-estradiol and G-1 promote the proliferation and invasive behavior of 
endometrial cancer cells, and the down-regulation of GPR30 or the blocking of MAPK 
pathway partly or completely prevented these effects (Vivacqua et al., 2006b; He et al., 2009; 
Ignatov et al., 2010b; Du et al., 2012). Moreover, there was a significant correlation between 
GPR30 expression and the TAM-induced endometrial pathology in breast cancer patients 
(Ignatov et al., 2010b). The expression of GPR30 in endometrial carcinoma was also 
considered an indicator of poor survival (Smith et al., 2007). In ovarian cancer cells, G-1 
increases the phosphorylation of Akt via the EGFR (Fujiwara et al., 2012) and the expression 
of both GPR30 and ERα along with active EGFR signaling are required for 17β-estradiol or 
G-1-stimulated cell proliferation (Albanito et al., 2007). However, as pointed by the authors, 
G-1 induces proliferation in ERα−/GPR30+ breast cancer cells and therefore the requirement 
for ERα expression in GPR30/EGFR signaling may vary according to the cell type (Albanito 
et al., 2007). Additionally, 17β-estradiol and G-1 increase ovarian cancer cells motility and 
invasiveness by increasing the expression and activity of MMP-9 via GPR30 (Yan et al., 
2013). The expression of GPR30 (Smith et al., 2009) or of both GPR30 and EGFR are 
significantly associated with a poor prognosis in patients with ovarian cancer (Fujiwara et 
al., 2012). On the other hand, Kolkova et al (2012) did not detect differences in GPR30 
expression at the mRNA or at the protein level in patients with benign and malignant ovarian 
tumors, and although it was overexpressed in about one third of the malignant tumors, no 
relation between GPR30 and clinical parameters was found (Kolkova et al., 2012). The 
involvement of GPR30 in the promotion of cancer cells proliferation induced by 17β-
estradiol and OHTAM was also demonstrated in thyroid cancer cells and involved the 
MAPK pathway (Vivacqua et al., 2006a).  
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In contrast to the reported promoting action of GPR30 on the proliferation of breast, 
endometrial, ovarian and thyroid cancer cells, inhibition was also demonstrated. Whereas 
GPR30 expression induces the growth of SkBr3 cells, G-1 inhibits MCF-7 cell progression 
stimulated by 17β-estradiol and RNA interference experiments supported the role of GPR30 
in the inhibition of proliferation (Ariazi et al., 2010). Recently, it was also reported that the 
knockdown of the GPR30 decreases either basal or agonist-stimulated proapoptotic receptor 
signaling in MCF-7 cells (Broselid et al., 2013). Furthermore, it was demonstrated that the 
combination of G-1 with trastuzumab exhibit an additive effect on the reduction of breast 
cancer cells proliferation (Lubig et al., 2012). It was also shown that G-1 inhibits the 
proliferation of prostate cancer cells both in vitro and in vivo (Chan et al., 2010). The GPR30-
mediated inhibition of prostate cancer cell proliferation induced by G-1 involves a sustained 
activation of ERK 1/2 and cell cycle arrest in the G2 phase (Chan et al., 2010). Moreover, 
G-1 decreases the proliferation of endothelial cells by blocking cell cycle progression in S 
and G2 phases (Holm et al., 2011). This antiproliferative effect elicited by G-1 occurred 
through a pathway other than MAPK, and was reproduced by fulvestrant, suggesting that 
GPR30 agonists may prevent unwanted formation of new blood vessels, as observed in 
angiogenesis. Interestingly, it was also reported that the activation of epithelial GPR30 
antagonizes 17β-estradiol-induced uterine growth and mediates inhibition of ERK 1/2 and 
ERα phosphorylation (Gao et al., 2011). Thus, the effects resulting from the activation of 
GPR30 are complex and may depend on the specific cellular context. 
Despite the conflicting reports on the role of GPR30 in cancer, targeting its activity 
represents an important and innovative strategy in estrogen-sensitive cancers as well as in 
other diseases in which estrogen signaling is important. The potential contribution of 
GPR30-mediated signaling to the effects of existing clinically approved drugs, such as TAM, 
has just begun to be explored. However, the knowledge regarding the expression of GPR30 
and its role in malignancies other than endocrine-related cancers remains scarce so far. Since 
there is increasing evidence supporting the involvement of GPCRs in tumorigenesis and 
metastatic progression of melanoma, the evaluation of GPR30 function in melanoma 
requires investigation. 
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1.3 - Retinoids, retinoic acid receptors and melanoma 
 
Retinoids, the naturally occurring derivatives of vitamin A (all-trans retinol), play 
an important role in a wide range of physiological functions, including vision, immunity and 
embryonic development (Zusi et al., 2002; Brtko, 2007; Tang and Gudas, 2011). Mammals 
do not synthesize vitamin A, and obtain it from animal food sources, such as milk products, 
eggs and fish oils, or from the processing of pro-vitamin β-carotene, which is found in 
several vegetables (Zusi et al., 2002; Tang and Gudas, 2011). The synthesis of the main 
biologically active derivative of Vitamin A, all-trans retinoic acid (RA), also known as 
tretinoin, requires the irreversible oxidation of retinol in target cells (Zusi et al., 2002). 
The biological activity of retinoids in target cells is mainly mediated through the 
retinoic acid receptors (RAR) and the retinoid X receptors (RXR), which belong to the 
steroid/thyroid/vitamin D (VDR)/peroxisome proliferator-activated receptor (PPAR) family 
of intracellular or nuclear receptors that function as ligand-dependent transcription factors, 
modulating specific genetic programs (Tang and Gudas, 2011). In vertebrates, there are three 
isotypes (α, β and γ) for both RAR and RXR with distinct amino- and carboxy-terminal 
domains, each encoded by a different gene. Two major isoforms generated by alternative 
splicing or promoter use for RARα (α1 and α2), RARγ (γ1 and γ2), RXRα (α1 and α2), 
RXRβ (β1 and β2) and RXRγ (γ1 and γ2), as well as four major isoforms for RARβ (β1, β2, 
β3 and β4), have been identified up to now (Zusi et al., 2002; Brtko, 2007). RAR and RXR 
have different ligand specificity – whereas RA can only bind and activate RAR, with a 
similar affinity for all three isotypes, its isomer 9-cis can bind and activate all three RAR 
and RXR, but with different affinities (Zusi et al., 2002; Theodosiou et al., 2010).  
The retinoid receptors share the same structure as other nuclear receptors (Fig. 1.7). 
The amino-terminal A/B-domain contains the activator function 1 (AF-1) that is independent 
on ligand. The central C-domain is a cysteine-rich region, termed DNA binding domain 
(DBD), which recognizes specific DNA sequences, the retinoic acid response elements 
(RAREs). The RARE for RAR/RXR is composed by two or more degenerate copies of the 
(A/G)G(G/T)TCA or of the more relaxed (A/G)G(G/T)(G/T)(G/C)A half-site motif 
organized in direct repeats or palindromes normally separated by a nucleotide spacer 
(Theodosiou et al., 2010). RAR/RXR heterodimers regulate transcription from DR5, DR2 
and DR1 elements, which have five, two or one nucleotide spacer, respectively (Theodosiou 
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et al., 2010). The D-domain is a flexible structure that plays a role as a hinge of the receptor 
molecule. The carboxy-terminal E-domain harbors the ligand binding domain (LBD), 
comprising the activatior function 2 (AF-2), which is ligand-dependent, and a major 
dimerization interface (Zusi et al., 2002; Brtko, 2007; Theodosiou et al., 2010).  
The transcriptional activation by RAR depends on the formation of the RAR/RXR 
heterodimer (Fig. 1.8), which occurs on the DBD interface and on the LBD interface, that 
stabilizes, without changing, the binding directed by the DBD (Theodosiou et al., 2010). In 
the absence of RAR ligands, the DNA bound RAR-RXR heterodimers recruit corepressor 
proteins, including the nuclear receptor corepressor-1 and -2, and associated enzymes, such 
as histone deacetylases (HDAC) or DNA-methyl transferases, which lead to an inactive 
condensed chromatin structure hindering the transcription process (Zusi et al., 2002; Brtko, 
2007). Upon binding of a ligand, such as the agonist RA, the α-helix 12, which is at the 
carboxy-terminal end of the RAR LBD, alters the three-dimensional surface of the RAR. 
The heterodimer with bound ligand interacts with coactivator proteins, such as the steroid 
receptor coactivator-1, -2 and -3, and proteins with histone acetyltransferases activity, with 
a higher affinity and the corepressor proteins are released. RAR/RXR complexes also recruit 
adenosine 5’-triphosphate (ATP)-dependent chromatin remodeling complexes and the 
mediator complex to promoters. These events enable the communication of RAR-RXR 
heterodimers with the basal transcriptional machinery to initiate target gene expression (Zusi 
et al., 2002; Brtko, 2007; Tang and Gudas, 2011). Besides the RAR, the RXR can 
heterodimerize with many other members of nuclear receptor superfamily and thus play an 
integrative role in nuclear receptor mediated pathways. However, whereas RAR agonists 
autonomously activate transcription through RXR/RAR heterodimer, RXR are unable to 
respond to RXR specific ligands in the absence of a RAR ligand. This phenomenon, referred 
to as ‘‘RXR subordination’’, is due to the inability of RXR ligands to induce the dissociation 
of corepressor molecule from the RXR/RAR heterodimers (Brtko, 2007; Theodosiou et al., 
2010). 
Over the past decades, more that 500 genes have been identified as regulatory 
targets of RA. Although a direct regulation driven by liganded RAR/RXR heterodimers 
bound to RARE was demonstrated, it seems that in most cases the regulation of the gene 
target is indirect and occurs through intermediate transcription factors or nonclassical  
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Fig. 1.7 - Structural organization of nuclear receptors (Brtko, 2007).  
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Fig.1.8 - Mechanism of transcription regulation by RAR-RXR heterodimers. In the absence 
of a RAR ligand, RAR-RXR heterodimers form multiprotein complexes with corepressor 
(Co-R) proteins, resulting in transcription silencing. The presence of a RAR ligand generates 
a conformational change that disrupts Co-R binding and induces derepression of the 
chromatin. The association of coactivator (Co-A) with RAR-RXR enables the recruitment 
of basal transcription machinery to the promoter and the subsequent activation of various 
genetic programs (Modified from Altucci and Gronemeyer, 2001). 
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associations of receptors with other proteins (Theodosiou et al., 2010). Some of the RAR 
target genes include those encoding RARβ itself, laminin B1, cellular retinol-binding 
protein, cellular retinoic acid-binding protein, as well as the homeobox genes, which are key 
players during development (Balmer and Blomhoff, 2002; Theodosiou et al., 2010). Besides 
the proteins involved in RA metabolism, such as CYP26, RARs also regulate a number of 
factors involved in metabolism, for example the 17β-hydroxysteroid dehydrogenase, which 
is implicated in steroidogenesis, or the liver bile acid transporter sodium-taurocholate 
cotransporting polypeptide (Theodosiou et al., 2010). 
In addition to the effects promoted by binding to their receptors, retinoids also exert 
their effects via a transcription independent pathway (Bushue and Wan, 2010; Theodosiou 
et al., 2010). The activation of the PI3K signaling pathway is required for RA-induced 
differentiation of SH-SY5Y neuroblastoma cells (Masiá et al., 2007). Retinoids also inhibit 
the activation of activator protein 1 (AP-1), a heterodimeric transcription factor, which 
usually mediates cell proliferation signals (Fanjul et al., 1994; Benkoussa et al., 2002). Since 
transcriptional activation is not required for RAR-mediated AP-1 inhibition, the effects of 
retinoids on AP-1 involve the RAR-dependent control of transcription factors and cofactor 
assembly on AP-1-regulated promoters (Fanjul et al., 1994; Benkoussa et al., 2002). The 
activity of the nuclear factor-κB (NF-κB) is also regulated nongenomically by RA, probably 
in a RAR-dependent manner, suggesting that the modulation of immune and inflammatory 
responses by retinoids involves NF-κB signaling (Austenaa et al., 2004; Theodosiou et al., 
2010). In the absence of retinoid receptors, RA can also induce the rapid activation of CREB 
protein, which involves PKC, ERK 1/2 and p90 ribosomal S6 kinase activity, as 
demonstrated in human bronchial epithelial cells (Aggarwal et al., 2006). Importantly, it has 
been reported the existence of a specific RA-binding site on PKC and the interaction between 
RA and PKCα decreases PKC activity (Radominska-Pandya et al., 2000). The fact that RA 
treatment modulates PKC activity might be useful to alter malignant cells functions 
regulated by PKC isozymes, such as proliferation, differentiation or apoptosis.  
RA and its isomers 13-cis-retinoic acid and 9-cis-retinoic acid are widely used in 
the treatment of skin conditions, including acne, psoriasis and photoaging (Germain et al., 
2006). On the other hand, retinoid signaling is often compromised early in carcinogenesis 
and epidemiological studies have demonstrated that lower vitamin A intake results in a 
higher risk of developing cancer (Sun and Lotan, 2002). Several preclinical and clinical 
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studies have evaluated the use of RA and other synthetic retinoids, alone or in combination 
therapy, in the treatment of breast, ovarian, renal, head and neck, melanoma and prostate 
cancers (Tang and Gudas, 2011). However, it is not yet clarified whether retinoids induce 
cell proliferation arrest, cell death, cell differentiation, or all of these mechanisms, but 
positive therapeutic effects were reported (Tang and Gudas, 2011). 
In 1995, the FDA approved RA for the treatment of acute promyelocytic leukemia 
(APL), which remains the most studied and effective clinical use of RA up to now. APL is 
characterized by selected expansion of immature myeloid precursors or malignant myeloid 
cells blocked at the promyelocytic stage of hemopoietic development (Bushue and Wan, 
2010). Molecular studies identified the translocation of RARα gene on chromosome 17 and 
fusion to partner genes as the crucial event in APL pathogenesis. The fusion partners include 
the promyelocytic leukemia zinc finger (PLZF) gene, the nucleophosmin gene, the nuclear 
mitotic apparatus gene, and the signal transducer and activator of transcription 5B gene. 
However, the most common fusion partner is the promyelocytic leukemia protein (PML) 
gene on chromosome 15 yielding the PML-RARα chimeric gene t(15;17) (Zusi et al., 2002; 
Brtko, 2007; Bushue and Wan, 2010). The PML-RARα can form a homodimer through the 
coiled coil motif of PML, inhibiting RARα binding to RARE and the activation of 
downstream target genes (Brtko, 2007; Bushue and Wan, 2010). The higher affinity of PML-
RARα for HDAC leads to a ‘super-repression’ of RARα signaling pathways in APL blasts 
and to the disruption of PML function as a transcriptional coactivator of the tumor suppressor 
p53 (Zusi et al., 2002).  
The introduction of RA into the therapy of APL radically changed the management 
and the outcome of this disease, which was previously associated with a significant 
morbidity and mortality. RA induces the differentiation of cells by causing the degradation 
of the mutant PML-RARα and by inducing the dissociation of its corepressors (Brtko, 2007; 
Bushue and Wan, 2010). In addition, RA inhibits cell proliferation by blocking cell cycle 
progression in G1 and high concentrations of RA induce post-maturation apoptosis of APL 
blasts (Brtko, 2007; Bushue and Wan, 2010).  
Currently, RA is included in every phase of the treatment of pediatric APL in 
combination with anthracyclines, leading to a complete remission in 90-95 % of the cases 
(Masetti et al., 2012). Noteworthy, some RA-resistant human APL cells present impaired 
degradation of PML/RARα, while others show mutations in the LBD of RARα of PML-
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RARα (Zhou et al., 2002). A rare variant of APL, characterized by a chromosomal 
translocation of the RARα and the PLZF genes, causes expression of a PLZF-RARα fusion 
protein that has a second binding site for a nuclear corepressor complex with HDAC activity 
leading to a very stable association between PLZF-RARα and the corepressor complex. This 
leukemia is nonresponsive to RA, but the combination with HDAC inhibitors can lead to 
remission in animal models or blast differentiation in vitro (He et al., 2001; Petti et al., 2002). 
Thus, combination treatments can possibly overcome RA resistance in other types of tumors 
as well.  
The successful application of RA for the management of APL renewed the interest 
in the use of retinoids for the treatment of a variety of established malignancies due to their 
differentiation, antiproliferative, proapoptotic and antioxidant effects (Bushue and Wan, 
2010). Since the late 1970’s, the use of retinoids in malignant melanoma prevention and 
treatment has been extensively evaluated. Both normal human melanocytes and melanoma 
cells exhibit mRNA for RARs (α, β and γ) and RXRα (Rosdahl et al., 1997). Accordingly, 
the study of Zhang et al (2003) demonstrates the presence of RARs and RXRα in eleven 
primary and matched metastatic cutaneous melanoma cell lines, and no differences were 
detected between the primary and metastatic tumors.  
RA decreases the proliferation of melanoma cell lines S91, B16 and K1735-M2 
(Lotan et al., 1978; Helige et al., 1993). It has been proposed that the inhibition of the 
proliferation of primary and metastatic melanoma cells involves mitochondrial dysfunction, 
given that low concentrations of RA decrease the viability of melanoma cells mitochondria 
in a concentration-dependent manner (Zhang et al., 2003). Alterations of the cell cycle 
distribution and, at higher concentrations, apoptotic cell death were also reported (Zhang et 
al., 2003; Baroni et al., 2003). Noteworthy, the dysfunction of mitochondria and the 
induction of apoptosis are more pronounced in the primary tumor cells than in the metastatic 
cells from the same patients, suggesting that an early stage melanoma may have better 
response to retinoid adjuvant therapy than the late stage melanoma (Zhang et al., 2003). The 
antiproliferative effects reported in vitro are further supported by studies in animal models 
of melanoma. Retinal, retinol and RA decreased melanoma cell growth in vitro and in vivo, 
and RA was the most effective retinoid (Drewa and Schachtschabel, 1985). In another mouse 
model of melanoma, 13-cis retinoic acid treatment does not significantly affect the tumor 
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incidence, but decreases the tumor growth and the number of metastatic lesions (Schleicher 
et al., 1988).  
However, other studies provided conflicting results. In the study conducted by 
Lotan (1979), RA decreases the proliferation of two melanoma cell lines, but the remaining 
four cell lines tested do not respond to RA, indicating that human cells derived from tumors 
of similar histopathological type may differ in their responsiveness to RA. Several 
explanations may contribute to this discrepancy. Boehm et al (2004) demonstrate that RARβ 
and RXRα are present in normal skin, but RXRα is not detected in melanocytic tumors, 
neither in nevi, nor in melanomas, whereas RARβ is also absent from melanoma cells, but it 
is present in nevus cells (Boehm et al., 2004). In fact, melanoma progression seems to be 
characterized by a simultaneous loss or decrease in the expression of various RAR and RXR 
receptors, which result in deficient RAR/RXR heterodimers (Chakravarti et al., 2007). This 
decreased retinoid receptor expression may render retinoids unable to turn on normal cellular 
programs and contributes to retinoid resistance (Chakravarti et al., 2007). The patients with 
simultaneous loss of cytoplasmic staining for RARα and RXRα have decreased overall 
survival, indicating that the loss of retinoid receptor expression correlates with melanoma 
progression (Chakravarti et al., 2007). However, those with RARα−/RXRα+ phenotype have 
better prognosis suggesting that in patients lacking expression of RARs, RXRα can 
contribute to inhibit cell proliferation via a different pathway (Chakravarti et al., 2007).  
Considering that ERK is constitutively activated in up to 90 % of melanomas 
(Russo et al., 2009), and that the turnover of retinoid receptors is regulated by their 
phosphorylation status, it is possible that aberrant MAPK pathway signaling may contribute 
to decrease the expression of retinoid receptors (Chakravarti et al., 2007). The elevated levels 
of corepressors and/or the loss of expression of coactivator proteins, in addition to the 
increased activity of the Akt pathway, have also been proposed as possible explanations for 
the diminution of RAR-regulated signaling in tumor cells (Tang and Gudas, 2011). On the 
other hand, the study of Demary et al (2001) supports that RA resistance in A375 cells 
involves repressed RAR activity through an epigenetic mechanism. RA-resistant melanoma 
A375 cells present substantially higher intracellular reactive oxygen species (ROS) than S91 
cells and the reduction of oxidative stress is able to resensitize cells to RA (Demary et al., 
2001). As the functional activity of several important transcription factors is regulated by 
the cellular redox state and reducing conditions promote DNA binding, the redox state of 
 ______________________________________________________________________ General Introduction 
43 
melanoma cells provides for an epigenetic control mechanism of RAR activity and RA 
resistance (Demary et al., 2001). Moreover, hypermethylation of RARβ2 was found in 70 % 
of both primary and metastatic melanomas and the mRNA transcripts could be re-expressed 
following treatment with 5'-aza 2'-deoxycytidine, supporting that promoter methylation is 
responsible for silencing of RARβ2 in some melanoma cells (Hoon et al., 2004; Fan et al., 
2010). Importantly, it was demonstrated that the antiproliferative activity of RA correlates 
with the expression of RARβ2 (Fan et al., 2010).  
In addition to its antiproliferative activity, RA can also exhibit an anti-invasive 
effect on melanoma cells. RA inhibits B16a and K1735-M2 melanoma cells migration and 
invasion in vitro and in vivo, which adds to the decreased proliferation observed in these 
cells (McGarvey and Persky, 1989; McGarvey et al., 1990). N-(4-hydrophenyl) retinamide, 
a derivative of RA, also suppresses melanoma cells migration and invasion through 
reconstituted basement membrane (Wu et al., 2005). Tumor invasion is a complex process 
that involves changes in cellular adhesion, production of degradative enzymes that lead to 
host tissue degradation, alterations in the actin cytoskeleton and increased motility, and RA 
affects all of these processes in melanoma cells. 
Treatment of M14 melanoma cells with RA down-regulates the expression of 
vitronectin receptor (αvβ3), a member of the integrin superfamily, which is thought to play 
an important role in regulating tumor cell invasion, and closely correlate with the RA-
dependent inhibition of actin polymerization, cell adhesion and migration (Baroni et al., 
2003). On the other hand, melanoma cell lines treated with RA express decreased amounts 
of gp78, a cell surface receptor for motility factor implicated in invasion and metastasis 
(Hendrix et al., 1990; Lotan et al., 1992). In addition, the carbohydrate sulfotransferase 10 
is a RARγ target gene in S91 melanoma cells, where it functions as a suppressor of 
invasiveness (Zhao et al., 2009).  
RA at 1 µM only slightly decreases the directional migration of melanoma cells, an 
indicator of cell motility (Helige et al., 1993). The study conducted by Situ et al (1993) also 
demonstrates that RA treatment blocks adhesion and motility of mouse and human 
melanoma cells; the malignant cells are less sensitive to RA than normal melanocytes in the 
adhesion assay, although equally sensitive in the motility assay.  
Furthermore, A375 human melanoma cells treated with RA secrete lower levels of 
collagenolytic enzymes and decrease in a dose- and time-dependent manner the ability of 
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these cells to penetrate Matrigel-coated filters (Hendrix et al., 1990). Moreover, the 
evaluation of host tissue degradation induced by K1735-M2 melanoma cells invasion, 
revealed that after treatment with RA the stromal component is more intact (Helige et al., 
1993). RA also regulates the expression of MMP-1 and the tissue inhibitor of 
metalloproteinases-2 in a panel of melanoma cell lines (Jacob et al., 1998). Altogether, these 
data support that RA can decrease melanoma cell invasion through the modulation of several 
cellular properties.  
The differentiation process has been associated with reorganization of actin 
(Lehtonen et al., 1983) and retinoids are known to have profound effects on cellular 
differentiation (Bushue and Wan, 2010). Accordingly, studies using rhodamine-labeled 
phalloidin demonstrate that K1735-M2 melanoma cells treated with RA exhibit alterations 
of the actin cytoskeleton, exhibiting numerous filament bundles (Helige et al., 1993). 
Recent studies also suggest that retinoids may be useful as antiangiogenic agents. 
RA has demonstrated anti-inflammatory activity in an animal model of carrageenan-induced 
acute inflammation and a formaldehyde-induced chronic inflammation (Siddikuzzaman and 
Grace, 2013). In addition, it inhibited in about 56 % the tumor-associated capillary formation 
in mice induced by the highly metastatic B16F10 melanoma cells (Siddikuzzaman and 
Grace, 2013). Accordingly, 13-cis-retinoic acid inhibited vascular endothelial cell 
proliferation, migration and tube formation and regulated the levels of proinflammatory 
cytokines during the onset of angiogenesis (Guruvayoorappan and Kuttan, 2008).  
Regarding the use of retinoids in the preventive setting, both acitretin and 13-cis-
retinoic acid are effective for the prevention of non-melanoma skin cancer, but further 
studies are required to establish the most suitable retinoid, the dosage and the duration of the 
preventive treatment and how to manage side effects in the case of long-lasting treatment 
(Bettoli et al., 2013). Moreover, a recent large prospective cohort supported that 
supplemental intake of retinol is associated with a reduction in risk of melanoma (Asgari et 
al., 2012). Whereas the risk reduction in females is pronounced, the risk reduction in males 
is not statistically significant, which may be related with gender differences in melanoma 
outcomes (Asgari et al., 2012).  
In spite of the strong rationale supporting the inclusion of retinoids in melanoma 
prevention and therapeutic regimens, their use in clinical practice has been hampered by 
their adverse effects. Vitamin A excess is toxic to several organs and tissues, including the 
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liver, CNS, musculoskeletal system, internal organs and skin and can lead to reduced mineral 
bone density and to malformations during embryonic development (Theodosiou et al., 2010). 
Retinoids are also known teratogens and inhibit chondrogenesis and induce mucocutaneous 
cytotoxicity (Zusi et al., 2002). In phase I/II studies, RA induced cheilitis, skin reactions, 
headache, nausea and vomiting, as well as transient hypertriglyceridemia and elevations of 
liver enzymes (Lee et al., 1993; Budd et al., 1998). Skin toxicities and headaches were 
considered to be the dose-limiting toxicity, and the maximum tolerated dose established is 
in the 150-190 mg/m2/day range (Lee et al., 1993; Budd et al., 1998). RA syndrome is a life-
threatening complication seen in patients treated with RA, characterized by dyspnea, fever, 
weight gain, hypotension, edema, pleural or pericardial effusions and, occasionally, renal 
failure and increased leukocyte counts (Zusi et al., 2002; Bushue and Wan, 2010).  
A possible strategy to decrease the retinoid associated toxicity is the combination 
with other chemotherapeutic agents. Besides minimizing the development of resistance, the 
combination of drugs with complementary mechanisms of action and different toxicity 
profiles allows to obtain equivalent or even superior efficacy, while substantially reducing 
toxicity, through the use of lower doses. 
The interconnection between retinoid and estrogen signaling in breast cancer has 
garnered significant attention in the last years. Whereas retinoids decrease the proliferation 
of ERα+ breast cancer cells, ERα− cells are usually resistant, but can be turned into retinoid-
responsive when transfected with ER (Sheikh et al., 1993; Rubin et al., 1994; Rosenauer et 
al., 1998). Noteworthy, the effects of 9-cis retinoic acid are similar to those of RA, 
suggesting that the ability to bind both RAR and RXR does not enhance the growth inhibition 
induced by retinoids and that RARs are the key players regarding the antiproliferative effects 
of retinoids in breast cancer cells (Rubin et al., 1994). Furthermore, an additive/synergism 
of action was reported for the combination of RA with either TAM or OHTAM in breast 
cancer cells (Wetherall and Taylor, 1986; Wang et al., 2007; Koay et al., 2010). Moreover, 
in a phase I/II trial in patients with potentially hormone responsive advanced breast cancer, 
significant responses were observed in patients taking the combination of RA with TAM 
who had previously shown evidence of TAM resistance (Budd et al., 1998). These 
observations support the existence of a cross-talk between the RAR and ERα pathways in 
human breast cancer and suggest a possible combination therapy in ERα+/RAR+ breast 
General Introduction ______________________________________________________________________  
46 
cancers. Several studies conducted to clarify the mechanism underlying this interplay have 
supported this hypothesis.  
Both 9-cis retinoic acid and RA induce down-regulation of the expression of ER 
itself or estrogen-responsive genes in MCF-7 cells (Rubin et al., 1994). Rousseau et al (2003) 
demonstrated that in ERα+ cells the basal expression of the RARE RARβ2 is suppressed but 
can be strongly induced in the presence of RA, while in the ERα− cells the transcription is 
only weakly induced by RA (Rousseau et al., 2003). The induction of RARβ2 transcriptional 
activity when ERα is expressed involves the N-terminal AF-1-containing region, including 
the DBD, and it is independent of the C-terminal LBD (Rousseau et al., 2003). Accordingly, 
OHTAM, which inhibits AF-2-mediated transcriptional activity of ERα, while allowing the 
activity from the AF-1, had no significant effect on βRARE activity, but the full ER 
antagonist fulvestrant, which blocks both the AF-1 and AF-2 activities of ERα, was able to 
relieve the repression of basal βRARE activity (Rousseau et al., 2003). The fact that ERα 
does not alter the transcription mediated by the VDR or thyroid hormone receptors, which 
also heterodimerize with the RXR, indicates that the effect of ERα is specific for RAR-
mediated transcription (Rousseau et al., 2003). More recently, using chromatin 
immunoprecipitation, Hua et al (2009) demonstrated that RARα/RARγ binding throughout 
the genome is highly coincident with ERα binding in MCF-7 human breast cancer cells, 
often leading to competitive binding activity to the same element or nearby cis-regulatory 
elements. The subsequent transcriptional analysis revealed an antagonistic regulation of 
breast cancer-associated genes by RA and estrogen (Hua et al., 2009). Importantly, the 
putative direct targets of ERα and RAR identified in MCF-7 cells were found to be highly 
expressed in luminal type breast tumors, indicating that their antagonistic effects may be 
relevant for primary ER+ tumors. On the other hand, considering that estrogen is the 
predominant hormone in breast cancer biology, Ross-Innes et al (2010) studied the 
interaction between ER and RARα in the presence of estrogen. Under these circumstances, 
RARα and ERα can co-occupy regulatory regions together within the chromatin (Ross-Innes 
et al., 2010). In fact, RARα is part of the ER transcription complex, where it plays an 
essential role in the regulation of estrogen-mediated gene expression by maintaining ER-
cofactor interactions (Ross-Innes et al., 2010). The authors proposed that RARα can have 
two independent functions: a classic role as a heterodimeric partner of RXR and another one, 
as an ER-associated protein (Ross-Innes et al., 2010). The presence of RA ligands promotes 
 ______________________________________________________________________ General Introduction 
47 
the classic RARα role, leading to activation of the classic RARα pathways; that way RARα 
is depleted from its role as a component of the estrogen-ER pathway, sacrificing estrogen-
mediated gene expression (Ross-Innes et al., 2010). This occurs either when RARα agonists 
or antagonists are used, explaining why both can decrease breast cancer cell proliferation 
(Dawson et al., 1995; Toma et al., 1998). Thus, the balance between the classic and the novel 
pathways of RARα is an important regulator of ER function in breast cancer cells. 
Considering that estrogen-independent ER signaling has been implicated in the 
development of resistance to adjuvant therapy, a recent study conducted by Salazar et al 
(2011) evaluated the interplay between the apo- forms (ligand free) of ER and RAR and its 
impact on basal proliferation, under the conditions of hormonal adjuvant therapy of hormone 
depletion or antiestrogen antagonism. The basal cellular proliferation persists in estrogen-
sensitive breast cancer cells grown in hormone depleted conditioned media and it is inhibited 
by down-regulating ER (Salazar et al., 2011). Remarkably, the action of apo-ER is also 
insensitive to OHTAM at a dose that was clinically relevant (Salazar et al., 2011). According 
to this study, a major mechanism by which ER supports the cell cycle in hormone-sensitive 
cells depleted of hormone or treated with OHTAM is by promoting the basal expression of 
RARα1, through a direct regulation of the RARα and by additional post-transcriptional 
mechanisms (Salazar et al., 2011). Another important observation is that most of the 
common target genes of apo-ER and apo-RARα1 are insensitive to RA, suggesting that the 
apo-RARα1 acts by nonclassical mechanisms and that the hormone-sensitive breast cancer 
cells may not be sensitive to conventional RAR ligands, but specific inactivators or down-
regulators of RARα1 would be useful instead (Salazar et al., 2011). Thus, there is also an 
interaction between the ligand-free ER and RARα that contributes to the persistence of a 
small fraction of cells in S-phase during hormonal adjuvant therapy in breast cancer, 
contributing to the development and progression of resistant tumors (Salazar et al., 2011). 
Altogether, the studies performed up to now support that the combinations of 
antiestrogens and retinoids may be useful in the treatment of breast cancer, due to an 
interaction between retinoid and estrogen signaling in these cells. However, it is not known 
whether these combinations may be useful in other types of cancer cells as well. Given that 
the use of retinoids in melanoma therapy has been hindered by their adverse effects, a 
possible synergistic action with antiestrogens would largely contribute to turn retinoids into 
more suitable drugs for melanoma therapy. 
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1.4 - Glutamate receptor antagonists and cancer therapy 
 
Glutamate is the major excitatory neurotransmitter in the mammalian CNS and 
exerts its biological activity through a variety of receptors. Glutamate receptors (GluRs) are 
divided into two major classes on the basis of the mechanism by which they relay their 
signal: the ionotropic glutamate receptors (iGluRs), which are ligand-gated cation channels, 
and the metabotropic glutamate receptors (mGluRs) that are G protein-coupled receptors 
(Teh and Chen, 2012). The iGluRs are further subdivided into N-methyl-D-aspartate 
(NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and 2-carboxy-
3-carboxymethyl-4-isopropenylpyrrolidine (kainate, KA) receptors, according to the 
agonists that were originally identified to activate them selectively (Fig. 1.9) (Kew and 
Kemp, 2005). Eight subtypes of mGluRs have been identified so far and classified into three 
groups according to their sequence homologies, pharmacological responses and intracellular 
second messengers (Fig. 1.9). The group I (mGluR1 and mGluR5) upon activation stimulates 
PLC, whereas group II (mGluR2 and mGluR3) and group III (mGluR4, mGluR6, mGluR7 
and mGluR8) are negatively coupled to adenylate cyclase (Kew and Kemp, 2005; Niswender 
and Conn, 2010; Teh and Chen, 2012). 
The NMDA receptors (NMDARs) are composed of two obligatory GluN1 subunits, 
which impart on heteromeric NMDAR channels ion permeability, GluN2 subunits A, B, C, 
and D, as well as GluN3 subunits A and B, which determine the electrophysiological 
properties of the channel (Cull-Candy et al., 2001; Kew and Kemp, 2005). The NMDAR 
requires two obligatory coagonists binding at the glycine (or D-serine) and glutamate 
binding sites localized on the GluN1 and GluN2 subunits, respectively (Traynelis et al., 
2010). Thus, it seems likely that the NMDAR is a tetrameric structure composed of a GluN1 
dimer in combination with a GluN2 dimer; in the receptors containing GluN1, GluN2 and 
GluN3 subunits, the latter possibly substitutes one of the GluN2 subunits, creating a 
functional receptor that is not affected by glutamate (Cull-Candy et al. 2001; Kew and Kemp, 
2005). The opening of the NMDAR requires simultaneous activation by glutamate and 
depolarization to abrogate the magnesium block, allowing the entry of calcium and sodium 
into the cell and the efflux of potassium. Among the iGluRs, the NMDARs are 
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Fig. 1.9 - Classification of glutamate receptors (GluRs) according to the mechanism by 
which they relay their signal. 
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generally the most permeable to calcium (Chen and Lipton, 2006). AMPA receptors 
(AMPARs) are homo or heterotetramers composed of GluA1-GluA4 subunits (Palmer et al., 
2005). AMPAR gate Na+ (and Ca2+ in the absence of GluA2 subunit) in response to ligand 
binding, triggering a fast excitatory postsynaptic response in neurons and activating second 
messenger pathways. The conductance and kinetic properties of the AMPAR channel 
depend on the subunit composition. AMPAR containing the GluA2 subunit are impermeable 
for calcium as the genomic DNA of the GluA2 subunit contains a glutamine (Q) residue at 
amino acid 607, that is replaced by arginine (R) in the majority of neuronal cells during the 
process of nuclear RNA editing (Kew and Kemp, 2005; Palmer et al., 2005). KA receptors 
(KARs) are composed of GluK1-GluK5 that form tetrameric combinations (Kew and Kemp, 
2005). GluK4 and GluK5 subunits do not form functional homomeric receptors, but combine 
in heteromeric assemblies with GluK1-GluK3 to form functional receptors; on the contrary, 
the GluK1-GluK3 subunits can form functional homomeric receptors (Kew and Kemp, 
2005). Similarly to GluA2, GluK1 and GluK2 undergo glutamine/arginine editing that 
decreases the calcium permeability of these receptors (Lerma et al., 2001). In addition to 
RNA editing, iGluRs subunits undergo alternative splicing introducing additional 
heterogeneity (Dingledine et al., 1999; Kew and Kemp, 2005).  
Glutamate plays a key role in several physiological functions, including 
interneuronal signaling, sensory perception, memory, learning, and synaptic plasticity 
(Cavalheiro and Olney, 2001). On the other hand, abnormal glutamate signaling is involved 
in the pathogenesis of acute brain injury conditions, such as stroke, epilepsy and head 
trauma, and in chronic CNS diseases, including Parkinson’s and Alzheimer’s disease 
(Cavalheiro and Olney, 2001; Chen and Lipton, 2006).  
Several GluR antagonists have been developed to prevent excessive glutamate 
signaling. NMDAR channel blockers, like MK-801 or memantine, are drugs that enter the 
receptor-associated ion channel when it opens, thus preventing the flux of ions, and are 
considered uncompetitive antagonists (Chen and Lipton, 2006). These drugs require prior 
activation of the receptor and therefore lead to channel blockade in the presence of excessive 
levels of glutamate and little blockade at relatively lower levels (Chen and Lipton, 2006). 
Therefore, NMDAR channel blockers have been preferred over the competitive agonists, 
such as D-(-)-2-amino-5-phosphonopentanoic acid (APV), which compete with glutamate 
or glycine at the agonist binding sites (Chen and Lipton, 2006). The quinoxalinedione 
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compounds, including 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and 2,3-dihydroxy-6-
nitro-7-sulfamoylbenzo[f]quinoxaline (NBQX), are competitive antagonists that block 
AMPAR and KAR with very little selectivity between both receptors (Kew and Kemp, 
2005). CNQX also has activity at the glycine binding site on NMDAR, whereas NBQX, 
which has improved AMPAR selectivity with respect to CNQX, is used as the antagonist of 
choice in many in vitro models, in spite of the absence of in vivo activity following systemic 
administration (Kew and Kemp, 2005; Catarzi et al., 2007). GYKI52466 and CMF-2 are 
noncompetitive AMPAR antagonists, selective for AMPAR over KAR and NMDAR (Kew 
and Kemp, 2005).  
Although excessive glutamate signaling is related to cell death, glutamate has an 
important trophic function in the development of the CNS, regulating the proliferation and 
migration of neuronal progenitors (Cavalheiro and Olney, 2001). In fact, whereas the 
blockade of NMDAR in the developing rodent brain by NMDAR antagonists leads to 
apoptotic neuronal death (Ikonomidou et al., 1999; Hansen et al., 2004), the stimulation of 
AMPAR and NMDAR in neurons has been linked to activation of the MAPK and PI3K 
pathways, resulting in increased cell proliferation and migration (Perkinton et al., 1999; 
Platenik et al., 2000; Mao et al., 2004). Similarly, iGluRs are involved in the proliferation of 
tumor cells derived from neuronal tissue, such as glioma, glioblastoma, medulloblastoma 
and neuroblastoma, which have been shown to express iGluRs subunits (Yoshioka et al., 
1996; Aronica et al., 2001; Ishiuchi et al., 2002). Glutamate plays a central role in the 
malignant phenotype of gliomas via two main mechanisms: on the one hand, the glutamate 
produced and released from glioma cells causes excitotoxicity which contributes to the 
expansion of tumor cells; on the other hand, glutamate also activates iGluR and mGluR on 
glioma cells (de Groot and Sontheimer, 2010). The activation of AMPAR by glutamate 
induces intracellular calcium oscillations (Lyons et al., 2007) that seem to play a crucial role 
in the growth and motility of glioblastoma, the most aggressive malignant primary brain 
tumor in humans. Noteworthy, glioblastoma samples present higher levels of GluA1 
expression in comparison with low-grade tumors and silencing of GluA1 inhibits AMPAR-
mediated activation of MAPK pathway and decreases glioma cells proliferation (de Groot et 
al., 2008). Moreover, the AMPAR GluA2 subunit, which confers calcium impermeability, 
is absent in high-grade glioma specimens, but is expressed in low-grade gliomas (Beretta et 
al., 2009). Accordingly, Ishiuchi et al (2002) reported that overexpression of calcium-
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permeable AMPAR facilitates migration and proliferation of glioblastoma cells and that the 
conversion of calcium-permeable to calcium-impermeable AMPAR inhibits cell locomotion 
and induces apoptosis. Similar findings were reported by Beretta et al (2009) who 
demonstrated that GluA2 overexpression inhibits glioblastoma cells proliferation by 
inactivating the MAPK pathway and induces apoptosis. On the other hand, it was 
demonstrated that AMPAR-regulated proliferation of glioblastoma cells involves the Akt 
pathway (Ishiuchi et al., 2007; Schunemann et al., 2010). In addition, differentiated SK-N-
SH neuroblastoma cells express functional NMDAR (Pizzi et al., 2002). In the study 
conducted by Korczak et al (1995), mRNA for AMPAR and KAR subunits were detected in 
four neuroblastoma cell lines, but immunoblot analysis and electrophysiological recordings 
failed to confirm the expression of proteins and the formation of functional AMPAR or KAR 
channels (Korczak et al., 1995). Likewise, Yoshioka et al (1996) demonstrated the presence 
of mRNA encoding NMDAR, AMPAR and KAR subunits, but the treatment of the cells 
with L-glutamate, KA, AMPA or NMDA did not cause cell damage or increases in calcium 
influx. These observations are indicative of the existence of transcriptional and post-
transcriptional regulation of iGluRs expression.  
In the last decade, evidence has emerged implicating glutamate as a signal mediator 
in non-neuronal tissues and similarly to its trophic role in the CNS, glutamate stimulates the 
proliferation of non-neuronal tumor cells (Rzeski et al., 2001; Skerry and Genever, 2001; 
Hinoi et al., 2004). mRNA for iGluR subunits are differentially expressed in thyroid, lung 
and breast carcinomas, multiple myeloma, glioma, colon adenocarcinoma, T-cell leukemia 
(Stepulak et al., 2009), larynx (Stepulak et al., 2011), gastric cancer cells (Watanabe et al., 
2008) and osteosarcoma (Kalariti et al., 2005). For the majority of tumors, mRNA levels of 
GluA4, GluK2 and GluK5 are lower compared to human brain tissue and NMDAR subunits 
are much lower (Stepulak et al., 2009). Interestingly, Stepulak et al (2009) detected mRNA 
for GluN2D subunit in all the analyzed cancer cell lines. GluN2D subunits are usually 
present at high levels prenatally, but decrease postnatally, which may suggest that the re-
expression of GluN2D subunits in cancer cells may correlate with their proliferative 
phenotype (Stepulak et al., 2009). It was also reported the expression of GluR subunits at 
the protein level in prostate (Abdul and Hoosein, 2005), breast (North et al., 2010a) and lung 
(North et al., 2010b) cancers.  
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The expression of GluR subunits can also be associated with prognosis-related 
factors, as the GluN1 subunit expression was associated with tumor size, presence of lymph 
node metastases and poorer survival in patients with oral squamous cell carcinoma (Choi et 
al., 2004). Moreover, positive staining for the GluN1 subunit was detected in samples of 
high-grade invasive ductal and lobular breast cancer (North et al., 2010a). 
The knockdown of selected GluR subunits has supported the relevance of the 
iGluR-mediated signaling in cancer cells proliferation and invasion. Reduced expression of 
GluA4 in human rhabdomyosarcoma/medulloblastoma cells markedly increased the 
propensity of cancer cells to proliferate, as well as their mobility, as a result of an up-
regulation of the expression of key genes that encode proteins involved in signal transduction 
(γ-synuclein and myc proto-oncogene protein), in invasion and metastasis (MMP-2 and 
metastasis-associated protein MTA-2) and adhesion proteins (integrin beta-3) (Luksch et al., 
2011). In agreement with these observations, the blockade of AMPAR with GYKI52466 
significantly decreased rhabdomyosarcoma/medulloblastoma cells proliferation and 
migration (Rzeski et al., 2001). Furthermore, in a human gastric cancer cell line, silencing 
of the GluN2A subunit increased the proportion of cells in the G1 phase of the cell cycle, 
indicative that the GluN2A subunit promotes cell proliferation by accelerating the cell cycle 
(Watanabe et al., 2008). 
It was reported that NMDAR and AMPAR antagonists limit the proliferation of 
several non-neuronal cancer cells, including colon, larynx, breast, prostate, lung and thyroid, 
in addition to glial and neuronal tumors (Rzeski et al., 2001; Abdul and Hoosein, 2005; North 
et al., 2010a, b). Importantly, NMDAR antagonists memantine and MK-801 reduce the 
viability of the NCI H82 variant cell line, which is a model of recurrent and drug-resistant 
small-cell lung cancer (North et al., 2010b). 
The antiproliferative effect of GluR antagonists was reported to be calcium-
dependent, since tumor cells grown under calcium deprivation are resistant to the 
antiproliferative effects of NMDAR and AMPAR antagonists (Rzeski et al., 2001). In fact, 
it was proposed that glutamate-dependent receptor/ion channel complexes on tumor cells 
contribute to regulate their proliferation and migration by modulating calcium fluxes; 
glutamate can depolarize membranes and induces an elevation of intracellular calcium 
(Rzeski et al., 2001) which stimulates tumor growth (Celli et al., 1999), regulates protein 
trafficking through the nuclear membrane (Stehno-Bittel et al., 1995) and cell migration 
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(Marks and Maxfield, 1990; Clapham, 1995; Lawson and Maxfield, 1995; Gomez and 
Spitzer, 1999). In accordance with this hypothesis, the resting membrane potential in tumor 
cells varies between −30 and −50 mV (Iwata et al., 1999) and at such membrane potentials 
magnesium block of NMDAR channels in neurons is reduced whereas AMPAR channels 
are permeable to cations (Burnashev et al., 1995; Rzeski et al., 2001). Moreover, calcium-
permeable AMPAR are required for the agonist-induced proliferation of glioma cells 
(Ishiuchi et al., 2002). 
However, further studies have challenged this hypothesis. Experiments carried out 
in lung carcinoma and rhabdomyosarcoma/medulloblastoma cells show that the expression 
of mRNA of the GluR subunits and the receptor-mediated evoked currents are low compared 
to the brain, questioning the functional significance of iGluR as ion channels in cancer cells 
(Stepulak et al., 2009). In addition, lung cancer cells express mRNA of the GluA2 subunit, 
and therefore it is not plausible that the antiproliferative effect of AMPAR antagonists is 
related to blockade of calcium entry within the cell (Stepulak et al., 2007). Thus, Stepulak 
et al (2009) suggest that GluR may activate intracellular signaling pathways that modulate 
the survival and proliferation of cancer cells.  
The mechanisms underlying the antiproliferative effects of GluRs antagonists are 
not yet entirely clarified, but it seems that the inhibition of the MAPK pathway plays a key 
role. The activation of NMDAR in neurons results in the phosphorylation of ERK 1/2 and 
CREB (Kemp and McKernan, 2002; Hardingham and Bading, 2003). Accordingly, AMPAR 
antagonists and NMDAR antagonists inhibit the growth of lung cancer cells promoted by 
EGF and insulin-like growth factor (IGF) and at higher concentrations decrease the ERK 1/2 
phosphorylation (Stepulak et al., 2005, 2007). Moreover, AMPAR and NMDAR 
antagonists, by inhibiting the MAPK pathway, reduce the phosphorylation of CREB and the 
expression of CREB-regulated genes, including cyclin D1, and up-regulate the cell cycle 
regulators and tumor suppressor proteins p21 and p53 (Stepulak et al., 2005, 2007). The 
decreased expression of cyclin D1, that promotes the progression through the G1-S phase of 
the cell cycle (Fu et al., 2004), as well as the increased expression of p21 and p53, provides 
a link to the cell cycle machinery, explaining the decreased number of lung adenocarcinoma 
cells in G2 and S phases of the cell cycle after treatment with NMDAR and AMPAR 
antagonists (Stepulak et al., 2005, 2007). The inhibition of the MAPK pathway by AMPAR 
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and NMDAR antagonists was also demonstrated in laryngeal cancer cells (Stepulak et al., 
2011).  
In addition to their antiproliferative activity, it was also demonstrated that GluR 
antagonists alter the morphology and decrease the motility of cancer cells. Thyroid 
carcinoma cells exhibit marked membrane ruffling and numerous pseudopodia characteristic 
of an invasive phenotype, whereas cells treated with NMDAR antagonist MK-801 or the 
AMPAR antagonist GYKI52466 for 96 h present fewer pseudopodia protrusions (Rzeski et 
al., 2001). The motility of lung carcinoma, rhabdomyosarcoma/medulloblastoma and 
thyroid carcinoma cells is also decreased after 96 h of treatment with MK-801 or 
GYKI52466 (Rzeski et al., 2001).  
The evidences obtained in vitro were further supported by the promising results 
obtained in vivo. MK-801 at a daily dose of 0.1 mg/kg body weight doubles the survival of 
mice with metastatic lung adenocarcinoma and it is well tolerated by the animals (Stepulak 
et al., 2005). Accordingly, the administration of escalating doses of MK-801 (ranging from 
0.1 up to 0.3 mg/kg body weight) for ten days reduces in approximately 50 % the tumor 
growth rate of animal models of small-cell lung cancer (North et al., 2010b). The escalating 
dose range was selected by the authors to produce maximal effects without inducing 
significant adverse behavioral changes and MK-801 seemed well tolerated by the animals 
(North et al., 2010b). Furthermore, MK-801 (0.3 mg/kg body weight twice a day) slows the 
growth of neuroblastoma/rhabdomyosarcoma in mice, but using this dose, mild increases in 
the locomotor activity for up to 1 h after administration were reported (Stepulak et al., 2005). 
Daily treatments with MK-801 over 5 days (two daily doses of 0.3 mg/kg body weight) also 
arrested the growth of mice bearing breast cancer without inducing apparent negative effects 
on the health of animals (North et al., 2010a).  
Importantly, the GluR antagonists may be useful agents in therapeutic association. 
MK-801 and GYKI52466 enhance the antiproliferative effect of cyclophosphamide and 
thiotepa in rhabdomyosarcoma/medulloblastoma, neuroblastoma, lung carcinoma and 
astrocytoma cells due to both increased tumor cell death and to diminished cell division 
(Rzeski et al., 2001). 
In the last years, several studies have implicated mGluR signaling in the onset and 
progression of melanoma. mGluR1 is expressed in several human melanoma biopsies and 
cell lines, but not in benign nevi and melanocytes (Pollock et al., 2003), and its expression 
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is required for the development and growth of melanoma in vivo (Pollock et al., 2003; Ohtani 
et al., 2008). In fact, treatment of human melanoma cells expressing mGluR1 with a mGluR1 
antagonist or with the glutamate release inhibitor riluzole decreases cell proliferation and the 
levels of extracellular glutamate (Namkoong et al., 2007). Likewise, a selective 
noncompetitive mGluR1 antagonist significantly inhibits the proliferation of human 
melanoma cell lines (Haas et al., 2007). Interestingly, inhibitors of the PLC, PKC, calcium 
release, calmodulin and MAPK inhibit melanoma development in mGluR1 transgenic mice, 
but only the MAPK inhibitor is able to inhibit melanoma growth once it develops (Abdel-
Daim et al., 2010). The results reported by Abdel-Daim et al (2010) suggest that the 
activation of every signaling pathway from mGluR1 is required for the development of 
melanoma and that the MAPK pathway plays a key role in its progression. Recently, Choi 
et al (2011) demonstrated that overexpression of mGluR5 also induces melanoma in 
transgenic mouse lines and implicated ERK 1/2 as a key downstream effector of mGluR5 
(Choi et al., 2011). Another mGluR, mGluR3, is frequently mutated in melanoma and by 
regulating the phosphorylation of MEK leads to increased growth and migration (Prickett et 
al., 2011). On the other hand, a mGluR1 antagonist significantly enhances the effects of 
docetaxel, suggesting that GluRs antagonists may potentiate the anticancer activity of 
existing therapies of melanoma (Haas et al., 2007). 
Although these studies support the importance of mGluR signaling in melanoma, 
the information regarding the role played by iGluR remains scarce. Hoogduijn et al (2006) 
demonstrated that GluA2 and GluN2A subunits are expressed in melanocyte cultures; since 
the stimulation with AMPA or NMDA elevated intracellular calcium concentrations, the 
authors concluded that melanocytes present functional AMPAR and NMDAR. Moreover, 
treatment with AMPAR and NMDAR antagonists (CFM-2 and MK-801) changes 
melanocyte morphology and induces alterations in the actin cytoskeleton (Hoogduijn et al., 
2006). Importantly, CFM-2 markedly decreases the expression of the microphthalmia-
associated transcription factor (MiTF), a master regulator of melanocyte differentiation and 
proliferation (Hoogduijn et al., 2006). More recently, it was reported that melanoma cells 
WM451 express functional NMDAR, as shown by the increase in intracellular calcium 
concentrations induced by NMDA, which are decreased by MK-801 (Song et al., 2012). The 
treatment of melanoma cells with MK-801 induces changes in the cellular morphology that 
resemble that of normal melanocytes and decrease cell motility, as well as proliferation 
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(Song et al., 2012). Furthermore, MK-801 (0.6 mg/kg every three days) decreases tumor 
volume and growth in mouse models inoculated with melanoma cells (Song et al., 2012).  
Therefore, further studies devoted to the investigation of the effects of iGluR 
antagonists on melanoma proliferation either individually or in combination with other 
anticancer agents are required.  
 
1.5 - Mitochondria as drug targets 
 
Mitochondria are dynamic cytoplasmatic organelles, which present varying shape, 
size, number and location within the cell (Campello and Scorrano, 2010). Mitochondria 
possess an outer membrane (OMM) that is rich in cholesterol and essentially permeable to 
ions and solutes up to 14 kDa, similarly to other cell membranes (Wallace and Starkov, 
2000). The intermembrane space (IMS) is located between the OMM and the inner 
mitochondrial membrane (IMM), and contains proteins such as the adenylate kinase and the 
creatine kinase (CK), as well as the cytochrome c and the apoptosis-inducing factor (AIF), 
which translocate to the cytoplasm during the apoptotic process, and other protein involved 
in cellular metabolism. The IMM is folded, forming the cristae, and in contrast to the OMM, 
is rich in cardiolipin and impermeable to ions and polar molecules. The IMM possesses 
transporters for ATP/adenosine 5’-diphosphate (ADP), aspartate/malate, among others that 
regulate the movements of molecules across the IMM, and also the five multisubunit 
complexes (Complex I, II, III, IV, and V) involved in the oxidative phosphorylation. The 
space enclosed by the IMM is the matrix, which contains the proteins involved in the Krebs 
cycle, in the fatty acid oxidation, as well as in the synthesis of the heme and steroids (Scatena 
et al., 2007; Pereira et al., 2009; Nadanaciva and Will, 2009; Cohen, 2010). The 
mitochondrial matrix also contains the mitochondrial DNA (mtDNA), maternally inherited, 
which is circular and lacks histones, resembling the bacterial DNA. The mtDNA encodes 13 
polypeptides that are the subunits of the complexes I, III, IV and V that are synthesized in 
mitochondrial ribosomes. The majority of the other mitochondrial proteins, including the 
subunits of complex II, are encoded by nuclear DNA, and imported into mitochondria after 
synthesis on cytosolic ribosomes (Wallace, 2005; Pereira et al., 2009; Cohen, 2010; 
Nadanaciva and Will, 2011a). Therefore, mitochondria are not only responsible for the 
synthesis of most of the ATP produced in the cell, but they are multifunctional organelles 
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with diverse roles, including the fatty acid oxidation, the synthesis of the heme and steroids, 
calcium regulation and cell death. Importantly, the electron leak during the transfer of 
electrons along the electron transport chain to oxygen, the ultimate acceptor of electrons, 
turns mitochondria into the major source of ROS. Although the formation of ROS can be 
damaging to the organelle, ROS generation is also required to maintain the redox balance, 
which is critical to regulate the functions that assist the normal cellular physiology (Cohen, 
2010).  
Considering the key role played by mitochondria in the cell survival and death, 
mitochondria are often implicated in disease and xenobiotic-induced toxicity (Pereira et al., 
2009; Cohen, 2010; Nadanaciva and Will, 2011a, b). 
The mtDNA is not protected by histones and due to the proximity to the sites where 
ROS are routinely generated and the less efficient DNA repair processes, the frequency of 
mtDNA mutation is much higher than that of nuclear DNA (Scatena et al., 2007). The 
mutations of mtDNA can lead to mitochondrial diseases, including the mitochondrial 
encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), myoclonic epilepsy 
associated with ragged-red fibres (MERRF) and Leber’s hereditary optic neuropathy 
(LHON) (Pereira et al., 2009; Nadanaciva and Will, 2011a). Additionally, a pathogenic role 
for mitochondrial dysfunction has also been invoked in neurodegenerative disease, cancer, 
type 2 diabetes and aging (Wallace, 2005).  
In the least years, the evaluation of drug-induced mitochondrial damage has 
received considerable attention, as several classes of drugs have been shown to compromise 
mitochondrial functions (Nadanaciva and Will, 2009, 2011a). For instance, cerivastatin, 
troglitazone, tolcapone and nefazodone, which have been implicated in mitochondrial 
dysfunction were withdrawn from the market by the FDA due to safety concerns 
(Nadanaciva and Will, 2009). Thus, the study of the effects of drugs on mitochondria allows 
for a better understanding of the pharmacological and toxicological mechanisms underlying 
the mode of action of drugs. Moreover, the use of isolated mitochondria fractions to predict 
drug safety can also decrease the number of laboratory animals and the costs of preclinical 
studies (Pereira et al., 2009).  
Mitochondrial dysfunction is more pronounced in tissues with high energetic 
demands and that rely heavily on oxidative phosphorylation (heart, kidney and CNS). On 
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the other hand, considering the exposure to high concentrations of drugs, the liver is often 
another target of mitochondrial toxicity (Nadanaciva and Will, 2009).  
Drugs can compromise mitochondrial functions in a multitude of ways. The table 1 
shows examples of drugs that affect mitochondrial functions by different mechanisms. 
Drugs can damage hepatic mitochondria in some individuals but not in others, and 
our current knowledge does not allow to predict the idiosyncratic liver injury related with 
drug-induced mitochondrial dysfunction. It seems that genetic, metabolic and environmental 
factors that impair mitochondrial function can add their effects to those of mitochondria-
targeting drugs, compromising mitochondrial function to an extent where hepatic 
manifestations start to occur (Labbe et al., 2008). In addition, drug-induced mitochondrial 
dysfunction can also trigger diverse extrahepatic or general manifestations. The syndromes 
associated to mitochondrial toxicity are not uncommon and include lactic acidosis, 
myopathy, peripheral neuropathy, rhabdomyelosis and pancreatitis (Scatena et al., 2007; 
Labbe et al., 2008; Nadanaciva and Will, 2009, 2011b). 
However, the interaction of drugs with mitochondria may not always be negative, 
and the therapeutic effects obtained from the pharmacological modulation of mitochondrial 
activity are being investigated, particularly in cancer therapy (Scatena et al., 2007; Fulda et 
al., 2010).  
 
1.5.1 - Bioenergetic functions  
 
Mitochondria are considered the powerhouses of the cell, since they generate most 
of the ATP produced (Nadanaciva and Will, 2009). In the IMM are located the five 
complexes involved in the oxidative phosphorylation. The nicotinamide adenine 
dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) generated in glycolysis, 
fatty acid oxidation and Krebs cycle are oxidized by Complex I (NADH ubiquinone 
reductase) and Complex II (succinate dehydrogenase), respectively, and the electrons are 
passed to ubiquinone (coenzyme Q), a mobile electron carrier within the IMM that shuttles 
electrons to Complex III (ubiquinol:cytochrome c reductase) (Fig. 1.10). The complex III 
oxidizes the reduced ubiquinol and reduces the cytochrome c, a small protein that rotates 
freely in the cytosolic side of the IMM. The cytochrome c shuttles the electrons to complex 
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Target Effect on mitochondria Examples of drugs 
Bioenergetic functions 
Inhibitors of electron transport 
Tamoxifen, fenofibrate, 
metformin 
Uncouplers 
Diclofenac, 
chlorpromazine 
Mitochondrial 
permeability transition 
Inducers Retinoic acid, nimesulide 
Inhibitors Tamoxifen 
mtDNA 
Inhibitors of mtDNA 
replication 
Stavudine, lamivudine 
Inhibitors of mtDNA-encoded 
protein synthesis 
Linezolid, 
chloramphenicol 
 Oxidative stress Doxorrubicin 
Lipid metabolism 
Inhibitors of fatty acid 
oxidation 
Valproic acid 
 
Table 1 - Examples of mechanisms by which drugs can impair mitochondrial function 
(Modified from Nadanaciva and Will, 2009).  
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Fig. 1.10 - Schematic representation of the oxidative phosphorylation. The electrons donated 
from NADH and FADH2 to Complex I and Complex II are passed to ubiquinone (Q), a 
mobile electron carrier that shuttles protons to the complex III, which oxidizes the reduced 
ubiquinol and reduces the cytochrome c. The cytochrome c then shuttles the electrons to 
complex IV, where molecular oxygen is reduced to water. In parallel to the electron transfer, 
the complexes I, III and IV pump protons from the matrix to the IMS generating an 
electrochemical gradient, which is used by Complex V to synthesize ATP from ADP and 
inorganic phosphate (Murray, 2009).  
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IV (cytochrome c oxidase) which directly reduces molecular oxygen to water (Wallace and 
Starkov, 2000; Pereira et al., 2009). Complexes I, III and IV are redox-driven proton pumps 
that use the energy derived from oxidation-reduction reactions to pump protons from the 
matrix to the IMS, in parallel to the electron transfer, generating an electrochemical proton 
gradient (proton motive force) (ΔµH+), which is comprised of two components: a pH 
gradient (ΔpH) and a membrane potential (ΔΨ) (Fig. 1.10).  
The energy contained in the ΔµH+ is used by Complex V (ATP synthase) to 
synthesize ATP from ADP and inorganic phosphate (Fig. 1.10). The complex V consists of 
the F1 subunit, a soluble portion situated in the mitochondrial matrix, and the Fo subunit, 
bound to the IMM. When cells need energy, the levels of ADP within the mitochondria rise 
and induce the re-entry of protons into the matrix through the Fo portion of complex V, 
partially dissipating the ΔΨ. The energy released is then used by the F1 subunit to 
phosphorylate ADP into ATP. The transient decrease in ΔΨ promotes the electron transfer 
along the electron transport chain and the coupled ejection of protons towards the IMS, 
restoring the ΔΨ (Labbe et al., 2008; Jonckheere et al., 2012). Oxidative phosphorylation 
requires the presence of NADH or FADH2, oxygen, ADP and phosphate. However, as 
discussed above, the levels of ADP are the most critical factor regulating the rate of 
phosphorylation. Thus, the oxidative phosphorylation is coupled to the ATP requirements 
and the electron flow along the electron transport chain only occurs when the synthesis of 
ATP is required. The impermeability of the IMM to protons is crucial for ensuring that the 
electron transfer along the electron transport chain is coupled to ATP synthesis by Complex 
V, so that there is no respiration without proton pumping and vice-versa (Wallace and 
Starkov, 2000; Nadanaciva and Will, 2009; Pereira et al., 2009). 
However, and particularly at complexes I and III, some of these electrons escape 
and directly react with oxygen (Labbe et al., 2008). This process generates the superoxide 
anion radical which is then dismutated by the mitochondrial manganese superoxide 
dismutase into hydrogen peroxide; the latter is detoxified into water by the mitochondrial 
glutathione peroxidase and hence, in normal circumstances, most of the ROS generated by 
the electron transport chain are neutralized by the mitochondrial antioxidant defences (Labbe 
et al., 2008). 
Xenobiotics can compromise mitochondrial bioenergetics either by interfering with 
the generation of ΔΨ or by causing its dissipation (Wallace and Starkov, 2000). The 
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inhibition of the electron transport chain has great impact on tissue metabolism by 
compromising the reoxidation of NADH and FADH2 into NAD
+ and FAD, respectively, 
required for the activity of several dehydrogenases of the Krebs cycle and the mitochondrial 
β-oxidation (Begriche et al., 2006; Rolo et al., 2012). Furthermore, the damaged electron 
transport chain will increase the levels of oxidative stress that promote several deleterious 
effects (Begriche et al., 2006; Rolo et al., 2012). On the other hand, drugs that increase the 
membrane permeability to ions, such as channel-forming proteins, ionophores, uncouplers 
of oxidative phosphorylation and inducers of the mitochondrial permeability transition 
(MPT) dissipate the proton gradient between the IMS and the matrix without ATP 
generation, resulting in the generation of heat (Wallace and Starkov, 2000; Scatena et al., 
2007; Nadanaciva and Will, 2009). 
The antiestrogen TAM depresses the phosphorylation efficiency and the 
mitochondrial levels of ATP in a concentration-dependent manner, possibly due to a 
decrease in the active adenine nucleotide transporter (ANT) content and a partial inhibition 
of the phosphate carrier (Cardoso et al., 2001, 2004). At high concentrations, TAM 
uncouples the mitochondrial respiration (Tuquet el al., 2000; Cardoso et al., 2001). 
Considering that TAM is a highly hydrophobic molecule that strong partitions in 
biomembranes (Custódio et al., 1991), it is possible that TAM amine group may bind and 
shuttle protons across the IMM like a classic protonophore (Cardoso et al., 2001). Indeed, 
amphiphilic drugs like TAM are protonated within the acidic IMS and ‘pulled’ into the 
mitochondrial matrix, which is basic and negatively charged, where the protonated molecule 
releases its proton; this abnormal entry of protons bypasses the Fo fraction of Complex V, 
thus uncoupling the oxidative phosphorylation (Labbe et al., 2008). On the other hand, high 
concentrations of TAM can also affect the IMM integrity (Custódio et al., 1996; Chen et al., 
1999), enhancing the proton leak (Cardoso et al., 2001). Thus, depending on the 
concentrations used, TAM can induce mitochondrial uncoupling by a proton shuttling 
mechanism or by disrupting the structure of the IMM.  
The stimulation of mitochondrial respiration is then followed by its inhibition, as 
the TAM accumulated eventually reaches concentrations capable of compromising the 
electron transfer along the electron transport chain (Tuquet el al., 2000; Cardoso et al., 2001). 
Further studies conducted by Moreira et al (2006) revealed that TAM at 25 µM significantly 
affects complex I and identified the flavin mononucleotide site of complex I as the target of 
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TAM. However, the inhibition of respiration induced by high concentrations of TAM can 
also be related to the disruption of the IMM (Cardoso et al., 2001). The rigidifying effect of 
TAM on membrane fluidity (Custódio et al., 1993a) may also compromise the diffusional 
mobility of membrane proteins, hampering the electron transfer along the electron transport 
chain (Cardoso et al., 2001). In addition to the inhibition of the electron transport chain as a 
consequence of the impaired electron flow demonstrated in vitro (Cardoso et al., 2001; 
Moreira et al., 2006), TAM also significantly depletes hepatic mtDNA in mice treated with 
0.5 mmol/kg for more than 12 days (Larosche et al., 2007), which further contributes to 
inhibit mitochondrial electron transport chain activity. 
The inhibition of the electron transport chain secondarily inhibits mitochondrial β-
oxidation through the decreased regeneration of the oxidized cofactors (NAD+ and FAD) 
required for β-oxidation, and can also lead to the depletion of ATP within the hepatocytes 
and trigger cell death (Labbe et al., 2008). The slight and prolonged inhibition of 
mitochondrial β-oxidation induced by TAM can cause macrovacuolar steatosis, a benign 
liver lesion in the short term that is characterized by the presence of a single, large lipid 
vacuole in the cytoplasm of the hepatocytes (Labbe et al., 2008). However, macrovacuolar 
steatosis can progress in some patients towards steatohepatitis after several years (Labbe et 
al., 2008).  
Another consequence of the inhibition of the electron transport chain is the 
accumulation of electrons in the electron transport chain complexes that can escape and 
directly react with oxygen to form the superoxide anion radical (Labbe et al., 2008). Thus, 
the impairment of mitochondrial electron transport chain activity is also associated with 
enhanced ROS production and increased lipid peroxidation that is favored by lipid 
accumulation. Hence, the augmented ROS production is possibly a key event in the 
pathogenesis of drug-induced steatohepatitis (Labbe et al., 2008). 
Importantly, according to the study performed by Cardoso et al (2002a), the TAM 
active metabolite OHTAM is less toxic to mitochondrial functions than the prodrug. 
OHTAM slightly affects the phosphorylation efficiency of rat liver mitochondria in 
comparison with TAM, and only at concentrations above those reached in tissues (Cardoso 
et al., 2002a). Like TAM, OHTAM increases the state 4 of respiration and decreases the ΔΨ 
in a concentration-dependent manner, but the effects are much less pronounced than those 
of TAM (Cardoso et al., 2002a). The authors proposed that OHTAM increases the membrane 
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permeability to protons by acting as a proton shuttle, whereas the same concentrations of 
TAM induce a much more potent proton leak, possibly related with the disruption of 
mitochondrial membrane (Cardoso et al., 2001; Cardoso et al., 2002a). 
RA has been shown to affect mitochondrial bioenergetics as well. RA above 0.25 
nmol/mg protein induces uncoupling of mitochondria, which is related to the ability of 
retinol and RA to increase IMM permeability (Stillwell et al., 1982; Stillwell and Nahmias, 
1983). On the other hand, a recent study conducted by Xun et al (2012) demonstrated that 
during RA-induced differentiation of neuroblastoma cells the oxygen consumption rate is 
increased and that this effect of RA on mitochondria may be beneficial in cancer therapy. 
Thus, further studies are required to clarify the effects of RA on mitochondrial bioenergetics. 
 
1.5.2 - Mitochondrial permeability transition  
 
MPT can be defined as a sudden increase of IMM permeability to solutes with 
molecular masses up to 1 500 Da, due to the opening of a voltage and calcium-dependent, 
cyclosporine A (CyA)-sensitive channel (Rasola and Bernardi, 2007). For several years, it 
was considered that the MPT pore was composed by cyclophilin-D (CypD) in the matrix, 
the ANT in the IMM and the voltage-dependent anion channel (VDAC) in the OMM (Fig. 
1.11) (Halestrap, 2009; Zorov et al., 2009). Additional proteins, such as the CK, hexokinase 
II (HKII) and the peripheral benzodiazepine receptor (PBR) were also proposed to take part 
in the MPT pore (Halestrap, 2009; Zorov et al., 2009). However, emerging evidences have 
challenged this model. The fact that the loss of CypD does not prevent MPT pore opening, 
and only increases the calcium load required, suggests that MPT pore opening involves a 
conformational change in a membrane protein, which is triggered by calcium and facilitated 
by CypD, but can occur even in the absence of CypD if sufficient stimulus is given (Basso 
et al., 2005; Halestrap, 2009). Recent studies have also eliminated the VDAC as an essential 
component of the MPT pore complex and the ANT is considered to play a regulatory role 
rather than a structural one (Fig. 1.11) (Javadov et al., 2009). Recently, the mitochondrial 
phosphate carrier was also proposed as a possible key component of the MPT pore complex 
(Leung et al., 2008). The evidence regarding the involvement of the other proteins remains 
largely circumstantial (Halestrap, 2009). 
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Fig. 1.11 - Classical (A) and current (B) views of the MPT pore complex. (A) The MPT pore 
complex is formed by the VDAC, the ANT and the CypD complex. HKII, CK and PBR were 
considered possible regulatory components. (B) The CypD and the ANT are now considered 
key regulators of the MPT, whereas the VDAC is no longer seen as an essential or even 
regulator MPT pore component. The involvement of HKII, CK and PBR remains 
controversial (Zorov et al., 2009). 
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Although the MPT pore opening is intimately related with the calcium 
concentration in the mitochondrial matrix, the levels required are largely dependent on other 
factors. Oxidative stress, depletion of ADP and ATP and high concentrations of phosphate 
increase the sensitivity of MPT to calcium, while a low pH inhibits MPT pore opening 
(Halestrap, 2009). The ΔΨ is another critical factor regulating MPT – a high (negative) ΔΨ 
inhibits MPT pore opening, but if mitochondria are depolarized before the addition of 
calcium, the calcium accumulation is prevented and MPT pore opening requires a much 
higher concentration of calcium (Halestrap, 2009). 
As a consequence of MPT pore opening, the IMM loses its impermeability to 
protons, leading to depolarization of ΔΨ and the dissipation of ΔpH, resulting in oxidative 
phosphorylation uncoupling. Moreover, the proton-translocating ATPase goes into reverse 
and hydrolyses the ATP generated by glycolysis further contributing to ATP depletion and 
bioenergetic failure (Helestrap, 2009). Another consequence of MPT pore opening is the 
increased permeability of the IMM to solutes with molecular weight up to 1 500 Da, allowing 
their movement and equilibration between the matrix and the cytosol whilst proteins are 
retained within their respective compartments. Since the protein concentration is higher in 
the matrix than in the cytosol, a high osmotic pressure is generated and leads to 
mitochondrial swelling and eventually to the rupture of OMM. In this scenario, cytochrome 
c and other proapoptotic proteins are released to the cytosol and may initiate the apoptotic 
cell death (Halestrap, 2009; Kinnally et al., 2011). The AIF leads to the fragmentation of 
nuclear DNA, whereas the second mitochondria-derived activator of caspase/direct inhibitor 
of apoptosis-binding protein with low pI (Smac/DIABLO) inactivates the inhibitor of 
apoptosis proteins (Fig. 1.12) (Labbe et al., 2008). The released cytochrome c binds to the 
apoptotic protease-activating factor 1 to activate caspase-9, and since it is a key component 
of the electron transport chain, its leakage from the mitochondria eventually impairs electron 
transfer within the electron transport chainand enhances ROS generation (Labbe et al., 
2008). If there are no sufficient levels of ATP, necrotic death may predominate over 
apoptosis (Baines et al., 2009).  
In addition, MPT plays a relevant role in pathological situations, contributing to cell 
death. That is the case of ischemia-reperfusion in cardiac myocytes, where mitochondrial 
ROS generation after reperfusion promotes MPT onset and subsequent myocyte death,  
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Fig. 1.12 - Mitochondrial permeability transition (MPT). (A) In physiological conditions, 
the permeability transition pore (PTP) is inactive and mitochondria exhibit a high ΔΨ, which 
is generated by the electron transport chain and used for ATP generation. In these conditions, 
mitochondrial solute carriers regulate the exchange of small metabolites between the cytosol 
and the mitochondrial matrix. (B) In pathological situations or in response to some drugs, 
the opening of the PTP allows the deregulated entry of small solutes into the mitochondrial 
matrix driven by electrochemical forces. MPT leads to the dissipation of the ΔΨ and to the 
osmotic swelling of the mitochondrial matrix, which eventually results in mitochondrial 
outer membrane permeabilization (MOMP). Consequently, proteins normally confined 
within the IMS, such as cytochrome c and Smac/DIABLO, as well as caspase-independent 
cell death effectors, like AIF and endonuclease G are released into the cytosol [Modified 
from Fulda et al (2010)]. 
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turning the inhibition of MPT pore opening a possible approach for cardioprotection 
(Javadov et al., 2009; Lemasters et al., 2009).  
MPT can also be induced by xenobiotics, either by an interference with the proteins 
that regulate the MPT pore opening or through the modulation of critical factors to the onset 
of MPT (Pereira et al., 2009). Importantly, the induction of MPT in liver mitochondria can 
trigger apoptosis and/or necrosis, and cause ‘cytolytic’ hepatitis leading occasionally to 
fulminant hepatic failure (Labbe et al., 2008). Therefore, the induction of MPT is recognized 
as a mechanism by which drugs can induce hepatotoxicity (Labbe et al., 2008) and several 
hepatotoxic drugs have been shown to cause MPT pore opening, such as diclofenac, 
nimesulide, troglitazone and gemfibrozil (Nadanaciva and Will, 2009). On the other hand, 
the induction of MPT has been investigated as a therapeutic strategy, particularly in cancer 
therapy, due to its ability to activate the cell death machinery. It is thought that this strategy 
may bypass the resistance mechanisms related with conventional chemotherapy that do not 
target mitochondria directly, but interfere with signaling pathways which lie upstream of 
mitochondria that are frequently deregulated in cancer (Fulda et al., 2010). However, further 
studies are required to clarify the differences between mitochondria in normal and cancer 
cells to increase the level of selectivity of mitochondria-targeted anticancer agents and turn 
the triggering of MPT into a possible therapeutic strategy for cancer therapy (Fulda et al., 
2010). 
The ability of antiestrogens TAM and OHTAM to inhibit MPT pore opening is well 
documented. TAM prevents and reverses the MPT induced by calcium and phosphate 
(Custódio et al., 1998), by pro-oxidants (Cardoso et al., 2004), by carboxyatractyloside 
(CATR) (Hernández-Esquivel et al., 2011a) and by mercury (Hernández-Esquivel et al., 
2011b). Likewise, OHTAM also prevents and reverses the MPT induced by calcium and 
phosphate (Cardoso et al., 2002b). The mechanisms underlying the inhibition of MPT by 
TAM and OHTAM are not entirely clarified. Both TAM and OHTAM have been shown to 
scavange peroxyl radicals (Custódio et al., 1994). Considering that oxidative stress is one of 
the mechanisms regulating the MPT pore opening (Halestrap, 2009), the antioxidant activity 
of antiestrogens could possibly account for the inhibition of MPT (Cardoso et al., 2004; 
Hernández-Esquivel et al., 2011b). However, Custódio et al (1998) suggest that the 
protective effect afforded by TAM is due to some factor other than its antioxidant action, as 
no change in the oxidation state of mitochondrial glutathione was detected during the course 
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of calcium and phosphate-induced MPT. In fact, TAM inhibits the MPT induced by agents 
that do not increase the levels of oxidative stress, such as CATR (Hernández-Esquivel et al., 
2011a). TAM and OHTAM are highly hydrophobic molecules that strongly partition in 
biomembranes (Custódio et al., 1991, 1993a, b; Kazanci and Severcan, 2007), affecting the 
dynamic properties of lipids. The ability of TAM to prevent the MPT induced by CATR is 
substantially decreased when experiments are carried out at higher temperatures, suggesting 
that this effect may be related with the interference with membrane fluidity (Hernández-
Esquivel et al., 2011a); this could lead to a configurational change of the ANT and explain 
the effects of TAM and OHTAM on MPT. On the other hand, TAM and OHTAM decrease 
the content of active ANT and inhibit the phosphate carrier (Cardoso et al., 2003), but the 
concentrations required are possibly too high to explain the inhibition of MPT. It is also not 
possible to exclude that the antiestrogens bind to CypD, and inhibit the MPT in a similar 
way to CyA (Zoratti and Szabo, 1995). Therefore, the MPT inhibition by antiestrogens may 
be related with different effects exerted by these drugs on mitochondria. 
On the other hand, retinoids (retinol, RA and its isomers 9-cis and 13-cis) induce 
mitochondrial swelling and decrease the ΔΨ of rat liver mitochondria. Their action is 
stimulated by calcium and inhibited by CyA, suggesting that retinoids are inducers of MPT 
pore opening (Rigobello et al., 1999; Notario et al., 2003; Klamt et al., 2005). The fact that 
RA binds to the ANT, decreasing its activity (Notario et al, 2003), can possibly explain the 
ability of retinoids to induce MPT. 
As discussed above, mitochondria are targets of RA and antiestrogens actions. It is 
plausible that the effects of both classes of compounds on mitochondrial bioenergetics and 
calcium homeostasis are closely related with the cases of hepatotoxicity observed in patients 
treated with these drugs, since mitochondrial dysfunction is widely recognized as a major 
mechanism underlying drug-induced liver injury (Labbe et al., 2008; Nadanaciva and Will, 
2009; Russmann et al., 2009). 
In fact, relatively high concentrations of TAM and its metabolites were detected in 
the liver (Lien et al., 1991), and patients with breast cancer treated with TAM had elevated 
plasma concentrations of aspartate aminotransferase, alanine aminotransferase or both (Liu 
et al., 2006). Moreover, hypertriglyceridemia and fatty liver were reported in approximately 
33 % of patients who took TAM (Liu and Yang, 2003; Sakhri et al., 2010), whereas 
nonalcoholic steatohepatitis is present in 2.2 % of the patients with breast cancer treated with 
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TAM (Saphner et al., 2009). Although TAM is a drug capable of inducing hepatotoxicity 
caused by mitochondrial dysfunction, it was not withdrawn from the market considering the 
favorable benefit-risk ratio, but it has received a Black Box warning from drug agencies 
(Labbe et al., 2008). It was also reported that retinoids induce hepatotoxicity, either during 
dietary supplementation (Stickel et al., 2011) or treatment of APL patients (de-Medeiros et 
al., 1998) and hypertriglyceridemia (Standeven et al., 1996). Moreover, vitamin A 
supplementation in rats induced slight enlargement of mitochondria (Leo et al., 1982), 
hepatic oxidative insult and mitochondrial dysfunction (de Oliveira et al., 2009), supporting 
the view that mitochondria are a target of retinoid toxicity. 
As the clinical utilization RA has been limited by its adverse effects (Zusi et al., 
2002), the development of combinations of drugs that can enhance RA therapeutic activity, 
while minimizing its toxic effects is highly desirable. The combination of RA with TAM has 
shown synergistic antitumor activity in breast cancer cells (Danforth, 2004; Wang et al., 
2007; Searovic et al., 2009; Koay et al., 2010). However, the combination of drugs, which 
have both been shown to be hepatotoxic, such as RA and TAM, can be a problem. For 
instance, retinol has been shown to potentiate acetaminophen-induced heptatoxicity in 
mouse models (Bray and Rosengren, 2001). Thus, the future use of RA in combination with 
antiestrogenic compounds should be carefully evaluated, and the study of the effects of these 
combinations on liver mitochondrial functions can help to predict the toxicity and, therefore, 
the value of this therapeutic association. 
 
1.6 - Aims and structure of the dissertation 
 
Malignant melanoma is the most aggressive form of skin cancer and its incidence 
is rapidly increasing. Given the poor prognosis for locally advanced and metastatic disease 
and the severe side effects induced by the currently available therapies, more effective and 
less toxic therapeutic strategies are urgently required.  
The antiestrogen TAM is widely used in the treatment of ER+ breast carcinoma, 
but has also been used in the management of malignant melanoma individually or, more 
commonly, in therapeutic association. However, TAM induces multiple effects on 
mitochondrial functions that may account for the hepatotoxicity and the alterations in lipid 
metabolism frequently observed in patients treated with TAM. Meanwhile, the benefits of 
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the inclusion of TAM in therapeutic regimens and its mechanism of action in melanoma 
remain unclear. Recent studies demonstrate that the efficacy of TAM in breast cancer is 
limited by CYP2D6 polymorphisms or by the coadministration of medication acting as a 
CYP2D6 inhibitor or inducer, suggesting that the use of an active metabolite instead of the 
prodrug may present strong therapeutic advantages. On the other hand, considering the 
heterogeneity and the plasticity of melanoma, it is unlikely that a single agent can provide a 
significant response in most patients. The combination of drugs can possibly allow to 
achieve therapeutic efficacy in melanoma with lower concentrations, this way minimizing 
the adverse effects typical of systemic chemotherapy. Therefore, in the present dissertation 
we aimed to investigate whether EDX, a key active metabolite of TAM, is a less toxic drug 
in cancer therapy and a more effective alternative to TAM in the management of melanoma, 
either individually or in combination with the retinoid RA or with the NMDAR antagonist 
MK-801. 
Since the study of the effects of drugs on mitochondrial function has gained 
recognition as an important part of the preclinical evaluation of drug safety, the effects of 
EDX on rat liver mitochondria were evaluated, either individually or in combination with 
RA.  
The effects of EDX on mitochondrial bioenergetics, MPT and oxidative stress were 
monitored and compared to those promoted by TAM and OHTAM. Our results demonstrate 
that EDX only compromises mitochondrial bioenergetics functions at concentrations much 
higher than those reached in patient tissues, suggesting that EDX is less toxic to 
mitochondria than TAM. Moreover, similarly to TAM and OHTAM, EDX prevents the MPT 
pore opening induced by calcium and phosphate. These results were published in Toxicol. 
Appl. Pharmacol. 267, 104-112 and are presented in chapter II. 
It has been reported that mitochondria are implicated in the pharmacological actions 
of RA, namely in the inhibition of the proliferation of melanoma cells, as well as in the 
differentiation and suppression of the proliferation of neuroblastoma cells, and the induction 
of MPT has also considered a possible strategy to trigger cancer cell death. On the other 
hand, the utilization of RA is limited due to its several side effects, including hepatotoxicity 
and hypertriglyceridemia, which are related with mitochondrial dysfunction.  
Since the combinations of RA with TAM demonstrated a synergism of action in 
breast cancer cells and our results demonstrate that EDX promotes less deleterious effects 
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on mitochondria, we evaluated the effects of EDX in combination with RA on mitochondrial 
bioenergetic functions, MPT and oxidative stress, providing relevant mechanistic 
information regarding the pharmacological action and the potential toxicity of this 
combination. The effects of EDX in combination with RA were also compared to those 
promoted by the association of RA with TAM and OHTAM. Our results show that RA 
compromises mitochondrial bioenergetics in a concentration-dependent manner, but its 
effects are not enhanced by EDX. Moreover, EDX similarly to the other antiestrogens 
prevents the MPT induced by RA. These results were published in Life Sci. 93, 96-107 and 
are presented in chapter III. 
As EDX at the concentrations reached in patient tissues does not significantly affect 
mitochondrial functions and decreases the toxicity of RA through the inhibition of MPT, we 
monitored the effects of EDX in combination with RA on melanoma cell proliferation and 
migration and compared to those promoted by the combination with TAM. Furthermore, the 
effects of these combinations on endothelial cells were also evaluated to provide the first 
clues on the potential toxicity for non-neoplasic cells of the combinations of RA with 
antiestrogenic compounds. The data obtained demonstrate that EDX is more effective than 
TAM in the inhibition of melanoma cell biomass. The combination of this metabolite with 
RA enhances the antiproliferative effect induced by each drug individually, by blocking cell 
cycle progression in G1 phase, and decreases the migration of melanoma cells without 
significant toxicity in normal cells. The results were published in the Eur. J. Pharmacol. 
715, 354-362 and are presented in chapter IV. 
There are strong evidences suggesting that glutamate plays an important role in the 
regulation of tumor cells proliferation. Accordingly, NMDAR antagonists limit the 
proliferation of several non-neuronal cancers, including melanoma, and enhance the effects 
of cytostatic drugs. Thus, the effects of iGluR antagonists on melanoma cells proliferation 
were monitored and the NMDAR antagonist MK-801 was selected for further studies in 
combination with antiestrogenic compounds. The antiestrogens EDX, TAM and OHTAM 
combined with MK-801 potentiate the antiproliferative effect induced by the compounds 
individually and the combinations with EDX or OHTAM were able to block cell cycle 
progression in G1. These results were submitted for publication in Exp. Dermatol. and are 
presented in chapter V. 
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In spite of the several studies conducted up to now, the inclusion of TAM in 
melanoma therapeutic regimens remains controversial. Our results demonstrate that EDX is 
a more powerful cytostatic in melanoma than TAM, suggesting that the variability in TAM 
metabolism can affect the treatment outcome in melanoma, as demonstrated in breast cancer. 
However, the mechanisms of action of antiestrogens in melanoma remain poorly defined 
after several years of research and it is possible that certain patients, according to the specific 
traits of their lesions, can benefit from the treatment with antiestrogens, while others do not. 
Therefore, it is a matter of crucial importance the identification of the action mechanisms of 
antiestrogens in melanoma and the clarification for the superior cytostatic activity of EDX 
over TAM. The identification of the GPR30 as a new ER, which can be activated by TAM 
and OHTAM, led us to investigate the expression and the role played by GPR30 in 
melanoma cells. Our study demonstrates that K1735-M2 melanoma cells express GPR30 
and its activation by the selective agonist G-1 markedly decreases melanoma cell 
proliferation. Therefore, this work identifies GPR30 as a new target in melanoma therapy 
that is possibly involved in the antiproliferative effects promoted by antiestrogens. On the 
other hand, considering the intracellular signaling pathways commonly involved in cell 
proliferation, EDX was the only compound that was able to induce a significant decrease in 
ERK 1/2 activation in our experimental setting, which can contribute to explain the higher 
efficacy of EDX in the reduction of melanoma cell proliferation when compared with TAM. 
These results are shown in chapter VI and are presented as a manuscript for future 
publication. 
 
Thus, EDX may represent an advantageous therapeutic alternative to TAM in the 
management of malignant melanoma, either individually or in association, which is a new 
indication for this drug that is already being tested in humans. 
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CHAPTER II 
 
 
 
THE ANTIESTROGEN ENDOXIFEN PROTECTS RAT LIVER 
MITOCHONDRIA FROM PERMEABILITY TRANSITION PORE 
OPENING AND OXIDATIVE STRESS AT CONCENTRATIONS 
THAT DO NOT AFFECT THE PHOSPHORYLATION EFFICIENCY 
 
 
 
 
 
 
[Ribeiro, M.P., Silva, F.S., Santos, A.E., Santos, M.S. and Custódio, J.B. 
(2013) The antiestrogen endoxifen protects rat liver mitochondria from 
permeability transition pore opening and oxidative stress at 
concentrations that do not affect the phosphorylation efficiency. 
Toxicol. Appl. Pharmacol. 267, 104-112] 
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Abstract  
 
Endoxifen (EDX) is a key active metabolite of tamoxifen (TAM) with higher 
affinity and specificity to estrogen receptors that also inhibits aromatase activity. It is safe 
and well tolerated by healthy humans, but its use requires toxicological characterization. In 
this study, the effects of EDX on mitochondria, the primary targets for xenobiotic-induced 
toxicity, were monitored to clarify its potential side effects. EDX up to 30 nmol/mg protein 
did not affect the mitochondrial oxidative phosphorylation. At 50 nmol EDX/mg protein, 
EDX decreased the ADP phosphorylation rate and a partial collapse of mitochondrial 
membrane potential (ΔΨ), that parallels a state 4 stimulation, was observed. As the 
stimulation of state 4 was not inhibited by oligomycin and 50 nmol EDX/mg protein caused 
a slight decrease in the light scattering of mitochondria, these data suggest that EDX 
promotes membrane permeabilization to protons, whereas TAM at the same concentration 
induced mitochondrial membrane disruption. Moreover, EDX at 10 nmol/mg protein 
prevented and reversed the Ca2+-induced depolarization of ΔΨ and the release of 
mitochondrial Ca2+, similarly to cyclosporine A, indicating that EDX did not affect Ca2+ 
uptake, but directly interfered with the proteins of the mitochondrial permeability transition 
(MPT) megacomplex, inhibiting MPT induction. At this concentration, EDX exhibited 
antioxidant activity that may account for the protective effect against MPT pore opening. In 
conclusion, EDX within the range of concentrations reached in tissues did not significantly 
damage the bioenergetic functions of mitochondria, contrarily to the prodrug TAM, and 
prevented the MPT pore opening and the oxidative stress in mitochondria, supporting that 
EDX may be a less toxic drug for women with breast carcinoma.  
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2.1 - Introduction  
 
Introduced in the market 30 years ago, tamoxifen (TAM) remains the standard 
endocrine therapy for the treatment of estrogen receptor (ER)-positive breast cancer. 
However, TAM utilization has been questioned due to its carcinogenic action on uterus and 
endometrium and many women experience hot flushes (Henry et al., 2009), muscle aches 
and other symptoms that limit their compliance with treatment, resulting in increased rates 
of breast cancer recurrence (Thompson et al., 2011).  
TAM is a prodrug that is extensively metabolised by cytochrome P450 (CYP) 
enzymes, namely CYP3A4 and CYP2D6, generating two active metabolites, 4-
hydroxytamoxifen (OHTAM) and endoxifen (EDX) (Kiyotani et al., 2012). In the last years, 
it was raised the possibility that CYP3A4 and CYP2D6 polymorphisms could explain the 
large variations among patients in both the therapeutic efficacy and side effects (Kiyotani et 
al., 2012). Recent studies confirmed an association between CYP2D6 variation and clinical 
outcome in women treated with TAM and indicated that coadministration of CYP2D6-
inhibiting medication diminishes the treatment efficacy of TAM (Kelly et al., 2010; 
Lammers et al., 2010). In fact, after 6 weeks of therapy with TAM, the steady-state levels 
are in the range of 24-317 ng/mL (Ingle et al., 1999). This important patient intervariability 
suggests that the same dose of TAM may not be suitable for all patients and that TAM may 
not be the appropriate drug for some patients (Ingle, 2008). On the other hand, TAM has 
been associated with cases of idiosyncratic liver injury (DeLeve, 2007) and different patterns 
of elevated liver enzymes have been observed in both human and animal models (Ching et 
al., 1992; Oien et al., 1999; Moreira et al., 2007). Moreover, approximately 33 % of patients 
who took TAM developed fatty liver and nonalcoholic steatohepatitis was present in 2.2 % 
of the patients with breast cancer treated with TAM (Saphner et al., 2009). Some patients 
also develop hepatic fibrosis, cirrhosis and hepatic necrosis (Storen et al., 2000; Farrel, 
2002). In addition, the damaging effects on the lipid metabolism may also account for the 
hypertriglyceridemia observed in some patients treated with TAM (Liu and Yang, 2003; 
Sakhri et al., 2010).  
It is plausible that the hepatotoxicity induced by TAM may be related with its 
effects on mitochondrial functions, as previous studies have described the multiple effects 
of TAM on liver mitochondria and emerging evidence points to an important role played by 
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mitochondrial dysfunction in drug-induced liver injury (Labbe et al., 2008). TAM has been 
shown to inhibit the mitochondrial permeability transition (MPT) promoted by different 
inducers (Custódio et al., 1998; Hernández-Esquivel et al., 2011a) and to affect the 
mitochondrial complex I, the respiration rate and the phosphorylation efficiency (Cardoso et 
al., 2001; Moreira et al., 2006). The impairment of the respiratory chain compromises the 
reoxidation of nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide 
(FADH2) into NAD
+ and FAD, respectively, which are required for the activity of several 
dehydrogenases of the Krebs cycle and the mitochondrial β-oxidation, leading to the 
inhibition of fatty acid oxidation and lipid metabolism alterations (Begriche et al., 2006; 
Rolo et al., 2012). Furthermore, the damaged respiratory chain will increase the 
mitochondrial reactive oxygen species (ROS) formation, which will induce lipid 
peroxidation and the release of aldehydic derivatives that promote deleterious effects on 
hepatocytes and other hepatic cells (Begriche et al., 2006; Rolo et al., 2012).  
EDX, a key active metabolite of TAM, presents a plasma concentration over 6-fold 
higher than that of OHTAM in breast cancer patients (Lee et al., 2003). Moreover, EDX has 
demonstrated to be 100 times more potent than TAM, and has a potency similar to that of 
OHTAM with respect to ER binding affinity, in suppression of estrogen-dependent cell 
growth and gene expression (Kiyotani et al., 2012). It has been reported that EDX targets 
ERα for degradation by the proteosome in breast cancer cells (Wu et al., 2009) and inhibits 
aromatase activity, which are mechanisms that may contribute to its efficacy in the treatment 
of breast cancer (Lu et al., 2012). Importantly, EDX demonstrated the ability to inhibit the 
growth of human mammary tumor xenografts in female mice (Ahmad et al., 2010a). 
Additionally, in healthy human subjects orally administered EDX was safe and well tolerated 
(Ahmad et al., 2010b). According to the pharmacokinetic studies performed by Ahmad et al 
(2010b), EDX reaches systemically effective levels in human subjects and the authors 
propose that multiple daily doses of 2.0-4.0 mg of EDX would result in EDX exposures that 
would be similar to those found in patients with normal CYP2D6 function who are 
administered TAM at 20 mg/day. Altogether, these data suggest that the use of EDX would 
be a possible strategy to overcome TAM limitations. However, the available information 
regarding the potential toxic effects of EDX on mitochondria is very limited at the moment. 
Therefore, the aim of this study was to investigate the effects of EDX on 
mitochondrial bioenergetic functions, MPT and oxidative stress, in order to understand the 
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potential toxic effects induced by EDX in relation to the effects promoted by TAM and 
OHTAM, which will provide new evidences that can contribute to the safe use of EDX in 
breast cancer therapy. To achieve our goal, we have evaluated several mitochondrial 
parameters from the respiratory chain (states 3 and 4 of respiration, respiratory control ratio 
(RCR) and ADP/O index) and oxidative phosphorylation system [transmembranar potential 
(ΔΨ), depolarization induced by ADP, lag phase and active adenine nucleotide translocase 
(ANT) content]. Moreover, we have studied the susceptibility of mitochondria to MPT pore 
opening and the effects of EDX on the oxidative stress evaluated by oxygen consumption 
and thiobarbituric acid reactive substances (TBARS) levels. 
 
2.2 - Materials and methods 
 
Animals 
Wistar rats (250-350g), of either sex, were maintained at 22 ± 2 ºC under artificial 
light for 12 h light/dark cycle and with access to water and food ad libitum. The experiments 
reported here were carried out in accordance with the National Requirements for Vertebrate 
Animal Research and in accordance with the European Convention for the Protection of 
Animals used for Experimental and other Scientific Purposes.  
 
Isolation of rat liver mitochondria 
Mitochondria were isolated from the liver of Wistar rats as previously described 
(Custódio et al., 1998). Briefly, liver was quickly removed from decapitated rats, finely 
minced and homogenized in an ice-cold homogenization medium containing 250 mM 
sucrose, 10 mM 4-(2-hydroxymethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4, 1 
mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’-tetra-acetic acid (EGTA), and 0.1 
% (w/v) bovine serum albumin (BSA). The homogenate was centrifuged at 800×g for 10 
min and mitochondria were recovered from the supernatant by centrifugation at 10 000×g 
for 10 min. The mitochondrial pellet obtained was suspended twice in the final washing 
medium, i.e., homogenization medium adjusted to pH 7.2, in the absence of EGTA and BSA. 
All the procedures were performed at 0-4 °C. Mitochondrial protein concentration was 
determined by the Biuret method using BSA as the protein standard. 
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Mitochondrial membrane potential (ΔΨ) 
Mitochondrial membrane potential (ΔΨ) was assessed by measuring the 
movements of the lipophilic cation tetraphenylphosphonium (TPP+) across the 
mitochondrial membrane with a TPP+ selective electrode and using a Ag/AgCl2 electrode as 
reference (model MI 402; Microelectrodes, Inc., Bedford, NH). The reactions were carried 
out in an open vessel with magnetic stirring in 2 mL of the standard respiratory medium 
containing 130 mM sucrose, 50 mM KCl, 5 mM MgCl2, 0.1 mM EGTA, 5 mM KH2PO4, 5 
mM HEPES, pH 7.4, supplemented with 3 µM TPP+ and glutamate/malate (5 mM/2.5 mM), 
at 37 °C. The assays were initiated by adding 1 mg of mitochondrial protein and the potential 
difference between the selective electrode and the reference electrode was measured with an 
electrometer and recorded continuously with a suitable recorder as described elsewhere 
(Moreira et al., 2007). After a steady-state distribution of TPP+ had been reached (ca. 1 min 
of recording), different concentrations of EDX were added to the reaction medium and 
allowed to incubate for 3 min prior the addition of ADP (250 nmol/mg protein). The voltage 
response of the TPP+ electrode to log [TPP+] was linear with a slope of 59 ± 1, in a good 
agreement with the Nernst equation. The ΔΨ was estimated by the following equation: ΔΨ 
= 59 × log(v/V) – 59 × log (10ΔE/59 − 1), where v, V, and ΔE stand for inner mitochondrial 
volume, incubation medium volume and deflection of the electrode potential from the 
baseline, respectively. A matrix volume of 1.1 μl/mg of protein was assumed. 
 
Mitochondrial respiration 
Oxygen consumption of isolated liver mitochondria was assessed polarographically 
with a Clark-type oxygen electrode (YSI model 5331, Yellow Spring Inst.) connected to a 
suitable recorder in a 1 mL thermostatted water-jacket closed chamber with magnetic stirring 
(Moreira et al., 2006). Liver mitochondria (1 mg) were suspended in 1 mL of standard 
respiratory medium containing 130 mM sucrose, 50 mM KCl, 5 mM MgCl2, 0.1 mM EGTA, 
5 mM KH2PO4, 5 mM HEPES, and pH 7.4, at 37 °C. Respiration was initiated upon addition 
of 10 mM glutamate/5 mM malate (state 2) and 250 nmol/mg protein of ADP was added to 
induce state 3 respiration. After phosphorylation of all the added ADP, the oxygen 
consumption rate decreased and state 4 respiration was resumed. The state 4 in the presence 
of oligomycin (state 4 olig) was induced by the addition of oligomycin (1 µg/mg protein) to 
evaluate the proton leak through the Fo fraction of complex V. The mitochondrial suspension 
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was incubated in the absence (control) and in the presence of different concentrations of 
EDX for 3 min before starting the reactions. Respiration rates were calculated assuming an 
oxygen concentration of 240 nmol O2/mL. The RCR was calculated as the ratio between 
state 3 (consumption of oxygen in the presence of substrate and ADP) and state 4 
(consumption of oxygen after ADP phosphorylation), and it is considered an indicator of 
mitochondrial membrane integrity. The ADP/O ratio is the number of ADP molecules added 
to the medium per oxygen atom consumed during phosphorylation, and it is an index of 
oxidative phosphorylation efficiency.  
For monitoring the active adenine nucleotide translocase (ANT) content, 
mitochondria were titrated with carboxyatractyloside (CATR) (Vignais, 1976). 
Mitochondria (0.5 mg) were incubated in 1 mL of standard reaction medium (200 mM 
sucrose, 5 mM KH2PO4, 20 mM Tris-HCl, pH 7.4). The active ANT content was determined 
by titrating the rate of state 3 respiration with increasing concentrations of CATR (Vignais, 
1976). Oxygen consumption rate was evaluated at 25 °C using a closed chamber fitted with 
a Clark-type oxygen electrode as described above. Mitochondria were incubated in the 
absence or presence of EDX and 3 min later CATR was added to mitochondria. After the 
incubation period, the reactions were started by the addition of 10 mM glutamate/5 mM 
malate and state 3 respiration was initiated by adding 0.2 mM ADP. Plots of O2 consumption 
versus CATR concentration are biphasic, with an increasing inhibitory effect followed by a 
steady-state effect which corresponds to the complete inhibition of state 3 respiration. The 
amount of CATR corresponding to complete inhibition of state 3 respiration was used to 
estimate the active ANT content assuming a 1:1 binding stoichiometry. The active ANT 
content was expressed as CATR amount per mg of mitochondrial protein (pmol CATR/mg 
protein) (Cardoso et al., 2003).  
 
Mitochondrial swelling  
Mitochondrial osmotic volume changes were followed by monitoring the decrease 
in absorbance (light scattering) at 540 nm with a Perkin Elmer, Lambda 45 UV/VIS 
spectrometer. The reactions were conducted at 25 °C with 1 mg mitochondrial protein in 2 
mL of standard MPT reaction medium containing 200 mM sucrose, 10 mM Tris-3-[N-
Morpholino]propanesulfonic acid (Mops), 1 mM KH2PO4, 10 μM EGTA, 3 μM rotenone 
and 3 µM TPP+, pH 7.4, in the presence of substrate (5 mM glutamate/2.5 mM malate). 
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Different concentrations of EDX, TAM (50 nmol/mg protein), OHTAM (50 nmol/mg 
protein) and Triton X-100 (0.01 %) were added to mitochondrial suspension after 3 minutes 
of recording (Cardoso et al., 2002a). 
 
Measurements of mitochondrial permeability transition pore (MPT) 
The Ca2+-dependent MPT was characterized by the evaluation of ΔΨ dissipation 
and Ca2+ fluxes as previously described (Custódio et al., 1998). For the ΔΨ determination, 
mitochondria (0.5 mg/mL) were suspended in 2 mL of standard MPT reaction medium 
containing 200 mM sucrose, 10 mM Tris-Mops, 1 mM KH2PO4, 10 μM EGTA, 3 μM 
rotenone and 3 µM TPP+, pH 7.4, at 30 °C and energized with 5 mM succinate. After 
reaching a steady-state distribution of TPP+, Ca2+ was added (90-120 nmol/mg protein, 
depending on mitochondrial preparation) and ΔΨ was measured as described above. EDX 
and cyclosporine A (CyA) were incubated for 3 min with mitochondria before the addition 
of succinate or after mitochondrial loading with Ca2+, as indicated in the figure legends.  
The mitochondrial Ca2+ uptake and release was monitored using the fluorescence 
probe Calcium Green 5-N (Moreira et al., 2007). Fluorescence was recorded continuously 
at 30 °C, using a Perkin Elmer LS 50B luminescence spectrometer with excitation and 
emission wavelengths of 506 and 531 nm, respectively. Liver mitochondria (0.5 mg protein) 
were suspended in 2 mL of standard MPT reaction medium supplemented with 3 µM 
rotenone and 100 nM calcium green. Mitochondria were energized with 5 mM succinate 
after 1 min of Ca2+ addition (90-120 nmol/mg protein), in the absence (control) or in the 
presence of EDX and CyA. In other experiments, EDX and CyA were added after Ca2+ and 
succinate energization, as indicated in the figure legends. 
 
Evaluation of oxidative stress 
Oxidative stress was evaluated by oxygen consumption monitored 
polarographically at 30 °C using a Clark-type oxygen electrode (YSI Model 5331, Yellow 
Springs Inst) placed in a glass chamber equipped with magnetic stirring (Moreira et al., 
2007). Reactions were carried out in 1 mL of reaction medium containing 175 mM KCl, 10 
mM Tris, pH 7.4 and 1 mg of liver mitochondria. The reactions were started by the addition 
of ADP/Fe2+ (1 mM/0.1 mM) and the changes in oxygen tension calculated assuming a 
concentration of 240 nmol O2/mL in the experimental medium at 30 °C. EDX was incubated 
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with mitochondria for 3 min before the addition of ADP/Fe2+. In parallel, the extent of lipid 
peroxidation was determined by measuring TBARS, using the thiobarbituric acid assay, 
according to a modified procedure as described elsewhere (Santos et al., 2001). The amount 
of TBARS formed was calculated using a molar extinction coefficient of 1.56 × 105 M− 1 
cm− 1 and expressed as percentage of control.  
 
Statistical analysis 
The results are presented as mean ± S.E.M. of the indicated number of experiments. 
Statistical significance between the different assays was determined using the one-way 
analysis of variance (ANOVA), followed by the Tukey post-test, for multiple comparisons. 
A p value <0.05 was considered statistically significant.   
 
2.3 - Results 
 
To assess whether EDX affects mitochondrial bioenergetic functions, we evaluated 
the ΔΨ fluctuations associated with the phosphorylation cycle induced by ADP, using 
glutamate/malate as substrate. Additionally, the effects induced by EDX were also compared 
to those induced by the prodrug, TAM, and the other active metabolite, OHTAM. The range 
of EDX concentrations used allows for a full characterization of the compound from the 
absence to the maximum effects. The figure 2.1 represents a typical recording of the 
phosphorylation cycle induced by ADP, and the table underneath shows the mean ± S.E.M. 
of the indicated parameters. As observed in figure 2.1, mitochondria energized with 
glutamate/malate, in the absence of EDX (control), developed a ΔΨ of 219.9 ± 1.3 mV 
(negative inside) and the addition of ADP dropped the ΔΨ in 21.2 ± 1.2 mV (ADP 
depolarization). The time required for the phosphorylation of ADP (lag phase) was 71.7 ± 
3.6 s and after ADP phosphorylation, the ΔΨ returned to −217.7 ± 1.5 mV (repolarization 
ΔΨ), which is close to its initial value. In the range of 5-30 nmol/mg protein, EDX did not 
significantly affect the phosphorylation cycle induced by ADP (Fig. 2.1). At 50 nmol/mg 
protein, EDX significantly increased the phosphorylation lag phase and decreased the ΔΨ 
developed after substrate energization, as well as the repolarization ΔΨ, but the ADP 
depolarization was not significantly affected (Fig. 2.1). At 70 nmol/mg protein, EDX 
markedly decreased both the ΔΨ developed after substrate energization and the 
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repolarization ΔΨ, whereas the phosphorylation lag phase increased (Fig. 2.1). The effects 
induced by 20 nmol/mg protein of EDX were then compared to those induced by the same 
concentration of TAM and OHTAM (Fig. 2.1). OHTAM at 20 nmol/mg protein did not 
present significant effects on the phosphorylation cycle induced by ADP, similarly to EDX 
(Fig. 2.1). In contrast, TAM at 20 nmol/mg protein significantly depressed the ΔΨ developed 
after substrate energization and the repolarization ΔΨ, and increased the phosphorylation lag 
phase (Fig. 2.1). 
The effects of EDX on mitochondrial bioenergetics were also investigated by the 
analysis of several respiration parameters (Fig. 2.2). As shown figure 2.2, respiration was 
initiated by adding glutamate/malate (state 2 respiration). When 250 nmol/mg protein of 
ADP was added, the rate of oxygen consumption increased (state 3 respiration) and after the 
phosphorylation of all the added ADP, the oxygen consumption rate decreased and state 4 
respiration was resumed. The state 4 respiration in the presence of oligomycin (state 4 olig) 
was induced by the addition of oligomycin, in order to assess the proton leak through the Fo 
fraction of complex V. EDX between 5 and 30 nmol/mg protein did not significantly affect 
the respiration parameters, except the RCR, which is decreased as a consequence of both the 
stimulation of state 4 and the inhibition of state 3 respiration (Fig. 2.2). At 50 nmol/mg 
protein, EDX significantly decreased the state 3 and stimulated the state 4 respiration, 
significantly decreasing the RCR ratio (Fig. 2.2), in agreement with the results obtained in 
the ΔΨ associated to mitochondrial respiration and the phosphorylation lag phase (Fig. 2.1). 
We have also observed that the stimulation of state 4 was not inhibited in the presence of 
oligomycin (Fig. 2.2). The stimulation of state 4 is followed by a pronounced decrease in the 
states 3 and 4 respiration at 70 nmol/mg protein (Fig. 2.2). The effects induced by 20 
nmol/mg protein of EDX on respiration parameters were also compared to those induced by 
the same concentration of TAM and OHTAM (Fig. 2.2). OHTAM at 20 nmol/mg protein 
did not present significant effects on the respiration parameters, except for the RCR, 
similarly to EDX (Fig. 2.2). In contrast, at 20 nmol/mg protein, TAM significantly 
stimulated the state 4 respiration and diminished the state 3, the ADP/O ratio and the RCR 
(Fig. 2.2). Is it noteworthy that the RCR of TAM and its metabolites was significantly 
depressed above 20 nmol/mg protein, but as expected, TAM induced a more pronounced 
decrease of the RCR, reflecting the more intense effects on both state 3 and state 4 respiration 
(Fig. 2.2).  
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Fig. 2.1 - Effect of EDX on the mitochondrial transmembrane potential (ΔΨ). The reactions 
were started by adding 1 mg of mitochondrial protein (Mitoc) to 2 mL of the standard 
respiratory medium, supplemented with 3 µM TPP+ and glutamate/malate (5 mM/2.5 mM). 
After a steady-state distribution of TPP+ had been reached (ca. 1 min of recording), different 
concentrations of EDX were added to the reaction medium and allowed to incubate for 3 
min prior the addition of ADP (250 nmol/mg protein). The traces are typical recordings 
representative of several experiments obtained in the absence of drugs (control), and in the 
presence of different EDX concentrations (nmol/mg protein) indicated by the numbers 
adjacent to traces. The table underneath shows the mean ± S.E.M. of membrane potential 
and phosphorylation time at the indicated concentrations of EDX, TAM and OHTAM. *** 
p<0.001, * p<0.05 when compared with control. The results are the mean ± S.E.M. of four 
independent experiments. 
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Fig. 2.2 - Effect of EDX on respiration parameters of rat liver mitochondria. Mitochondria 
(1 mg) in 1 mL of standard respiratory medium were energized with 10 mM glutamate/5 
mM malate (Glu/Mal). ADP (250 nmol/mg protein) was added to induce state 3 respiration. 
Inhibition of state 3 respiration was induced by adding 2 µg/mL oligomycin (Olig). The 
mitochondrial suspension was incubated in the absence (control) and in the presence of 
different concentrations of EDX for 3 min before starting the reactions at 37 ºC. The traces 
are typical recordings representative of several experiments obtained in the absence of drugs 
(control), and in the presence of different EDX concentrations (nmol/mg protein) indicated 
by the numbers adjacent to traces. The table underneath shows the mean ± S.E.M. of 
respiratory parameters at the indicated concentrations of EDX, TAM and OHTAM. State 3, 
state 4, state olig are expressed in nmol O2/mg protein/min. *** p<0.001, ** p<0.01, * 
p<0.05 when compared with control. The results are the mean ± S.E.M. of six independent 
experiments. 
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In order to clarify the effects on ΔΨ and respiration rates induced by high 
concentrations of EDX, the mitochondrial membrane integrity was evaluated by following 
the decrease in light scattering at 540 nm of mitochondria in the presence of substrate (Fig. 
2.3). In control condition, the light scattering was sustained over 25 min (Fig. 2.3, trace a). 
At 25-50 nmol/mg protein (Fig. 2.3, traces b and c, respectively), EDX causes a small dose-
dependent decrease in light scattering, reflecting a slight direct effect of this drug on 
mitochondrial membrane integrity. This effect becomes more pronounced at 70 nmol/mg 
protein (Fig. 2.3, trace d), suggesting that high concentrations of this drug may compromise 
the integrity of mitochondrial membranes, interfering with their permeability. When we 
compare the effects on mitochondrial swelling induced by 50 nmol/mg protein of EDX, with 
the same concentration of OHTAM or TAM, it is possible to observe that EDX (Fig. 2.3, 
trace c) was the compound that least decreased the light scattering, followed by OHTAM 
(Fig. 2.3, trace e). Both metabolites presented significantly less effects than TAM (Fig. 2.3, 
trace f), which at 50 nmol/mg protein caused an extensive swelling of mitochondria, similar 
to that induced by triton X-100 (Fig. 2.3, trace g). 
The effect of EDX on Ca2+-induced MPT of rat liver mitochondria was also 
evaluated by monitoring Ca2+ release (Fig. 2.4) and ΔΨ dissipation (Fig. 2.5). As shown in 
figure 2.4A, mitochondria energized with succinate in the presence of Ca2+ (90-120 nmol/mg 
protein), rapidly release the accumulated Ca2+ to the reaction medium (Fig. 2.4A, control) as 
indicated by the increase in the fluorescence intensity. The coincubation with EDX (10 
nmol/mg protein) enables mitochondria to accumulate and sustain Ca2+, similarly to CyA, a 
specific and potent inhibitor of MPT (Fig. 2.4A). Moreover, EDX or CyA, when added after 
energization of mitochondria with succinate and loading with Ca2+, reverses the release of 
Ca2+ to the reaction medium, which is accumulated by mitochondria once again (Fig. 2.4B). 
To provide further evidence regarding the effects of EDX on Ca2+ homeostasis, we 
evaluated the effects of EDX on ΔΨ fluctuations associated with MPT induction (Fig. 2.5). 
Under succinate energization, mitochondria built up a potential of about −220 mV. In control 
conditions, upon addition of Ca2+ (90-120 nmol/mg protein), the potential drops, since the 
Ca2+ uniport consumes membrane potential to transport Ca2+ into mitochondria and returns 
to nearly its initial value, which is followed by an irreversible depolarization of mitochondria 
over the next 10 min (Fig. 2.5A). Mitochondria preincubated with either EDX (10 nmol/mg  
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Fig. 2.3 - Effects of EDX on mitochondrial swelling. Mitochondria (1 mg) were suspended 
in 2 mL of standard MPT reaction medium, at 25 ºC, energized with glutamate/malate (5 
mM/2.5 mM) and incubated in the absence (control, a) or in the presence of EDX at 25 (b), 
50 (c) and 70 (d) nmol/mg protein, added after 3 min of recording. Experiments with 
OHTAM (e) and TAM (f) at 50 nmol/mg protein were also performed. An experiment using 
Triton X-100 (g) was performed. The traces, obtained by following the light scattering at 
540 nm for 25 min, are typical of three separate experiments with different mitochondrial 
preparations. 
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Fig. 2.4 - Inhibitory effect of EDX on mitochondrial Ca2+ release associated with MPT 
induction. Freshly isolated mitochondria (0.5 mg protein) were suspended in 2 mL of 
standard MPT reaction medium, supplemented with 3 µM rotenone and 100 nM Calcium 
Green. Fluorescence was recorded continuously at 30 ⁰C, with excitation and emission 
wavelengths of 506 and 531 nm, respectively. After a stable baseline was obtained, Ca2+ (90-
120 nmol/mg protein) was added to the reaction medium, prior the energization with 5 mM 
succinate (Succ). EDX (10 nmol/mg protein) and CyA (1 µM) were preincubated with 
mitochondria for 3 min before starting the record (A) or added after mitochondria Ca2+ 
loading and energization with succinate, during the course of MPT, as indicated by the 
correspondingly labeled arrows (B). The traces are typical of three different mitochondrial 
preparations.  
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Fig. 2.5 - Inhibitory effect of EDX on Ca2+-induced mitochondrial membrane depolarization. 
Mitochondria (1 mg) were suspended in 2 mL of the standard MPT reaction medium, 
supplemented with 3 µM TPP+ and 3 µM rotenone. The reactions were started with 5 mM 
succinate (Succ) and Ca2+ (90-120 nmol/mg protein) was added after a steady-state 
distribution of TPP+ had been reached. Mitochondria were incubated for 3 min, at 37 ºC, in 
the absence (control) or in the presence of EDX (10 nmol/mg protein) or CyA (1 µM) (A). 
EDX (10 nmol/mg protein) or CyA (1 µM) was also added after Ca2+-induced membrane 
depolarization, where indicated by arrows (B). The traces are typical of three independent 
experiments with different mitochondrial preparations. 
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protein) or CyA are able to sustain the potential, as shown in Fig. 2.5A. Moreover, and in 
agreement with the effects on extramitochondrial Ca2+ movements (Fig. 2.4B), EDX 
reverses the Ca2+-induced membrane depolarization if added during depolarization of 
mitochondria (Fig. 2.5B). 
To clarify the mechanism underlying the ability of EDX to prevent the MPT 
induced by Ca2+ and phosphate, experiments that evaluate the effects of EDX on ANT 
activity (Fig. 2.6) and oxidative stress (Fig. 2.7) were carried out. The active ANT content 
in mitochondria can be estimated through titrations with CATR, an inhibitor of the 
mitochondrial ANT, which reacts with the ANT in a 1:1 stoichiometry (Vignais, 1976). The 
mitochondrial content of active ANT is determined by the amount of CATR required to 
reduce state 3 respiration to the state 4 respiratory rate, when CATR presumably saturates 
the translocase sites (Vignais, 1976). As shown in figure 2.6, in control conditions, the 
addition of 169.0 ± 8.6 pmol CATR/mg protein inhibited the ANT, i.e., mitochondria lost 
the ADP phosphorylative capacity and it was only observed the state 4 respiratory rate. When 
mitochondria were incubated with 20 nmol EDX /mg protein, ANT sites were saturated by 
the addition of 164.6 ± 8.3 pmol CATR/mg protein, similarly to control. In the presence of 
50 nmol EDX/mg protein the active ANT content was decreased to 131.0 ± 18.33 pmol 
CATR/mg protein. Consequently, the active ANT content was decreased by 50 nmol 
EDX/mg protein to approximately 78 % relatively to control (Fig. 2.6). Therefore, although 
EDX decreased the active ANT content of mitochondria in a concentration-dependent 
manner, this decrease was not significant at concentrations up to 50 nmol/mg protein and 
less drastic that those induced by TAM (Cardoso et al., 2003). 
The effects of EDX on oxidative stress induced by the pro-oxidant pair ADP/Fe2+ 
were evaluated by oxygen consumption (Fig. 2.7A) and TBARS formation (Fig. 2.7B). In 
the absence of EDX, after the addition of the pro-oxidant pair, it is possible to observe an 
initial phase characterized by slow oxygen consumption (lag phase). This lag phase probably 
reflects the time required for the generation of sufficient perferryl ion complex which is 
thought to initiate lipid peroxidation. The phase of slow oxygen consumption was followed 
by a rapid oxygen consumption phase that is probably related with the oxidation of the 
polyunsaturated fatty acid acyl chain of membrane phospholipids by ROS and, consequently, 
to the propagation of lipid peroxidation. EDX at concentrations up to 25 nmol/mg protein  
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Fig. 2.6 - Determination of mitochondrial active ANT content by titration of active 
respiration with carboxyatractiloside (CATR). A representative pattern of titration curves 
shows the method of estimation of the active ANT content (A). Mitochondria (0.5 mg) in 1 
mL of the standard reaction medium (200 mM sucrose, 5 mM KH2PO4, 20 mM Tris-HCl, 
pH 7.4) were preincubated with different concentrations of CATR during 2 min, after a 
previous incubation for 3 min, in the absence (○) or in the presence of 20 (Δ) and 50 nmol 
EDX/mg protein (▲). The reaction was started by the addition of 0.2 mM ADP to initiate 
state 3 respiration and mitochondrial respiration rates were determined by oxygen 
consumption with a Clark-type electrode. The individual active ANT contents (B) were 
determined from the types of experiments as shown in (A) and are expressed as pmol 
CATR/mg mitochondrial protein. The values represent the mean ± S.E.M. of four 
mitochondrial preparations. 
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Fig. 2.7 - Protective effect of EDX on oxidative stress of rat liver mitochondria induced by 
the pro-oxidant pair ADP/Fe2+. Oxidative stress was evaluated by oxygen consumption (A) 
and TBARS assay (B). Mitochondria (1 mg) were suspended in 1 mL of medium containing 
175 mM KCl, 10 mM Tris, pH 7.4, supplemented with 3 µM rotenone and preincubated for 
3 min, at 37 ºC, in the absence (control) or in the presence of different EDX concentrations 
(nmol/mg protein), before initiating the reaction by adding 1 mM ADP/0.1 mM Fe2+. The 
traces in (A) represent typical direct recordings representative of four experiments obtained 
from different mitochondrial preparations. Ten min after the addition of ADP/Fe2+, aliquots 
of 0.5 mL of mitochondrial suspensions were collected and the amount of TBARS (B) was 
determined as described under Materials and methods section. The data, expressed as 
percentage of control, correspond to the mean ± S.E.M. of four independent experiments. 
*** p<0.001, * p<0.05 when compared with control. 
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enlarged the lag phase of slow oxygen consumption before oxygen uptake burst induced by 
the complex ADP/Fe2+, and decreased the rate of the rapid oxygen consumption phase, in a 
concentration-dependent manner, with a total inhibition of lipid peroxidation at 25 nmol/mg 
protein (Fig. 2.7A). In parallel to oxygen consumption experiments, the effects of EDX on 
lipid peroxidation were also monitored by TBA assay (Fig. 2.7B). Accordingly to oxygen 
consumption, 5 nmol EDX/mg protein diminished TBARS formation to approximately 63.9 
% of control (Fig. 2.7B). This effect of EDX was much more pronounced at 10 and 25 
nmol/mg protein that induced a decrease in TBARS levels to about 24.1 % and 7.2 % of 
control, respectively (Fig. 2.7B). 
 
2.4 - Discussion  
 
The disruption of mitochondrial bioenergetics plays an important role in the lethal 
cell injury induced by xenobiotics (Wallace and Starkov, 2000), and may account for the 
hepatotoxicity and the alterations in lipid metabolism observed in patients under therapy 
with TAM. As previously reported for TAM and OHTAM (Cardoso et al., 2001, 2002a), 
EDX increases the time required for ADP phosphorylation (Fig. 2.1) and decreases the state 
3 respiration and the RCR ratio (Fig. 2.2). However, the effects on the phosphorylation lag 
phase and on the state 3 respiration only become significant at 50 nmol/mg protein of EDX, 
indicating that at concentrations above those reached in tissues (Lien et al., 1991; Borges et 
al., 2006) EDX depresses the phosphorylation capacity of mitochondria. Additionally, EDX 
at 50 nmol/mg protein induces a partial collapse of ΔΨ (Fig. 2.1) that parallels with an 
increase of state 4 respiration (Fig. 2.2). As the stimulatory effect on state 4 is not inhibited 
in the presence of oligomycin (Fig. 2.2), the effects on state 4 and on ΔΨ are not related with 
a proton leak through the Fo fraction of complex V. Considering that EDX at 50 nmol/mg 
protein decreases the light scattering of mitochondria, our data suggest that high 
concentrations of EDX promote membrane permeabilization to protons (Fig. 2.3). At 70 
nmol EDX/mg protein, the state 4 respiration (Fig. 2.2) and the ΔΨ developed after substrate 
energization, as well as the repolarization of ΔΨ (Fig. 2.1), are markedly diminished. Since 
a pronounced swelling of mitochondria is observed at this concentration (Fig. 2.3), the 
decrease in state 4 respiration and in ΔΨ is probably related with the disruption of 
mitochondrial membrane. However, TAM at 50 nmol/mg protein already promotes a much 
Effects of Endoxifen on liver mitochondria ____________________________________________________  
96 
more potent proton leak than that induced by EDX at 70 nmol/mg protein, indicating that 
EDX, as reported for OHTAM (Cardoso et al., 2002a), mildly affects membrane integrity, 
in comparison with TAM. This piece of information may be relevant when one considers 
that TAM disrupts unspecifically the structure of model membranes and that this lack of 
specificity may be responsible for several side effects. In fact, the hemolytic anemia caused 
by TAM was associated with the disruption of erythrocyte membrane (Cruz Silva et al., 
2000), while high concentrations of OHTAM induced hemolysis in a smaller extent than 
TAM (Cruz Silva et al., 2001). Therefore, the fact that EDX only compromises membrane 
integrity at higher concentrations than those observed with TAM suggests that the therapy 
with EDX may present less unspecific effects than the treatment with TAM. 
Deregulation of Ca2+ homeostasis has long been implicated in cell injury (Bernardi 
and von Stockum, 2012). This work demonstrates that EDX prevents the release of the 
mitochondrial accumulated Ca2+ (Fig. 2.4A) and the Ca2+-dependent membrane 
depolarization (Fig. 2.5A), similarly to CyA, a specific and potent inhibitor of the MPT, 
suggesting that EDX is an inhibitor of Ca2+-induced MPT. Furthermore, the protection 
against Ca2+-dependent MPT afforded by EDX is observed either when the drug is added 
before (Figs. 2.4A and 2.5A) or after (Figs. 2.4B and 2.5B) energization of mitochondria 
with succinate and loading with Ca2+. These evidences suggest a direct effect on the proteins 
that form the MPT complex, and exclude a possible interference with Ca2+ uptake across the 
uniport or other mitochondrial effects. Similar effects on MPT inhibition have already been 
reported for TAM (Custódio et al., 1998) and the other TAM active metabolite, OHTAM 
(Cardoso et al., 2002b). 
In spite of the extensive research carried out in the last years, the composition of 
the MPT pore remains controversial. It is now considered that the cyclophilin D (CypD) is 
the only essential component of the MTP pore complex, and that the ANT plays a regulatory 
role (Javadov et al., 2009). Recently, the mitochondrial phosphate carrier has also been 
proposed as a possible key component (Leung et al., 2008). Therefore, in order to clarify the 
mechanism underlying the ability of EDX to inhibit the MPT induced by phosphate, the 
effects of EDX on the active ANT content were evaluated (Fig. 2.6). Titrations with CATR 
revealed that EDX, even at high concentrations (50 nmol/mg protein), does not significantly 
decrease the active ANT content (Fig. 2.6). Moreover, mitochondrial phosphorylation 
efficiency is only compromised at concentrations much higher than those required to inhibit 
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MPT (Figs. 2.1 and 2.2). According to these data, neither the ANT nor the phosphate carrier 
seems to be involved in the inhibition of MPT by EDX.  
An important factor contributing to the regulation of MPT pore opening is oxidative 
stress (Halestrap et al., 1997; Kushnareva and Sokolove, 2000). Considering that both TAM 
and OHTAM have been shown to scavenge peroxyl radicals (Custódio et al., 1994), and that 
TAM inhibits the MPT induced by pro-oxidants (Cardoso et al., 2004), we have investigated 
the ability of EDX to prevent oxidative stress. At concentrations that inhibit phosphate 
induced-MPT, EDX significantly inhibits oxidative stress (Fig. 2.7), suggesting that the 
MPT inhibition by EDX may be related with its antioxidant properties. However, other 
mechanisms may be involved in this effect and cannot be excluded at this point. 
A recent study has described the protective effect of TAM on the MPT induced by 
CATR, due to a diminution of membrane fluidity (Hernández-Esquivel et al., 2011a). TAM 
is a highly hydrophobic molecule that strongly partitions in biomembranes (Custódio et al., 
1991), affecting the dynamic properties of lipids (Custódio et al., 1993a; Kazanci and 
Severcan, 2007). Similar effects were reported for OHTAM (Custódio et al., 1993b). 
Although the effects of EDX on biomembranes have not yet been described, it is plausible 
that due to its structural resemblance with OHTAM, which has an additional N-methyl 
group, it may also affect membrane dynamics. This ability to interfere with membrane 
fluidity could lead to a configurational change of the ANT and explain the effects of EDX 
on MPT. On the other hand, another possible mechanism would be related with the 
interaction with CypD, inhibiting the pore assembly in a similar way to what was described 
for CyA (Zoratti and Szabo, 1995). Therefore, the MPT inhibition by EDX may be related 
with different effects exerted by this drug on mitochondria and further studies are required 
to clarify them.  
Therapeutic concentrations of EDX are in the 10-150 nM range (Borges et al., 
2006). However, tissue concentrations of EDX are higher, especially in breast tumors, where 
they appear to be 10-60 times more, i.e., above 10 µM (Lien et al., 1991). In our experiments, 
a concentration of 10 nmol/mg protein was used to inhibit MPT. At 0.25-0.5 mg protein/mL, 
this translates to 2.5-5 µM of EDX. Therefore, at therapeutic plasma concentrations, EDX 
levels in the tissues are probably above the concentration required to inhibit induction of the 
MPT. Furthermore, in our bioenergetic studies, the concentrations of EDX were between 5-
70 nmol/mg protein, which at 0.5-1 mg protein/mL, corresponds to 2.5-70 µM. Considering 
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that bioenergetic functions were only significantly affected by EDX at 50 nmol/mg protein 
(25-50 µM), it is possible that, within the range of concentrations found in breast cancerous 
tissue, EDX may not compromise mitochondrial bioenergetics, while inhibiting MPT. In 
fact, studies in healthy humans have shown that single oral doses of EDX are safe and well 
tolerated and allow to obtain effective systemic levels reliably (Ahmad et al., 2010b).  
In conclusion, this work demonstrates that EDX, in the range of concentrations 
reached in tissues, slightly affects the mitochondrial bioenergetic functions, in contrast with 
the deleterious effects of TAM on liver mitochondria. Moreover, at concentrations that do 
not affect the phosphorylation capacity of mitochondria and present antioxidant activity, 
EDX inhibits the MPT. These data suggest that the increased therapeutic benefit obtained 
from the administration of EDX instead of the prodrug TAM, by eliminating the 
interindividual variability associated with TAM metabolism and avoiding potential serious 
drug interactions, may be accompanied by a significant reduction on mitochondrial toxicity, 
which is closely related with the hepatotoxicity observed in patients treated with TAM. 
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Abstract  
 
The clinical utilization of the combinations of all-trans-retinoic acid (RA) with 
antiestrogens, which present synergism of action in breast cancer, has been limited by RA 
adverse effects, including hepatotoxicity, which may be related with mitochondrial damage. 
This work evaluated the effects of RA alone and in combination with the antiestrogen 
endoxifen (EDX) on liver mitochondria. Mitochondrial permeability transition (MPT) was 
assessed by using Calcium Green-5N fluorescence and a tetraphenylphosphonium selective 
electrode. Oxidative stress was evaluated by oxygen consumption and thiobarbituric acid 
method. Mitochondrial bioenergetic parameters were monitored by measuring oxygen 
consumption and mitochondrial membrane potential (ΔΨ). Osmotic volume changes of 
mitochondria were followed at 540 nm. EDX prevents the MPT induced by RA, allowing 
mitochondria preincubated with RA to accumulate Ca2+ and inhibiting the depolarization of 
ΔΨ. RA above 10 nmol/mg protein depresses the phosphorylation capacity of mitochondria, 
as shown by the increase in the time required for ADP phosphorylation as well as by the 
decrease in state 3 respiration. At 20 nmol/mg protein, RA decreases the ΔΨ and increases 
the state 4 respiration, suggesting that high concentrations of RA permeabilize the membrane 
to protons, possibly due to a proton leak through the Fo fraction of complex V. Moreover, 
the effects of RA on mitochondrial bioenergetics are not changed by EDX. RA-induced 
hepatotoxicity may be related with induction of MPT and alterations in bioenergetic 
parameters; the combination with EDX, which reduces mitochondrial dysfunction and 
synergistically potentiates the anticancer activity, may provide a safer therapeutic strategy. 
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3.1 - Introduction  
 
All-trans-retinoic acid (RA), the most abundant natural retinoid, has been widely 
used in the treatment of visual and skin conditions, such as acne and psoriasis (Bushue and 
Wan, 2010; Tang and Gudas, 2011). RA exhibits antiproliferative and proapoptotic activity, 
and its use has been extensively evaluated in cancer prevention and therapy (Zusi et al., 
2002; Xun et al., 2012). However, the severe side effects induced by RA, including skin 
toxicities, teratogenic effects and elevation of serum cholesterol and triglycerides, have been 
a major obstacle to its clinical utilization (Lee et al., 1993; Zusi et al., 2002; Warren and 
Griffiths, 2008). The combination of RA with other agents can possibly afford superior 
therapeutic benefit, while minimizing the side effects related with retinoid therapy. In fact, 
the effects of RA in combination with several agents, such as cisplatin, taxol and tyrosine 
phosphatase inhibitors, have been studied in a variety of cancer cell lines (Karmakar et al., 
2007; Liu et al., 2008; Clark et al., 2013). Noteworthy, the combination of RA with 
antiestrogenic compounds, namely tamoxifen (TAM), has revealed a synergistic action in 
breast cancer cell lines (Danforth, 2004; Wang et al., 2007; Searovic et al., 2009; Koay et 
al., 2010) and recent work has pointed to the interplay between retinoid and estrogen 
signaling in breast cancer (Rousseau et al., 2003; Hua et al., 2009; Ross-Innes et al., 2010), 
suggesting that the combination of RA with antiestrogens is a promising strategy for cancer 
therapy. 
Endoxifen (EDX), a key metabolite of TAM, is considered a promising anticancer 
agent, as it presents higher affinity and specificity to estrogen receptors (ER) than TAM 
(Lim et al., 2005) and its anticancer activity is not limited by CYP3A4 and CYP2D6 
polymorphisms or by the coadministration of CYP2D6 inducers or inhibitors (Kelly et al., 
2010; Lammers et al., 2010; Binkhorst et al., 2012). Furthermore, our recent studies 
demonstrate that, as observed in breast cancer cells, the combination of RA with EDX 
synergistically inhibits the proliferation of melanoma cells (Ribeiro et al., 2013a). Thus, 
studies that evaluate the contributing factors for the therapeutic efficacy and side effects of 
RA in combination with EDX are required.  
Mitochondria, implicated as key effectors in RA-mediated differentiation process 
(Xun et al., 2012) and in several cases of hepatotoxicity reported in the course of dietary 
supplementation with retinoids (Stickel et al., 2011) or during therapy with RA in acute 
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promyelocytic leukemia patients (de- Medeiros et al., 1998), may be involved in both the 
therapeutic action and toxic effects induced by RA. In fact, it has been reported that RA 
modulates gene expression through its receptors in mitochondria (Everts and Bernadier, 
2002) and induces mitochondrial permeability transition (MPT) pore opening (Rigobello et 
al., 1999; Notario et al., 2003). This phenomenon ultimately results in cell death and it is 
widely recognized as a mechanism of drug-induced liver injury (Nadanaciva and Will, 2009; 
Russmann et al., 2009) and may be closely related with the hepatotoxicity induced by RA. 
On the other hand, it has been reported that RA induces the disruption of the mitochondrial 
membrane (Stillwell and Nahmias, 1983), which may contribute to RA-induced 
hepatotoxicity, while EDX at the concentrations reached in tissues does not affect 
mitochondrial bioenergetic functions and inhibits the MPT induced by calcium and 
phosphate (Ribeiro et al., 2013b). However, the possible toxicity of this combination of 
drugs in mitochondria was not evaluated.  
Therefore, considering that RA and EDX treatment is likely to synergistically 
amplify their therapeutic potential, the effects of the combinations of RA with EDX on 
mitochondrial functions were investigated and compared to those promoted by RA in 
combination with TAM and the other TAM active metabolite, 4-hydroxytamoxifen 
(OHTAM). 
 
3.2 - Materials and methods 
 
Chemicals 
RA, EDX, TAM and OHTAM were purchased from Sigma-Aldrich Quimica SA 
(Sintra, Portugal). Calcium Green-5N was obtained from Life Technologies (Paisley, United 
Kingdom). All other chemicals were commercial products of the highest purity grade 
available. RA, TAM and OHTAM were dissolved in absolute ethanol and EDX was 
dissolved in dimethyl sulfoxide (DMSO). All other solutions were prepared in deionized 
ultrapure water.  
 
Animals 
Wistar rats (250-350g), of either sex, were maintained at 22 ± 2 ºC under artificial 
light for 12 h light/dark cycle and with access to water and food ad libitum. The experiments 
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reported here were carried out in accordance with the National Requirements for Vertebrate 
Animal Research (DL 129/92) and in accordance with the European Convention for the 
Protection of Animals used for Experimental and other Scientific Purposes (CETS no.123).  
 
Isolation of rat liver mitochondria 
Mitochondria were isolated from the liver of Wistar rats as previously described 
(Custódio et al., 1998). Briefly, liver was quickly removed from decapitated rats, finely 
minced and homogenized in an ice-cold homogenization medium containing 250 mM 
sucrose, 10 mM 4-(2-hydroxymethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4, 1 
mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’-tetra-acetic acid (EGTA), and 0.1 
% bovine serum albumin (BSA). The homogenate was centrifuged for 10 min at 800×g and 
mitochondria were recovered from supernatant by centrifugation at 10 000×g for 10 min. 
The mitochondrial pellet was resuspended twice in the final washing medium adjusted to pH 
7.2, in the absence of EGTA and BSA. All the previously described procedures were 
performed at 0-4 ºC. Mitochondrial protein was determined by the Biuret method (Gornall 
et al., 1949) using BSA as the protein standard. 
 
Measurements of mitochondrial permeability transition pore (MPT) 
The Ca2+-dependent MPT was characterized by Ca2+ fluxes evaluation and 
mitochondrial membrane potential (ΔΨ) dissipation as previously described (Custódio et al., 
1998; Moreira et al., 2007).  
The mitochondrial Ca2+ uptake and release was monitored using the fluorescence 
probe Calcium Green 5-N, as described elsewhere (Moreira et al., 2007). Fluorescence was 
recorded continuously at 37 °C, using a Perkin Elmer LS 50B luminescence spectrometer 
with excitation and emission wavelengths of 506 and 531 nm, respectively. Liver 
mitochondria (0.5 mg protein) were suspended in the standard MPT reaction medium, 
containing 200 mM sucrose, 10 mM Tris-3-[N-Morpholino]propanesulfonic acid (Mops), 1 
mM KH2PO4, 10 μM EGTA, pH 7.4, supplemented with 3 µM rotenone and 100 nM 
Calcium Green-5N. Then, before starting the reactions, mitochondria were incubated for 3 
min in the absence (control) and in the presence of RA (10 nmol/mg protein) alone and in 
combination with 1 µM of cyclosporine A (CyA) or with the antiestrogens EDX, TAM and 
OHTAM (10 nmol/mg protein). After a stable baseline was obtained (ca. 1 min of recording), 
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Ca2+ (60-80 nmol/mg protein) was added to the reaction medium and mitochondria 
energized with 5 mM succinate (ca. 2 min of recording).  
For the ΔΨ determination, mitochondria (1 mg protein) were suspended in the 
standard MPT reaction medium, supplemented with 3 μM rotenone and 3 µM 
tetraphenylphosphonium (TPP+), at 37 °C, and energized with 5 mM succinate. After 
reaching a steady-state distribution of TPP+, Ca2+ was added (60-80 nmol/mg protein) and 
ΔΨ was measured with a TPP+ selective electrode and using a Ag/AgCl2 electrode as 
reference (model MI 402; Microelectrodes, Inc., Bedford, NH) and estimated as previously 
described (Custódio et al., 1998; Moreira et al., 2007; Ribeiro et al., 2013b). Mitochondria 
were incubated in the absence (control) and in the presence of 5 nmol RA/mg protein alone 
or in combination with CyA (1 µM) or the antiestrogens EDX, TAM and OHTAM (10 
nmol/mg protein) for 3 min before the addition of succinate. In other experiments, CyA, 
EDX, TAM or OHTAM was added after Ca2+ loading as indicated in the figure legends. In 
experiments using the thiol group protecting agents, glutathione (GSH, 1 mM), N-acetyl-L-
cysteine (NAC, 200 µM) and cysteine (Cys, 200 µM), or the adenine nucleotide translocase 
(ANT) ligands, ADP (75 µM) and ATP (150 µM), these compounds were added to the 
reaction medium prior to the addition of RA and allowed to incubate for 3 min before starting 
the reactions.  
 
Evaluation of oxidative stress 
Oxidative stress was evaluated by oxygen consumption monitored 
polarographically at 37 °C using a Clark-type oxygen electrode (YSI Model 5331, Yellow 
Springs Inst) placed in a glass chamber equipped with magnetic stirring (Moreira et al., 
2007). Reactions were carried out in 1 mL of reaction medium containing 175 mM KCl, 10 
mM Tris, pH 7.4, supplemented with 3 µM rotenone and 1 mg protein of liver mitochondria. 
The reactions were started by the addition of ADP/Fe2+ (1 mM/0.1 mM) and the changes in 
oxygen tension calculated assuming a concentration of 240 nmol O2/mL in the experimental 
medium at 37 °C. Mitochondria were incubated without (control) and with RA (5-30 
nmol/mg protein) or in combination of RA (5 nmol/mg protein) with EDX (10 nmol/mg 
protein) for 3 min before the addition of ADP/Fe2+. Ten min after the addition of ADP/Fe2+, 
aliquots of 0.5 mL of mitochondrial suspensions were collected and the extent of lipid 
peroxidation was determined by measuring thiobarbituric acid reactive substances 
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(TBARS), using the thiobarbituric acid assay, modified as described elsewhere (Santos et 
al., 2001). The amount of TBARS was calculated using a molar extinction coefficient of 
1.56 × 105 M− 1 cm− 1 and expressed as percentage of control.  
 
Mitochondrial membrane potential  
The ΔΨ was monitored with a TPP+ selective electrode as described above. The 
reactions were carried out in an open vessel with magnetic stirring in the standard respiratory 
medium containing 130 mM sucrose, 50 mM KCl, 5 mM MgCl2, 0.1 mM EGTA, 5 mM 
KH2PO4, 5 mM HEPES, pH 7.4, supplemented with 3 µM TPP
+ and glutamate/malate (5 
mM/2.5 mM), at 37 °C. The assays were initiated by adding 1 mg of mitochondrial protein 
and after a steady-state distribution of TPP+ had been reached (ca. 1 min of recording), 
mitochondria were allowed to incubate for 3 min in the absence (control) or in the presence 
of different concentrations of RA (5-30 nmol/mg protein) or 5-20 nmol RA/mg protein in 
combination with the antiestrogens EDX, TAM and OHTAM at 10 nmol/mg protein, prior 
the addition of ADP (150-250 nmol/mg protein) (Custódio et al., 1998; Moreira et al., 2007).  
  
Mitochondrial respiration 
Oxygen consumption was assessed polarographically with a Clark oxygen 
electrode (YSI model 5331, Yellow Spring Inst.) connected to a suitable recorder in a 1 mL 
thermostatted water-jacket closed chamber with magnetic stirring (Moreira et al., 2006). 
Mitochondria (1 mg) were suspended in the standard respiratory medium, at 37 °C. State 2 
respiration was initiated with 10 mM glutamate/5 mM malate and ADP (150-250 nmol/mg 
protein) was added to induce the state 3 respiration. After phosphorylation of all the ADP, 
the oxygen consumption rate decreased and state 4 respiration was resumed. The state 4 in 
the presence of oligomycin (state 4 olig) was induced by the addition of oligomycin (1 
µg/mL) plus ADP to evaluate the proton leak through the Fo fraction of complex V (Moreira 
et al., 2011). The mitochondrial suspension was incubated in the absence (control) or in the 
presence of different concentrations of RA (5-30 nmol/mg protein) or 5-20 nmol RA/mg 
protein in combination with the antiestrogens EDX, TAM and OHTAM at 10 nmol/mg 
protein, for 3 min before starting the reactions. Respiration rates were calculated assuming 
an oxygen concentration of 240 nmol O2/mL. The respiratory control ratio (RCR) is 
calculated as the ratio between state 3 (consumption of oxygen in the presence of substrate 
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and ADP) and state 4 (consumption of oxygen after ADP phosphorylation). The ADP/O 
ratio is the number of ADP molecules added to the medium per oxygen atom consumed 
during phosphorylation (Ribeiro et al., 2013b). 
 
Mitochondrial swelling 
Mitochondrial osmotic volume changes were followed by monitoring the decrease 
in absorbance (light scattering) at 540 nm with a Perkin Elmer, Lambda 45 UV/VIS 
spectrometer (Cardoso et al., 2002a). The reactions were conducted at 25 ºC with 1 mg 
mitochondrial protein suspended in the standard MPT reaction medium. Mitochondria were 
incubated in the absence (control) or in the presence of RA (30 nmol/mg protein) or Triton 
X-100 (0.01 %), which was added to the mitochondrial suspension after 2 min of recording, 
as indicated in the figure legend. 
 
Statistical analysis 
The results are presented as mean ± S.E.M. of the indicated number of experiments. 
Statistical significance between the different assays was determined using the one-way 
analysis of variance (ANOVA), followed by the Tukey post-test, for multiple comparisons. 
A p value <0.05 was considered statistically significant.  
 
3.3 - Results 
 
Effects of EDX, TAM or OHTAM on the MPT induced by RA 
The effect of the antiestrogen EDX on RA-induced MPT of rat liver mitochondria 
was evaluated by monitoring Ca2+ release (Fig. 3.1) and ΔΨ dissipation (Fig. 3.2). As shown 
in figure 3.1, in the control condition, after energization with succinate, mitochondria 
accumulated Ca2+ (60-80 nmol/mg protein) over the next 8-10 min (Fig. 3.1, trace a). In 
contrast, mitochondria previously incubated with RA released the accumulated Ca2+ to the 
reaction medium, as indicated by the increase in the fluorescence intensity (Fig. 3.1, trace b 
and table). This effect was significantly inhibited in the presence of CyA (Fig. 3.1, trace c 
and table). Similarly to what was observed for CyA, mitochondria were able to accumulate 
and to sustain Ca2+ when incubated with RA in combination with EDX (Fig. 3.1,  
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Fig. 3.1 - Inhibitory effect of the antiestrogens EDX, TAM and OHTAM on RA-induced 
MPT as assessed by following Ca2+ fluxes. Ca2+ fluxes were monitored using the 
fluorescence probe Calcium Green 5-N, as described in the Materials and methods section. 
After obtaining a stable baseline, Ca2+ was added and mitochondria were energized with 
succinate (Succ). Before starting the reactions, mitochondria were incubated in the absence 
(control, trace a) and in the presence of 10 nmol/mg protein of RA alone (trace b) or in 
combination with 1 µM of CyA (trace c) and 10 nmol/mg protein of the antiestrogens EDX, 
TAM or OHTAM (trace d). The traces are typical recordings of four separate experiments 
with different mitochondrial preparations. The data in the table below correspond to the 
fluorescence intensity (a.u.) at the indicated time points and are expressed as the mean ± 
S.E.M. of four experiments obtained from different mitochondrial preparations. *** p<0.001 
vs control. +++ p<0.001 vs RA.  
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trace d and table). Likewise, the incubation of mitochondria with RA in the presence of TAM 
or OHTAM prevented the release of the accumulated Ca2+ (Fig. 3.1, table). 
The inhibitory effect of EDX on the induction of MPT by RA was further confirmed 
by studying its effects on RA-induced depolarization of ΔΨ (Fig. 3.2A). Under succinate 
energization, mitochondria built up a membrane potential of approximately −225 mV. Upon 
the addition of Ca2+ (60-80 nmol/mg protein), the potential drops to −210 mV, due to the 
transport of Ca2+ into mitochondria by the Ca2+ uniport and then rises to nearly its initial 
value (Fig. 3.2A, trace a, control). When mitochondria were previously incubated with RA, 
an irreversible depolarization of mitochondria was observed 3 min after the addition of Ca2+ 
(Fig. 3.2A, trace b and table). On the contrary, mitochondria preincubated with the 
combinations of RA with EDX (Fig. 3.2A, trace c and table) or with CyA (Fig. 3.2A, trace 
d and table) were able to sustain the ΔΨ. In a similar manner, the combinations of RA with 
TAM or OHTAM were able to prevent the mitochondrial depolarization of ΔΨ induced by 
RA (Fig. 3.2 and table), in accordance with the results regarding mitochondrial Ca2+ fluxes 
(Fig. 3.1 and table). The effects of the antiestrogens EDX, TAM or OHTAM were also 
studied on the reversion of MPT induced by RA. As indicated in figure 3.2B, the addition of 
EDX, TAM or OHTAM during the depolarization induced by RA also reversed the ΔΨ 
depolarization associated to MPT induction (Fig. 3.2B, trace e). Again, CyA exhibited 
similar effects, but being able to completely restore the ΔΨ (Fig. 3.2B, trace f).  
In order to clarify the mechanisms involved in RA-induced MPT and its prevention 
by antiestrogens, described as intramembranous antioxidants (Custódio et al., 1994; Ribeiro 
et al., 2013b), we evaluated the effects of EDX and RA on the mitochondria oxidative stress 
induced by the pro-oxidant pair ADP/Fe2+ assessing the oxygen consumption (Fig. 3.3A) 
and lipid peroxidation by analysis of TBARS formation (Fig. 3.3B). In the absence of drugs 
(control) and after the addition of the pro-oxidant pair, it was possible to observe an initial 
phase characterized by slow oxygen consumption (lag phase). It is commonly assumed that 
this lag phase reflects the time required for the generation of sufficient perferryl ion complex 
which is thought to initiate lipid peroxidation. The lag phase was followed by a rapid oxygen 
consumption phase that is probably related with the oxidation of the polyunsaturated fatty 
acid acyl chain of membrane phospholipids by reactive oxygen species and, consequently, 
to the propagation of lipid peroxidation. In the range of 5-20 nmol/mg protein,  
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Fig. 3.2 - Inhibitory effect of the antiestrogens EDX, TAM and OHTAM on RA-induced 
ΔΨ depolarization associated with MPT induction. The dissipation of ΔΨ was monitored as 
described in the Materials and methods section. Mitochondria were energized with succinate 
(Succ) and after the steady-state distribution of TPP+ had been reached, Ca2+ was added. (A) 
Mitochondria were previously incubated in the absence (control, trace a) and in the presence 
of 5 nmol RA/mg protein alone (trace b) or in combination with 10 nmol/mg protein of EDX, 
TAM or OHTAM (trace c) and 1 µM of CyA (trace d). (B) EDX, TAM, OHTAM or CyA 
at the same concentrations was also added after the ΔΨ depolarization induced by 5 nmol 
RA/mg protein, as indicated by the arrows (traces e and f). The traces are typical recordings 
of four independent experiments and the data in the table below correspond to the ΔΨ at the 
indicated time points and are expressed as the mean ± S.E.M. of four experiments obtained 
from different mitochondrial preparations. *** p<0.001, ** p<0.01 vs control. +++ p<0.001, 
++ p<0.01, + p<0.05 vs RA.   
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Fig. 3.3 - Protective effect of RA and EDX on mitochondria oxidative stress induced by the 
pro-oxidant pair ADP/Fe2+. Oxidative stress was evaluated by oxygen consumption as 
described in the Materials and methods section. Before initiating the reaction by adding 
ADP/Fe2+, mitochondria were preincubated in the absence (control) and in the presence of 
different concentrations (nmol/mg protein) of RA (A, B) and in the presence of RA (5 
nmol/mg protein) and EDX (10 nmol/mg protein), alone or in combination (C, D). The traces 
in A and C represent the oxygen consumption rate and are typical recordings of four 
experiments obtained from different mitochondrial preparations. The amount of TBARS (B, 
D) was determined after 10 min of the addition of ADP/Fe2+. TBARS, expressed as 
percentage of control, correspond to the mean ± S.E.M. of four independent experiments. 
*** p<0.001 vs control. +++ p<0.001 vs RA. 
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RA slightly enlarged the lag phase before the oxygen uptake burst induced by the complex 
ADP/Fe2+, and decreased the rate of the rapid oxygen consumption phase, in a concentration-
dependent manner. At 30 nmol/mg protein, RA inhibited almost completely the oxygen 
consumption (Fig. 3.3A). In agreement with the oxygen consumption evaluation, 5-10 nmol 
RA/mg protein slightly diminished TBARS formation (Fig. 3.3B). This effect of RA was 
more pronounced at 20 nmol/mg protein that induced a decrease in TBARS levels to about 
70.1 % of control and at 30 nmol/mg protein a decrease to approximately 12.6 % of control 
was observed (Fig. 3.3B). Then, to evaluate whether the combination of RA with EDX could 
also prove beneficial against mitochondria oxidative stress, we used a combination of RA at 
5 nmol/mg protein with EDX at 10 nmol/mg protein, which were the concentrations used to 
induce and to prevent the ΔΨ depolarization associated to MPT, respectively (Figs. 3.3C-
D). As shown in figure 3.3C, EDX by itself significantly diminished lipid peroxidation as 
previously described (Ribeiro et al., 2013b) and when RA was combined with EDX the 
decrease in lipid peroxidation was significantly enhanced. Accordingly, RA and EDX 
individually diminished TBARS formation to about 96.2 and 26.7 % of control, respectively, 
and their combination decreased TBARS formation to approximately 11.7 % of control, 
which is significant when compared with the effects exerted by RA alone (Fig. 3.3D). 
In addition, we investigated the effects of the thiol group protecting agents GSH, 
Cys and NAC (Fig. 3.4) and of the ANT ligands ADP and ATP (Fig. 3.5) on the RA-induced 
ΔΨ depolarization associated to MPT. The incubation of mitochondria with RA in the 
presence of 1 mM GSH (trace c), 200 µM Cys (trace d) or 200 µM NAC (trace e), before 
energization with succinate, did not prevent the ΔΨ depolarization due to the RA-induced 
MPT (Fig. 3.4). In contrast, mitochondria coincubated with RA and ADP or ATP (Fig. 3.5, 
traces c and d) were able to significantly sustain the ΔΨ in comparison with RA 7 min after 
the addition of Ca2+ (Fig. 3.5, table), indicating that ANT ligands prevented the MPT induced 
by RA. 
 
Effects of RA on bioenergetic functions of rat liver mitochondria 
To assess whether RA affects mitochondrial bioenergetic functions, we evaluated 
the ΔΨ developed and the fluctuations associated with the phosphorylation cycle induced by 
ADP. A typical recording of the phosphorylation cycle induced by ADP is shown in figure  
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Fig. 3.4 - Thiol protecting agents do not prevent RA-induced MPT evaluated by ΔΨ 
depolarization. ΔΨ was measured as described in the Materials and methods section. 
Mitochondria were preincubated in the absence (control, trace a) or in the presence of 5 
nmol/mg protein RA alone (trace b) or in combination with 1 mM GSH (trace c), 200 µM 
Cys (trace d) or 200 µM NAC (trace e) before energization with succinate (Succ). After a 
steady-state distribution of TPP+ had been reached, Ca2+ was added. The traces are typical 
of four separate experiments and the data in the table below correspond to the ΔΨ at the 
indicated time points and are expressed as the mean ± S.E.M. of four experiments obtained 
from different mitochondrial preparations. *** p<0.001, ** p<0.01 vs control. ++ p<0.01, + 
p<0.05 vs RA. 
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Fig. 3.5 - Inhibitory effect of ANT ligands on RA-induced ΔΨ depolarization associated to 
MPT induction. ΔΨ was measured as described in the Materials and methods section. 
Mitochondria were energized with succinate (Succ) and after the steady-state distribution of 
TPP+, Ca2+ was added. Mitochondria were preincubated in the absence (control, trace a) or 
in the presence of 5 nmol RA/mg protein alone (trace b) or in combination with 75 µM ADP 
(trace c) or 150 µM ATP (trace d). The traces are typical of four separate experiments and 
the data in the table below correspond to the mean ± S.E.M. of the ΔΨ evaluated in four 
different mitochondrial preparations. *** p<0.001, * p<0.05 vs control.  +++ p<0.001, + 
p<0.05 vs RA. 
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3.6, while the table underneath shows the mean ± S.E.M. of the indicated parameters. The 
data demonstrated that mitochondria energized with glutamate/malate in the absence of RA 
(control) developed a ΔΨ of 219.8 ± 0.6 mV (negative inside) and the addition of ADP 
dropped the ΔΨ in 16.5 ± 1.1 mV (ADP depolarization). The time required for the 
phosphorylation of ADP (lag phase) was 66.8 ± 2.3 s and after ADP phosphorylation, the 
ΔΨ returned to 218.9 ± 0.6 mV (repolarization of ΔΨ), which is close to its initial value. 
While RA at 5 nmol/mg protein did not significantly affect the ΔΨ and the phosphorylation 
cycle induced by ADP, at 10 nmol/mg protein the phosphorylation lag phase was 
significantly increased and above 20 nmol/mg protein, RA also significantly decreased the 
ΔΨ developed, the ADP depolarization as well as the repolarization of ΔΨ (Fig. 3.6, table). 
To provide further evidence regarding the effects of RA on mitochondrial 
bioenergetics, we also investigated the respiration parameters of mitochondria as assessed 
by measuring oxygen consumption (Fig. 3.7). As shown in figure 3.7 recordings, respiration 
was initiated by adding glutamate/malate (state 2 respiration) and after the addition of 150-
250 nmol/mg protein of ADP, the rate of oxygen consumption increased (state 3 respiration) 
and when all the ADP was phosphorylated, the oxygen consumption rate decreased (state 4 
respiration). Oligomycin was added in order to assess the proton leak through the Fo fraction 
of complex V (state 4 olig). At 5 nmol/mg protein, RA did not significantly affect the 
respiration parameters (Fig. 3.7). RA at 10 nmol/mg protein did not present significant 
effects on state 4 respiration, but significantly depressed the state 3 respiration, the ADP/O 
ratio, as well as the RCR, which is decreased as a consequence of the significant inhibition 
of state 3 respiration (Fig. 3.7, table). At concentrations above 20 nmol/mg protein, RA 
decreased the state 3, the RCR and the ADP/O and the state 4 respiration was significantly 
stimulated, but it was decreased in the presence of oligomycin (Fig. 3.7).  
In order to clarify whether the effects of a high concentration of RA (30 nmol/mg 
protein) on the ΔΨ and on the respiration rates could be due to a loss of mitochondrial 
membrane integrity, this parameter was evaluated by following the light scattering at 540 
nm (Fig. 3.8). In the absence of RA (control), the light scattering of mitochondrial 
suspension was about 1.5 and it was sustained over 30 min (Fig. 3.8 trace a, and table). After 
25 min of recording, the light scattering at 540 nm in the presence of RA was approximately 
1.4, which was not significant relative to control (Fig. 3.8, trace b and table), whereas triton  
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Fig. 3.6 - Effects of RA on the ΔΨ and phosphorylation cycle induced by ADP. Mitochondria 
were energized with glutamate/malate (Glu/Mal) and after a steady-state distribution of TPP+ 
had been reached, RA was added and incubated for 3 min prior to the addition of ADP. The 
traces are typical recordings representative of several experiments obtained in the absence 
of drugs (control), and in the presence of different concentrations of RA (nmol/mg protein) 
as indicated by the numbers adjacent to traces. The table underneath shows the mean ± 
S.E.M. of the ΔΨ and phosphorylation lag phase at the indicated concentrations of RA for 
several independent experiments. *** p<0.001, ** p<0.01 vs control.  
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Fig. 3.7 - Effects of RA on the respiration parameters of rat liver mitochondria. Oxygen 
consumption was assessed with a Clark oxygen electrode as described in the Materials and 
methods section. Mitochondria were energized with glutamate/malate (Glu/Mal). ADP was 
added to induce state 3 respiration and when all the ADP was phosphorylated (state 4), state 
4 oligomycin (state 4 olig) was induced by adding oligomycin plus ADP. The traces are 
typical recordings representative of several experiments obtained in the absence (control) 
and in the presence of different RA concentrations (nmol/mg protein) as indicated by the 
numbers adjacent to traces. The table underneath shows the mean ± S.E.M. of respiratory 
parameters at the indicated concentrations of RA of four independent experiments. State 3, 
state 4 and state 4 olig are expressed in nmol O2/mg protein/min. *** p<0.001, * p<0.05 vs 
control. ººº p<0.001 vs state 4.  
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X-100 promoted an extensive swelling, significantly decreasing the light scattering to about 
0.3 (Fig. 3.8, trace c and table). 
 
Effects of EDX, TAM or OHTAM in combination with RA on the ΔΨ and O2 
consumption 
In addition to the action in the MPT, the effects of EDX (10 nmol/mg protein) in 
combination with increasing concentrations of RA (5-20 nmol/mg protein) on the ΔΨ 
developed and the phosphorylation cycle induced by ADP (Fig. 3.9) and on the 
mitochondrial respiration parameters (Fig. 3.10) were also evaluated using 
glutamate/malate. The antiestrogen EDX did not significantly affect the ΔΨ developed or 
the phosphorylation cycle induced by ADP (Fig. 3.9). The combination of 5 nmol/mg protein 
of RA with the antiestrogen at 10 nmol/mg protein did not induce significant effects on any 
of the parameters evaluated, either in comparison with control (0) or the compounds 
individually (Fig. 3.9). The combination of EDX with 10 nmol/mg protein of RA 
significantly increased the phosphorylation lag phase and decreased the ΔΨ developed and 
the repolarization, while the ADP depolarization was unaffected, as compared with the 
control (0), but the effects were not significant relative to the compounds individually (Fig. 
3.9). When EDX was combined with 20 nmol/mg protein of RA the phosphorylation lag 
phase was significantly increased, while the ΔΨ, the depolarization and the repolarization of 
ΔΨ were decreased in comparison with control and EDX (Fig. 3.9). The combinations of 
RA with TAM or OHTAM presented similar effects to those observed with EDX, but the 
effects of TAM were slightly more pronounced on depolarization and phosphorylation lag 
phase (Fig. 3.9).  
The effects on oxygen consumption (Fig. 3.10) demonstrated that EDX either 
individually (10 nmol/mg protein) or in combination with 5 nmol/mg protein of RA did not 
affect the state 3, the state 4 and the ADP/O ratio. However, the RCR was significantly 
depressed by the combination relative to the control, reflecting the effects on both states 
3and 4. EDX combined with 10 nmol/mg protein of RA did not affect the state 4 respiration, 
but significantly decreased the state 3 respiration, the RCR and the ADP/O ratio relative to 
the control. However, these effects were not significant in comparison with the compounds  
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Fig. 3.8 - Effect of a high concentration of RA on mitochondrial swelling. Mitochondrial 
volume changes were followed as described in the Materials and methods section. 
Mitochondria were incubated in the absence (control, trace a) or in the presence of 30 nmol 
RA/mg protein (trace b) and a positive control using Triton X-100 (trace c) was performed. 
The compounds were added where indicated by the arrow. The traces are typical of three 
separate experiments with different mitochondrial preparations. The data in the table 
correspond to the absorbance at the indicated time points and are expressed as the mean ± 
S.E.M. of three experiments obtained from different mitochondrial preparations. * p<0.05 
vs control.  
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individually (Fig. 3.10). The combination of EDX with 20 nmol/mg protein of RA 
significantly depressed the state 3 respiration, the RCR and the ADP/O ratio, and stimulated 
the state 4 relative to the control and the antiestrogen (Fig. 3.10); the state 4 respiration was 
inhibited in the presence of oligomycin (Fig. 3.10). The combinations of RA with TAM or 
OHTAM promoted similar effects to those described for EDX on oxygen consumption. 
However, when RA at 5 nmol/mg protein was combined with TAM, the effects on the RCR 
were much more drastic than the combinations with OHTAM or EDX, occurring a decrease 
in the RCR that was also significant in comparison with RA individually (Fig. 3.10). 
 
3.4 - Discussion  
 
Our experiments demonstrate that RA is an inducer of the MPT, in agreement with 
already published literature (Rigobello et al., 1999; Notario et al., 2003), since its action is 
inhibited by CyA, a specific and potent inhibitor of the MPT (Broekemeier et al., 1989). 
EDX resembles CyA in the ability to prevent the MPT induced by RA, allowing 
mitochondria preincubated with RA to accumulate Ca2+ (Fig. 3.1) and inhibiting the 
depolarization of ΔΨ after Ca2+ uptake (Fig. 3.2A). Moreover, the inhibition of RA-induced 
depolarization occurs regardless of whether EDX is added before or after energization with 
succinate and Ca2+ loading (Figs. 3.2A and 3.2B), supporting that EDX prevents the 
membrane depolarization induced by RA due to a direct influence on the proteins that form 
the MPT pore complex, and excludes an interference with Ca2+ uptake across the uniport. 
Similarly to EDX, the antiestrogens TAM and OHTAM also prevented and reversed the 
MPT promoted by RA (Figs. 3.1 and 3.2). These observations are consistent with previous 
reports that have shown that antiestrogenic compounds inhibit the MPT induced by several 
agents (Cardoso et al., 2002b; Custódio et al., 1998; Hernández-Esquivel et al., 2011a, b; 
Ribeiro et al., 2013b). 
Since MPT induction is an important mechanism associated with cell death, the 
inhibition of MPT by the antiestrogens would possibly compromise the anticancer activity 
of RA. However, the combination of RA with antiestrogenic compounds has revealed a 
synergism of action in breast cancer (Danforth, 2004; Wang et al., 2007; Searovic et al., 
2009; Koay et al., 2010) and melanoma cells (Ribeiro et al., 2013a), indicating that MPT 
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Fig. 3.9 - Effects of the antiestrogens EDX, TAM and OHTAM in combination with RA on 
the ΔΨ and the phosphorylation cycle induced by ADP. Mitochondria were incubated with 
the drugs RA (5, 10 and 20 nmol/mg protein) and antiestrogens (10 nmol/mg protein) and 
the experiments were performed as described in the legend of figure 3.6. The data represent 
the mean ± S.E.M. of five independent experiments. *** p<0.001, ** p<0.01, * p<0.05 vs 
control. ### p<0.001, ## p<0.01, # p<0.05 vs 10 nmol/mg protein of the respective 
antiestrogen.  
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Fig. 3.10 - Effects of the antiestrogens EDX, TAM and OHTAM in combination with RA 
on the respiration parameters of rat liver mitochondria. Mitochondria were incubated with 
the drugs RA (5, 10 and 20 nmol/mg protein) and antiestrogens (10 nmol/mg protein) and 
the assays were carried out as described in the legend of figure 3.7. The data represent the 
mean ± S.E.M. of several independent experiments. *** p<0.001, ** p<0.01, * p<0.05 vs 
control. ### p<0.001, ## p<0.01, # p<0.05 vs 10 nmol/mg protein of the respective 
antiestrogen. ººº p<0.001, ºº p<0.01 vs state 4. ++ p<0.01 vs 5 nmol/mg protein of RA.  
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induction is not required for RA to exert toxicity against tumor cells. On the contrary, the 
protection afforded by the antiestrogens against RA-induced MPT may contribute to prevent 
or reduce the hepatotoxicity promoted by RA, as several inducers of MPT have been shown 
to be hepatotoxic (Nadanaciva and Will, 2009). 
An important factor contributing to the regulation of the induction of MPT is the 
oxidative stress (Halestrap, 2009). Considering the recent reports on the antioxidant activity 
of EDX (Ribeiro et al., 2013b), we investigated the possible involvement of oxidative stress 
mechanisms in the prevention of RA-induced MPT by EDX. RA at a low concentration (5 
nmol/mg protein) that we showed to induce the MPT did not present antioxidant activity, 
but the combination with EDX significantly enhanced the effects of RA (Fig. 3.3). These 
experiments suggest that the protection against MPT induction by RA may be related with 
the antioxidant properties of the antiestrogen. However, the thiol protecting agents tested 
GSH, Cys and NAC did not prevent the depolarization induced by RA (Fig. 3.4), indicating 
that some factor other than the antioxidant properties of EDX may account for the protection 
against the induction of the MPT by RA. On the other hand, considering a recent study which 
has proposed the mitochondrial phosphate carrier as a possible key component of the MPT 
pore complex in addition to the regulatory role played by the ANT (Leung et al., 2008), we 
evaluated the effects of ANT ligands on RA-induced depolarization (Fig. 3.5). Both ADP 
and ATP inhibit the depolarization of ΔΨ induced by RA (Fig. 3.5), indicating a direct 
interaction between RA and the ANT. These results are in agreement with previous studies 
that have demonstrated that RA can be considered an ANT modulator (Notario et al., 2003). 
However, as shown in figures 3.9 and 3.10, none of the three antiestrogens tested 
significantly affects the mitochondrial phosphorylation efficiency at concentrations that 
inhibit the MPT, suggesting that neither the ANT nor the phosphate carrier seems to be 
related with the inhibition of MPT by EDX and the other antiestrogens TAM and OHTAM. 
Therefore, it is plausible that the inhibition of RA-induced MPT by these compounds may 
be related with the interaction with cyclophilin D, in a similar way to CyA (Zoratti and 
Szabo, 1995). Another possible explanation would be related with the effects of 
antiestrogens on biomembranes, as they are hydrophobic molecules that affect the dynamic 
properties of lipids (Custódio et al., 1991, 1993a, b; Kazanci and Severcan, 2007). The 
interference with membrane dynamics can lead to a configurational change of the ANT, 
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explaining the inhibition of RA-induced MPT by the antiestrogens, as previously suggested 
(Hernández-Esquivel et al., 2011a). 
Beyond the MPT, the disruption of mitochondrial bioenergetics has also been 
recognized to participate in the lethal cell injury induced by xenobiotics (Wallace et al., 
1997). In our experiments, RA at 10 nmol/mg protein increases the time required for ADP 
phosphorylation (Fig. 3.6) and diminishes the state 3 respiration, the RCR, as well as the 
ADP/O ratio (Fig. 3.7), indicating that at this concentration RA depresses the 
phosphorylation capacity of mitochondria. These results are in agreement with other studies 
which have reported that RA above 5 nmol/mg protein significantly inhibits the ANT activity 
(Notario et al., 2003). Additionally, at 20 nmol/mg protein, RA decreases the ΔΨ developed 
after substrate addition and the repolarization of ΔΨ (Fig. 3.6) and increases the respiratory 
rate of state 4 (Fig. 3.7), suggesting that high concentrations of RA induce a permeabilization 
of mitochondrial membrane to protons. Since high concentrations of RA do not decrease the 
light scattering of mitochondria (Fig. 3.8), and the stimulatory effect on state 4 is inhibited 
in the presence of oligomycin (Fig. 3.7), the effects on state 4 and on ΔΨ are possibly related 
to a proton leak through the Fo fraction of complex V. Our results differ from those described 
by Stillwell and Nahmias (1983) that reported that RA above 0.25 nmol/mg protein induces 
the uncoupling of mitochondria by disrupting the mitochondrial membrane. On the other 
hand, our observations correlate with a recent work by Xun et al (2012) in a clonal human 
neuroblastoma cell line that has demonstrated that RA increases the rate of oxygen 
consumption and that this stimulation, which decreases in the presence of oligomycin, may 
play a role in the therapeutic efficacy of RA. 
Bioenergetic studies revealed that the combinations of RA (5-10 nmol/mg protein) 
with EDX (10 nmol/mg protein), at the concentrations used to induce and inhibit MPT, do 
not present effects significantly different from those induced by the compounds individually 
either on the ΔΨ and the phosphorylation cycle induced by ADP or on the oxygen 
consumption (Figs. 3.9 and 3.10). Similar effects were observed when RA at 5-10 nmol/mg 
protein was incubated with 10 nmol/mg protein of TAM or OHTAM, but the combination 
of TAM with 5 nmol/mg protein of RA significantly diminished the RCR relative to RA, 
suggesting that the combination with TAM has more drastic effects on mitochondrial 
bioenergetics than the combinations with its active metabolites EDX or OHTAM (Fig. 3.10). 
As recent studies confirmed an association between CYP2D6 polymorphisms or the 
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coadministration of CYP2D6-inhibiting medication with the clinical outcome in women 
treated with TAM (Kelly et al., 2010; Lammers et al., 2010), it is an emerging view that the 
active metabolite EDX may be a more suitable drug for clinical utilization in therapeutic 
association than its prodrug TAM. When the antiestrogens at 10 nmol/mg protein are 
combined with a high concentration of RA (20 nmol/mg protein), the toxic effects induced 
by these combinations are significantly enhanced relative to those induced by antiestrogens 
individually, but not in comparison with RA alone (Figs. 3.9 and 3.10). These results suggest 
that the eventual toxicity of the combination of antiestrogens with high concentrations of RA 
is related to RA. Accordingly, a phase I/II study performed in patients with advanced breast 
cancer which has reported that 20 mg TAM/day and RA up to 190 mg/m2/day can be given 
together with acceptable toxicity, but patients treated with 230 mg/m2/day of RA present 
unacceptable toxic effects (Budd et al., 1998). 
In the presence of Ca2+, the concentration of RA necessary to induce the MPT is 5-
10 nmol/mg protein, which corresponds to 2.5 µM. The antiestrogens were able to 
effectively inhibit RA-induced MPT at 10 nmol/mg mitochondrial protein which translates 
to 2.5-5 µM. In breast cancer cells, a concentration of 1 µM of RA and TAM was sufficient 
to obtain a synergism of action (Wang et al., 2007). However, the RA receptors and the 
cellular retinoic acid binding protein that keep RA in mitochondria (Ruff and Ong, 2000; 
Everts and Bernadier, 2002), as well as the synergism with Ca2+, explain that RA 
compromises intact cells at lower concentrations than those necessary to affect isolated 
mitochondria, suggesting that RA is able to regulate the MPT at physiological 
concentrations. On the other hand, the plasma concentrations of EDX are in the 10-150 nM 
range, but tissue concentrations are much higher, close to 10 µM (Lien et al., 1991; Borges 
et al., 2006), whereas the tissue concentrations of TAM are within the range of 3-60 µM 
(Jordan, 1990; Custódio et al., 1991; Lien et al. 1991; Ingle et al., 1999). Therefore, it is 
plausible that at the concentrations reached in tissues the antiestrogens can prevent the 
induction of MPT by RA, thus contributing to decrease the RA side effects. 
In conclusion, here we report that EDX inhibits the induction of MPT by RA, 
without enhancing the deleterious effects on mitochondrial bioenergetics induced by RA. 
Altogether, these data suggest that the synergistic action of the combination of retinoids and 
antiestrogens observed in breast cancer and melanoma cells may parallel with a decrease in 
the hepatotoxic effects induced by RA, as a consequence of the inhibition of MPT. Since the 
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use of RA has been limited by its adverse effects, the therapeutic association with EDX may 
be a promising strategy to turn RA into a more suitable drug for clinical utilization. 
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THE COMBINATION OF THE ANTIESTROGEN ENDOXIFEN 
WITH ALL-TRANS-RETINOIC ACID HAS ANTIPROLIFERATIVE 
AND ANTIMIGRATION EFFECTS ON MELANOMA CELLS 
WITHOUT INDUCING SIGNIFICANT TOXICITY IN NON-
NEOPLASIC CELLS 
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Abstract 
 
Melanoma incidence is dramatically increasing and the available treatments beyond 
partial efficacy have severe side effects. Retinoids are promising anticancer agents, but their 
clinical use has been limited by their toxicity, although a combination with other agents can 
possibly generate a therapeutic action at lower dosage. Thus, we investigated the effects of 
all-trans-retinoic acid (RA) combined with the antiestrogen endoxifen (EDX) on melanoma 
cell proliferation and the effects were compared with its prodrug tamoxifen (TAM). 
Moreover, we evaluated the effects of these combinations on non-neoplasic cells and 
assessed mitochondrial bioenergetic functions, to predict their potential toxicity. 
Individually, RA and the antiestrogens EDX and TAM decreased melanoma cell biomass, 
cell viability and DNA synthesis, without increased cell death, suggesting that the 
compounds inhibited cell proliferation. Noteworthy, EDX decreased cell proliferation more 
efficiently than TAM. The combination of EDX with RA enhanced the antiproliferative 
effects of the compounds individually more potently than TAM, which did not enhance the 
effects induced by RA alone, and blocked cell cycle progression in G1. Moreover, the 
combination of RA with EDX significantly decreased melanoma cells migration, whereas 
the combination with TAM did not present significant effects. At the concentrations used 
the compounds did not induce cytotoxicity in non-neoplasic cells and liver mitochondrial 
bioenergetic function was not affected. Altogether, our results show for the first time that a 
combined treatment of RA with EDX may provide an antiproliferative and antimigration 
effect upon melanoma cells without major toxicity, offering a powerful therapeutic strategy 
for malignant melanoma. 
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4.1 - Introduction 
 
Malignant melanoma remains among the most notoriously aggressive and 
treatment-resistant human cancers and its incidence has increased dramatically over the last 
decades (Jemal et al., 2009). In recent years, there has been a great progress in understanding 
the biology and molecular basis of melanoma, leading to the identification of several disease 
variants with different subpopulations of cells within one tumor, and the involvement of 
multiple signaling pathways, rather than the existence of a crucial individual alteration (Ko 
and Fisher, 2011). Considering this scenario, it is unlikely that a single therapeutic agent will 
provide a satisfactory response and new combinations of drugs with specific and 
complementary mechanisms of action will be required in order to increase the therapeutic 
benefit while allowing to reduce the adverse effects of the anticancer therapy. 
Retinoids, the naturally occurring derivatives of vitamin A, play an important role 
in the regulation of several cellular processes, namely cell differentiation, development, 
growth, and apoptosis, through the regulation of gene transcription (Bushue and Wan, 2010). 
Retinoids have been widely used in the treatment of skin conditions, such as acne and 
psoriasis, and have also been shown to inhibit the proliferation and survival of cancer cells, 
including melanoma cells (Lotan, 1979; Drewa and Schachtshhabel, 1985). In 1995, the 
Food and Drug Administration (FDA) approved all-trans-retinoic acid (RA) for the 
treatment of a rare leukemia, acute promyelocytic leukemia (APL), which is caused by 
translocations of the retinoic acid receptor (RAR)-α gene (Tang and Gudas, 2011). However, 
the clinical utilization of retinoids has been limited by their adverse effects, including 
varying degrees of teratogenicity, mucocutaneous cytotoxicity, chondrogenesis inhibition, 
and hypertriglyceridemia (Zusi et al., 2002). Possibly, the combination of retinoids with 
other agents may allow to obtain therapeutic efficacy with lower doses through a synergism 
of action.  
Tamoxifen (TAM) is a selective estrogen receptor (ER) modulator used routinely 
in the treatment of breast carcinoma. However, some ER-negative breast cancers also 
respond to TAM treatment, suggesting that it has alternative ways to suppress tumor cell 
proliferation independent of the expression of ER (Toma et al., 1999). On the other hand, in 
vitro experiments established that TAM effectively inhibits melanoma cell proliferation and 
migration (Kanter-Lewensohn et al., 2000; Matsuoka et al., 2009). Nevertheless, the clinical 
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use of TAM in the management of malignant melanoma has been controversial. Several 
studies have tried to establish the benefit of the inclusion of TAM in combination schemes, 
but the results remain contradictory (Beguerie et al., 2010). However, to our knowledge, 
these studies in melanoma patients have not considered the fact that the efficacy of TAM in 
breast cancer therapy is limited by CYP2D6 polymorphisms or by CYP2D6-inhibiting 
medication (Kelly et al., 2010; Lammers et al., 2010). Therefore, to avoid the therapeutic 
inefficacy due to the variability on TAM metabolism, we propose the use of endoxifen 
(EDX), a key active metabolite of TAM that has been considered responsible for its 
anticancer activity (Kiyotani et al., 2012), instead of the prodrug. Moreover, EDX has been 
shown to be less toxic for mitochondria than TAM (Cardoso et al., 2001; Ribeiro et al., 
2013b). 
Both antiestrogens and retinoids exhibit a cytostatic action in breast cancer cells, 
by blocking cell cycle progression in G1 (Wilcken et al., 1996) and the therapeutic 
combination of retinoids or retinamides with antiestrogens, has revealed synergism of action 
in breast cancer cell lines (Danforth, 2004; Searovic et al., 2009; Koay et al., 2010). 
Additionally, recent work has pointed to the interplay between retinoid and estrogen 
signaling in breast cancer (Hua et al., 2009; Ross-Innes et al., 2010). Thus, considering the 
activity of both retinoids and antiestrogens individually on melanoma cells and their 
synergistic interaction in breast cancer cells, we aimed to investigate the benefits of a 
combined therapy of RA and the antiestrogens EDX and TAM against melanoma cells 
(K1735-M2) proliferation. Moreover, the effects of these combinations were also evaluated 
on non-neoplasic cells and on rat liver mitochondrial bioenergetics in order to provide the 
first clues on their potential toxicity. 
 
4.2 - Materials and methods  
 
Reagents 
RA, EDX and TAM were obtained from SIGMA-Aldrich (St Louis, MO, USA). 
Dulbecco’s modified Eagle’s medium (DMEM) and antibiotic/antimycotic solution (10 000 
units penicillin, 10 mg streptomycin, 25 µg amphotericin B per mL) were purchased from 
SIGMA-Aldrich (St Louis, MO, USA), Fetal Bovine Serum (FBS) and trypsin were obtained 
from Gibco, Invitrogen Life Technologies (Carlsbad, California, USA). All of the other 
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chemicals were purchased from SIGMA-Aldrich (St Louis, MO, USA) and were of the 
highest grade of purity commercially available. RA and TAM stock solutions were prepared 
in absolute ethanol. EDX was kept in dimethyl sulfoxide (DMSO). 
 
Animals 
Wistar rats (250-350g), of either sex, were maintained at 22 ± 2 ºC under artificial 
light for 12 h light/dark cycle and with access to water and food ad libitum. The experiments 
reported here were carried out in accordance with the National Requirements for Vertebrate 
Animal Research and in accordance with the European Convention for the Protection of 
Animals used for Experimental and other Scientific Purposes.  
 
Cell culture 
K1735-M2 mouse melanoma cells were cultured in DMEM, supplemented with 10 
% heat-inactivated FBS and 1 % antibiotic/antimycotic solution, and kept at 37 ºC in a 
humidified incubator with 5 % CO2. Cells were plated 6.1×10
4 cells/cm2. The drugs RA, 
EDX and TAM were added to the cultures from diluted stocks 24 h after plating. Vehicle 
controls were performed.  
 
Sulforhodamine B (SRB) assays  
The SRB assay allows to determine the toxicity induced by the anticancer drugs in 
melanoma cell cultures and it is based on the labeling of the cellular protein content (Holy 
et al., 2006). At designated time points, the plate was fixed with absolute methanol 
containing ice-cold 1 % acetic acid, and stored at −20 ºC overnight. Methanol was then 
decanted and the plate air-dried. SRB (0.5 % in 1 % acetic acid) was added to each well, and 
the plate incubated at 37 °C for 1 h. Plates were rinsed with 1 % acetic acid, air-dried, and 
the bound dye eluted with 10 mM Tris buffer, pH 10. The absorbance was measured in a 
Synergy HT plate reader at 540 nm. As SRB binds to basic amino acid of cellular proteins 
of adherent cells, the absorbance at 540 nm provides an estimate of total protein mass 
(biomass), which is related to cell number. The absorbance value obtained in control cultures 
was considered 100 %. The number of independent experiments is indicated in figure 
legends. 
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Cell viability assessment by trypan blue dye exclusion 
The effect of anticancer drugs on cell viability was investigated by staining cell 
suspensions with trypan blue, based on the principle that live cells with an intact cell 
membrane exclude the dye (Houben et al., 2009). At selected time points cells were 
trypsinized and the content of two wells was centrifuged and the pellet resuspended in 0.4 
% trypan blue for 2-3 min and then cells were counted in a hemocytometer under a 
transmitted light microscope. Cells presenting a blue stained cytoplasm were considered as 
dead cells while the cells excluding the dye were considered as viable. The number of 
independent experiments is indicated in figure legends. 
 
5-bromo-2'-deoxyuridine (BrdU) incorporation assay 
K1735-M2 cell proliferation was quantitated based on the measurement of BrdU 
incorporation during DNA synthesis in proliferating cells, which is a nonradioactive 
alternative to the [3H]-thymidine incorporation assay. We used the Cell Proliferation ELISA, 
BrdU, colorimetric kit (Roche) following the manufacturer’s protocol. After 48 h of 
incubation with the drugs, cultured cells were placed in BrdU-labeling solution for 90 min. 
Afterwards, the cells were fixed and the DNA denaturated with the FixDenat solution 
provided with the kit, and then incubated with a monoclonal antibody conjugated with 
peroxidase (anti-BrdU-POD) to bind the BrdU in the newly synthesized cellular DNA. The 
immune complexes were detected by using the 3,3’,5,5’-tetramethylbenzidine (TMB) 
substrate and quantified by measuring the absorbance in a Synergy HT plate reader at 370 
nm. The absorbance values directly correlate to the amount of DNA synthesis and, therefore, 
to the number of proliferating cells. The experiments were carried out in triplicate for each 
independent experiment and the absorbance value obtained in control cultures was 
considered 100 %. 
 
Cell cycle analysis by flow cytometry 
The effects of the drugs on cell cycle were monitored by flow cytometry (Carmo et 
al., 2011). Cells were plated in 6-multiwell plates and incubated with RA, EDX and TAM 
for 48 h. At the end of the incubation period, cells were trypsinized and centrifuged at 1 500 
rpm for 10 min, the culture medium was discarded and the pellet was fixed overnight at 4 ºC 
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with a solution of cold 70 % ethanol. The cells were then centrifuged at 1 500 rpm for 10 
min, the pellet was resuspended in a solution of phosphate-buffered saline (PBS) containing 
RNAse and, after 45 min, propidium iodide was added and incubated for 1 h in the dark, at 
room temperature (the final concentrations of RNase and propidium iodide were 10 µg/mL 
and 20 μg/mL, respectively). The propidium iodide fluorescence was measured on a 
FACScan flow cytometer (BD FACSCalibur™) and the data were gated to exclude cell 
debris and aggregates. Data were analyzed using the ModFit LT 3.0. software. The 
experiments were carried out in duplicate for each independent experiment and the results 
are expressed as % of total cells. 
 
Wound healing assay 
The effect of anticancer drugs on melanoma cell migration ability was monitored 
in vitro using a wound healing assay, which is based on the observation that after doing a 
scratch on a confluent cell monolayer the cells on the edge of the newly created gap will 
move towards that space to close the gap and establish new cell-cell contacts (Liang et al., 
2007). Thus, cells were seeded on glass coverslips and grown to confluency. The monolayer 
of cells was mechanically injured by scoring a line with a 21-gauge needle. Loose cells were 
removed by washing the well with culture medium and then the drugs were added to cells, 
except to control cells which were incubated with the vehicle. At 0 h, photographic images 
were captured by transmitted light microscopy under ×10 magnification (Axiovert, Zeiss).  
The multiwell plate was further incubated at 37 °C, 5 % CO2 for 3 h, and then photographic 
images were captured again. To determine cell migration we selected in the images obtained 
at 0 h an area of the scratch lacking cells (a rectangle marked by dotted lines) and 
subsequently superimposed this rectangle on the scratch area of the images obtained at 3 h 
after scratch. Then, the total number of cells migrating into the selected area at 3 h was 
counted. This assay was performed within a short time interval to minimize the influence of 
cell proliferation in the migration assay. Experiments were performed in triplicates for each 
independent experiment.  
 
Primary cultures of bovine aortic endothelial cells 
The bovine aortic endothelial cells (BAEC) were isolated from thoracic aorta as 
described elsewhere (Paixão et al., 2011). Briefly, after treatment with collagenase (2 
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mg/mL), cells were cultured on gelatin-coated (0.2 %) tissue culture plastic in DMEM, with 
100 U/mL penicillin and 100 µg/mL streptomycin, supplemented with 10 % heat-inactivated 
FBS, and kept at 37 ºC in a humidified incubator with 5 % CO2. Endothelial cells were 
identified by their cobblestone morphology. Cells were used between the fifth and the 
eleventh passage. For the experiments, cells were seeded in 24-multiwell plates at a 
concentration of 5×104 cells/cm2 and allowed to recover for 24 h prior to the addition of 
drugs. Cell viability was assessed by trypan blue dye exclusion after 72 h of incubation with 
the drugs. Experiments were performed in duplicates for each independent experiment.  
 
Isolation of rat liver mitochondria 
Mitochondria were isolated from the liver of Wistar rats as previously described 
(Custódio et al., 1998). Briefly, liver was quickly removed from decapitated rats, finely 
minced and homogenized in an ice-cold homogenization medium containing 250 mM 
sucrose, 10 mM 4-(2-hydroxymethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4, 1 
mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’-tetra-acetic acid (EGTA), and 0.1 
% bovine serum albumin (BSA). The homogenate was centrifuged for 10 min at 800×g and 
mitochondria were recovered from supernatant by centrifugation at 10 000×g for 10 min. 
The mitochondrial pellet was resuspended twice in the final washing medium adjusted to pH 
7.2, in the absence of EGTA and BSA. All the previously described procedures were 
performed at 0-4 ºC. Mitochondrial protein was determined by the Biuret method (Gornall 
et al., 1949) using BSA as the protein standard. 
 
Evaluation of mitochondrial membrane potential and oxygen consumption 
Mitochondria (1 mg) were suspended in the standard respiratory medium 
containing 130 mM sucrose, 50 mM KCl, 5 mM MgCl2, 0.1 mM EGTA, 5 mM KH2PO4, 5 
mM HEPES, pH 7.4, supplemented with 3 µM tetraphenylphosphonium (TPP+) and 
energized with glutamate/malate (10 mM/5 mM), at 37 °C. Mitochondrial membrane 
potential (ΔΨ) was assessed by measuring the movements of the lipophilic cation TPP+ 
across the mitochondrial membrane with a TPP+ selective electrode and using a Ag/AgCl2 
electrode as reference (model MI 402; Microelectrodes, Inc., Bedford, NH) as described 
elsewhere (Moreira et al., 2007). Oxygen consumption was assessed polarographically with 
a Clark oxygen electrode (YSI model 5331, Yellow Spring Inst.) connected to a suitable 
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recorder in a thermostatted water-jacket closed chamber with magnetic stirring (Ribeiro et 
al., 2013b). State 3 respiration (V3) was initiated upon the addition of 150-250 nmol/mg 
protein of ADP and after the phosphorylation of all the added ADP, the oxygen consumption 
rate decreased and state 4 respiration (V4) was resumed. Respiration rates (V3 and V4) were 
calculated assuming an oxygen concentration of 240 nmol O2/mL and are expressed as nmol 
O2/min/mg protein. 
 
Statistical analysis 
Results are presented as the mean ± S.E.M. of the indicated number of independent 
experiments. Statistical significance between the different assays was determined using the 
one-way analysis of variance (ANOVA), followed by the Tukey post-test, for multiple 
comparisons. A p value <0.05 was considered statistically significant. These statistical 
analyses were performed using the software package GraphPad Prism 4. 
 
4.3 - Results 
 
In order to investigate the cytotoxic effects of a combined therapy of RA and 
antiestrogens on a melanoma cell line we initially studied the dose-dependent effect of RA 
alone in a time-course experiment to establish the lowest effective RA concentration to 
pursue our work. Thus, melanoma cells were exposed to RA (0.5-40 µM) and the cytotoxic 
effects were assessed by the SRB assay, which evaluates the total cell protein content (cell 
biomass) that correlates with cell number (Fig. 4.1). At 24 h after drug addition, only the 
highest-RA concentration used in our study (40 µM) induced a significant decrease in cell 
biomass as compared with control condition (0), i.e., cells incubated in the absence of RA 
(Fig. 4.1). However, at 48 and 72 h, a significant decrease in cell biomass was already 
observed for all the concentrations tested, relatively to control, and these effects did not 
differ in intensity between this time period of exposure to RA except for the concentration 
of 40 µM (Fig. 4.1) Thus, in the following experiments, we used RA at 0.5 or 1 µM, which 
are the lowest concentrations tested inducing a toxic effect on melanoma cells. 
After studying the dose-dependent effect of antiestrogens in a likewise time-course 
experiment (data not shown), the concentration of 5 µM was considered the most suitable  
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Fig. 4.1 - Time-course of RA-induced toxicity on melanoma cells. Cells were incubated in 
the absence (0) or in the presence of RA (0.5–40 µM), for 24, 48 and 72 h. At the selected 
time points, melanoma cell biomass was evaluated by the SRB assay as described in the 
Materials and methods section. Bars represent the mean ± S.E.M. of eight independent 
experiments. *** p<0.001 vs the respective time point in the absence of RA, One-way 
ANOVA followed by Tukey post-test. 
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for use in combination treatments, as it corresponded to the lowest concentration of EDX 
required to elicit a cytotoxic effect on melanoma cells. The effects of RA (0.5-1 µM) and the 
antiestrogens EDX and TAM (5 µM), alone or in combination, were then evaluated on 
melanoma cells, over 72 h (Fig. 4.2). RA at 0.5-1 µM decreased cell biomass to about 54 % 
of control, while the TAM active metabolite EDX at 5 µM provided a significant decrease 
in cell biomass to about 62 % of control (Fig. 4.2A). The combination of EDX with RA (0.5-
1 µM) diminished cell biomass to about 26 % of control, which indicates that the drug 
combination enhances the effects induced by the compounds individually (Fig. 4.2A). In 
contrast, TAM at 5 µM did not significantly induce toxicity by itself, diminishing cell 
biomass to about 83 % (Fig. 4.2B). The combination of TAM with RA (0.5-1 µM) decreased 
cell biomass to about 41 %, which is significant relatively to TAM alone, but not in 
comparison with RA individually (Fig. 4.2B). It is noteworthy that increasing the 
concentration of RA up to 1 µM did not enhance the toxic effect relatively to the 
combinations including RA at 0.5 µM (Figs. 4.2A and 4.2B).  
In order to elucidate the mechanism underlying the cytotoxic effects of the 
combinations of RA (0.5 µM) with antiestrogens EDX and TAM (5 µM), we assayed cell 
viability at selected time points by using trypan blue dye exclusion assay. As shown in figure 
4.3A, RA reduced the number of viable cells within 48 and 72 h of drug incubation to about 
49 % and 54 % of control condition, respectively. EDX diminished the number of viable 
cells to approximately 49 % and 61 %, after 48 and 72 h of drug incubation, respectively 
(Fig. 4.3A), while TAM did not alter the number of viable cells over 72 h (Fig. 4.3B), in 
agreement with the results obtained in SRB assays (Fig. 4.2). The combination of EDX with 
RA, at 72 h, significantly potentiated the effects of the compounds alone, decreasing the 
percentage of viable cells to approximately 14 % as compared with control condition (Fig. 
4.3A). After 72 h of incubation, the combination of TAM with RA diminished the number 
of viable cells to about 30 % of control and did not further potentiate the effect of RA on the 
number of viable cells (Fig. 4.3B); hence, as observed in SRB assays, the effects of the 
combination with EDX were much more pronounced than those of the combination with 
TAM. On the other hand, the number of dead cells after exposure to RA and to the 
antiestrogens, alone or in combination, did not significantly increase during the course of 72 
h (Figs. 4.3C and 4.3D). The absence of an increase in the number of dead cells within 72 h  
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Fig. 4.2 - The combined treatment of RA with the TAM metabolite EDX enhances the 
toxicity on melanoma cells. Cells were incubated in the absence (control) or in the presence 
of RA (0.5-1 µM), 5 µM EDX (A) or 5 µM TAM (B), alone or in combination, for 72 h. The 
melanoma cell biomass was evaluated by the SRB assay after the incubation period. The 
combination of RA with the TAM metabolite EDX enhanced the decrease in cell biomass 
induced by the treatment with each compound individually. Bars represent the mean ± 
S.E.M. of eight independent experiments. *** p<0.001 vs control. +++ p<0.001 vs the 
respective RA concentration. ### p<0.001 vs the antiestrogen, One-way ANOVA followed 
by Tukey post-test. 
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Fig. 4.3 - Cell viability of melanoma cells treated with RA and the antiestrogens EDX and 
TAM. Melanoma cells were incubated in the absence (control) or in the presence of RA (0.5-
1 µM), 5 µM EDX (A, C) or 5 µM TAM (B, D), alone or in combination, and after 0, 24, 48 
and 72 h of incubation, cell viability was assessed by the trypan blue dye exclusion assay as 
described in the Materials and methods. The number of trypan blue-negative (viable) cells 
(A, B) and trypan blue-positive (dead) cells (C, D) is presented in the graphs. The 
combinations of RA and antiestrogens decreased the number of viable cells without 
increasing the number of dead cells. Data represent the mean ± S.E.M. of six independent 
experiments. Statistics for 24 and 48 h are not shown. *** p<0.001, ** p<0.01, * p<0.05 vs 
control. + p<0.05 vs RA. # p<0.05 vs the antiestrogen, One-way ANOVA followed by Tukey 
post-test.  
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of treatment with the drugs was confirmed by the lactate dehydrogenase (LDH) assay which, 
as the trypan blue assay, is a cytotoxicity test based on cell membrane integrity. The RA and 
the antiestrogens EDX and TAM, either alone or in combination, did not increase the activity 
of LDH in the extracellular medium of melanoma cells (data not shown). Thus, since we 
observed a reduction in the cell number without a simultaneous increase in cell death, our 
results suggest that the toxic effects of RA and antiestrogens on melanoma cells might be 
due to a decrease in cell proliferation. 
Therefore, we investigated the effects of the drugs on melanoma cell proliferation 
by means of the BrdU incorporation in DNA synthesis after a 48 h treatment with RA (0.5 
µM), alone or in combination with antiestrogens EDX and TAM (5 µM). As shown in figure 
4.4, RA significantly decreased the incorporation of BrdU to approximately 63 % of control, 
i.e., in the absence of drugs. The incubation of cells with EDX decreased BrdU incorporation 
to about 42 %, whereas its combination with RA diminished it to approximately 12 % (Fig. 
4.4). TAM diminished the BrdU incorporation to about 78 %, and the combination with RA 
induced a larger decrease in cell proliferation to about 12 %, as observed with EDX (Fig. 
4.4). Thus, our results indicate that RA and the antiestrogens have a cytostatic effect on 
melanoma cells, which is intensified when the drugs are applied in a combined treatment.  
To confirm whether the rate of proliferation of melanoma cells was in fact affected 
by the combinations of RA and antiestrogens, and that the reduction in BrdU signal was not 
a consequence of the decrease in cell number, the effect of the drugs on the cell cycle was 
analyzed by flow cytometry (Fig. 4.5). Untreated cells (control) were characterized by a long 
and a well defined G1 peak, a slightly prominent S peak, a least prominent G2 peak and 
relatively low G0/G1 fraction, which was considered as the apoptotic fraction (Fig. 4.5). The 
incubation of cells with 0.5 µM of RA increased the percentage of cells in the G1 phase and 
decreased the number of cells in S and G2 phases while 5 M EDX or TAM did not change 
the population of cells in each cell cycle phase relatively to the control condition (Fig. 4.5). 
The combination of RA with the antiestrogen EDX significantly enhanced the effects on cell 
cycle induced by the compounds individually (Fig. 4.5). In contrast, the combination of RA 
with TAM did not potentiate the effects of RA alone (Fig. 4.5).  
On the other hand, we sought to investigate whether RA and the antiestrogens could 
inhibit cancer cell migration that is related to metastatic potential. For that purpose, we  
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Fig. 4.4 - Melanoma cell treatment with RA and the antiestrogens EDX and TAM reduces 
cell proliferation. Cells were grown in the absence (control) or in the presence of RA (0.5 
µM), alone or in combination with 5 µM of EDX or TAM, for 48 h. Cell proliferation was 
assessed by the BrdU incorporation assay as described in the Materials and methods. The 
combination of RA with EDX and TAM enhanced the effects on cell proliferation induced 
by the compounds individually. Bars represent the mean ± S.E.M. of four independent 
experiments performed in triplicates. *** p<0.001, ** p<0.01 vs control. +++ p<0.001 vs 
RA. ### p<0.001, # p<0.05 vs the antiestrogen, One-way ANOVA followed by Tukey post-
test. 
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Fig. 4.5 - Melanoma cell treatment with RA and EDX blocks cell cycle progression in G1. 
Cells were grown in the absence (control) or in the presence of RA (0.5 µM), alone or in 
combination with 5 µM of EDX or TAM, for 48 h. Cell cycle distribution was evaluated by 
flow cytometry analysis of the content of DNA labeled with propidium iodide. The 
combination of RA with EDX enhanced the effects on the cell cycle induced by the 
compounds individually. Data are the mean ± S.E.M. of three independent experiments 
performed in duplicates. *** p<0.001, ** p<0.01, * p<0.05 vs control. ++ p<0.01, + p<0.05 
vs RA. ### p<0.001 vs the antiestrogen, One-way ANOVA followed by Tukey post-test. 
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performed the wound healing assay and analyzed the effect of the drugs on melanoma cell 
migration after 3 h of exposure to the combinations of RA (0.5-1 µM) with antiestrogens 
EDX and TAM (5 µM) (Fig. 4.6). This short time point was chosen to ensure that the effects 
observed in the wound healing assay were only related to the migration ability of melanoma 
cells and did not reflect the cell proliferation. In fact, we determined the number of cells per 
well at 0 and at 3 h and observed that during this time interval, the number of cells did not 
significantly change (cell number was, at 0 h, 5.660×105 ± 0.7743×105 and at 3 h, 5.600×105 
± 0.9431×105; p>0.05, Student’s t test). As shown in figure 4.6A, neither RA at 0.5 µM nor 
the antiestrogens, alone or in combination, affected melanoma cells migration significantly. 
However, when the antiestrogens were combined with RA at 1 µM, we observed a 
pronounced decrease of the number of migrating cells, particularly with the combinations 
including EDX (Fig. 4.6B). These results suggest that a combined treatment of RA with 
EDX, additionally to a stronger cytostatic effect, is much more efficient in the inhibition of 
the metastatic potential of melanoma cells than the combination with TAM. 
One possible advantage of a combined therapy of anticancer drugs is a reduction in 
the chemotherapy adverse effects due to a decrease in the dose of the drugs allowing a lower 
toxicity for non-neoplasic cells. To investigate the putative toxicity of RA (1 µM) in 
combination with the antiestrogens EDX and TAM (5 µM) for proliferative non-neoplasic 
cells, we assessed cell viability of BAEC cultures exposed to the drugs for 72 h. Cell 
counting with trypan blue staining revealed that RA and antiestrogens, individually or in 
combination, did not induce an increase in dead cells and the number of viable cells did not 
change significantly (Fig. 4.7).  
Additionally, the potential toxicity of the combinations of RA with the 
antiestrogens EDX and TAM was monitored using rat liver mitochondria as a model, and 
several bioenergetic function parameters were determined (Fig. 4.8). In agreement with the 
results obtained in non-neoplasic cells, RA (5 µM) and the antiestrogens (5 µM), alone or in 
combination, neither affected the rates of state 3 (V3) and 4 (V4) of respiration (Fig. 4.8A) 
nor the phosphorylation cycle parameters (Fig. 4.8B), suggesting that liver mitochondrial 
bioenergetics were spared to the toxic effects of these drugs.  
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Fig. 4.6 - The combination of RA with EDX inhibits melanoma cells migration. Confluent 
melanoma cell cultures were scratched and incubated in the absence (control) or in the 
presence of RA at 0.5 µM (A) or at 1 µM (B) in combination with 5 µM of EDX or TAM. 
The cells were visualized by transmitted light microscopy and images of the melanoma cells 
were acquired at 0 h and 3 h after scratch. The cells that moved into the gap in this time 
interval were counted, as described in the Materials and methods. Representative images 
collected at t=3 h are shown in C. Data represent the mean ± S.E.M. of six independent 
experiments performed in triplicates. * p<0.05 vs control. ## p<0.01 vs the antiestrogen, 
One-way ANOVA followed by Tukey post-test. 
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Fig. 4.7 - Cell viability of non-neoplasic endothelial cells treated with RA and the 
antiestrogens EDX and TAM. Cultures of BAEC were exposed for 72 h to RA (1 µM), EDX 
(5 µM) and TAM (5 µM), alone or in combination, and after the incubation period the 
endothelial cell viability was determined by the trypan blue dye exclusion assay. The number 
of trypan blue-negative (viable) cells and trypan blue-positive (dead) cells is presented. The 
RA and the antiestrogens, alone or in combination, did not induce toxicity in endothelial 
cells. Data represent the mean ± S.E.M. of five independent experiments performed in 
duplicates.  
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Fig. 4.8 - Effects of RA in combination with the antiestrogens EDX or TAM on liver 
mitochondrial bionenergetic function. Mitochondria (1 mg) were suspended in the standard 
respiratory medium and energized with 10 mM glutamate/5 mM malate. Oxygen 
consumption was assessed polarographically with a Clark oxygen electrode (A) and 
mitochondrial membrane potential (ΔΨ) was assessed using a TPP+ selective electrode (B) 
as described in the Materials and methods section. The compounds RA (5 µM) and the 
antiestrogens (5 µM), individually or in combination, did not affect mitochondrial 
bioenergetic function. The traces are typical recordings representative of several experiments 
and the table underneath shows the mean ± S.E.M. of mitochondrial bioenergetic parameters 
obtained from different mitochondrial preparations. 
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4.4 - Discussion 
 
Our study shows for the first time that the innovative combination of RA at 
concentrations of 0.5-1 µM with the TAM metabolite EDX (5 µM) enhanced the 
antiproliferative and antimigration effects induced by the compounds individually on 
melanoma cells. Importantly, RA is already approved for clinical use by the FDA and EDX 
has been shown to be safe and well tolerated by healthy individuals (Ahmad et al., 2010b). 
Thus, the fact that the drugs used in our work are already approved or in clinical trials may 
allow for a faster implementation of the proposed strategy.  
The toxic effects of RA and antiestrogens on melanoma cells were initially assessed 
by the SRB assay which showed that a combined treatment of RA with the TAM active 
metabolite EDX was more effective in the reduction of melanoma cell biomass relatively to 
the compounds individually and more efficient than the combination with TAM (Fig. 4.2). 
Likewise, the cell viability assay with trypan blue staining revealed that the combined 
treatment of RA with antiestrogens induced the largest decrease in the number of viable 
cells, without inducing cell death (Fig. 4.3). Thus, our results suggest that the observed toxic 
effect of RA and antiestrogens, alone or in combination, are related to the inhibition of cell 
proliferation. Moreover, the evaluation of LDH activity in the supernatant of melanoma cells 
supports the view that the decrease in viable cells is not due to increased cell death (data not 
shown). The BrdU incorporation assay allowed us to confirm that RA and the antiestrogens 
inhibit cell proliferation with maximal efficacy when the drugs were used in combination 
(Fig. 4.4). The analysis of the cell cycle revealed that RA induced the cell cycle arrest in the 
G1 phase and the combination with EDX enhanced the number of cells in G1 phase (Fig. 
4.5). On the other hand, the combination of RA (1 µM) with the TAM active metabolite 
EDX also decreased the migration ability of melanoma cells (Fig. 4.6), which adds to the 
benefits of a combined therapy with these drugs.  
The RA has been widely studied for many years in a variety of chemopreventive 
and chemotherapeutic settings (Bushue and Wan, 2010; Tang and Gudas, 2011). The 
expression of RAR was reported in melanoma cell lines (Boskovic et al., 2002; Zhang et al., 
2003; Fan et al., 2010) and it has been shown that the aberrant expression of retinoid 
receptors is a frequent event in melanoma and that the loss of retinoid receptor expression 
accompanies melanoma progression (Chakravarti et al., 2007). Thus, RA was found to 
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inhibit invasion in some tumor cell lines, including K1735-M2 melanoma cells (Helige et 
al., 1993), and to inhibit the proliferation of melanoma cells (Lotan, 1979; Drewa and 
Schachtshhabel, 1985) by inducing apoptosis and cell cycle arrest through up-regulation of 
p27, a cyclin-dependent kinase inhibitor that inhibits G1-to-S phase transition of the cell 
cycle (Zhang and Rosdahl, 2004). Nonetheless, at the concentrations used in our work, we 
only observed a cytostatic effect of RA (Figs. 4.3 and 4.5). 
On the other hand, several studies demonstrated a strong synergistic inhibition of 
breast cancer cells proliferation by the combinations of retinoids with antiestrogens 
(Danforth, 2004; Searovic et al., 2009; Koay et al., 2010), but the effects of these 
combinations in other types of cancer were unknown. Our results show, for the first time, 
that in melanoma cells the combination of RA (0.5 µM) with antiestrogens (5 µM) enhances 
the antiproliferative effect of the compounds of both classes, allowing to achieve a higher 
cytostatic effect than when the drugs are used individually. Moreover, we show that the 
TAM active metabolite EDX is more effective than TAM in inhibiting melanoma cells 
biomass, either when antiestrogens are applied in monotherapy or when they are applied in 
combination with RA (Figs. 4.2 and 4.3).  
The mechanisms underlying the ability of antiestrogens to decrease melanoma cell 
proliferation remain unclear. The presence of estrogen-binding proteins was reported in 
melanoma (Fisher et al., 1976; Walker et al., 1987), but further studies have failed to 
demonstrate their presence (Flowers et al., 1987; Cohen et al., 1990; Lecavalier et al., 1990; 
Kanter-Lewensohn et al., 2000). Recently, methylated ERα were detected in the tumor 
tissues and the sera of melanoma patients and their presence correlated with tumor 
progression (Mori et al., 2006). TAM has also been shown to suppress PKC/MEK/ERK and 
PKC/PI3K/Akt pathways and to inhibit the insulin-like growth factor-1 receptor signaling in 
melanoma cells (Kanter-Lewensohn et al., 2000; Matsuoka et al., 2009), suggesting that ER-
independent targets may also play an important role in the biological activity of TAM in 
melanoma. Importantly, TAM metabolites may have additional anticancer mechanisms 
relatively to TAM. In fact, Eto (2010) demonstrated that retinoids and the other TAM active 
metabolite, 4-hydroxytamoxifen (OHTAM), but not TAM, up-regulate the expression of p27 
in ER-positive and ER-negative breast cancer cells, using different pathways. Moreover, 
besides the 30-100-fold higher antiestrogenic potency of EDX relatively to TAM in breast 
cancer (Lim et al., 2005), EDX has also been shown to target ERα degradation by the 
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proteasome in breast cancer cells (Wu et al., 2009) and to inhibit aromatase activity, whereas 
similar concentrations of TAM or OHTAM do not significantly affect aromatase activity 
(Lu et al., 2012), suggesting that EDX may have additional mechanisms of action in breast 
cancer therapy in comparison with TAM. Additionally, the use of an active metabolite 
presents other advantages, since TAM requires CYP2D6-dependent bioconversion to its key 
active metabolites OHTAM and EDX to exert its anticancer activity (Kiyotani et al., 2012). 
In fact, it was established a correlation between a disadvantageous clinical outcome in breast 
cancer patients treated with TAM and CYP2D6 polymorphisms or the simultaneous 
administration of CYP2D6-inhibiting medication (Kelly et al., 2010; Lammers et al., 2010). 
To our knowledge, this is the first study using EDX in melanoma cells as an alternative to 
TAM. As our results demonstrate a superior cytostatic activity of EDX relatively to TAM, 
it is reasonable to hypothesize that, as observed in breast cancer, the steady-state levels of 
EDX will also have an impact on the treatment efficacy of TAM in melanoma, and the 
administration of the active metabolite would possibly avoid the therapeutic inefficacy due 
to the insufficient production of EDX in vivo. 
A major concern with cytostatic therapies is related to the inhibition of non-
neoplasic cell proliferation which leads to several side effects. Our studies revealed that at 
the concentrations used in our work, the combined therapy of RA and antiestrogens does not 
induce major toxic effects on endothelial cells (Fig. 4.7) and on rat liver mitochondrial 
bioenergetic function (Fig. 4.8), which suggests that the combinations of RA with 
antiestrogens may increase the therapeutic benefit without prohibitory side effects, 
particularly in the case of the combination of RA with EDX. Moreover, we showed that in 
isolated mitochondria EDX is less toxic than TAM, which adds to the advantages of an 
anticancer therapy including EDX (Cardoso et al., 2001; Ribeiro et al., 2013b). Our data are 
consistent with a phase I/II study performed in patients with advanced breast cancer which 
has reported that 20 mg TAM /day and RA up to 190 mg/m2/day can be given together with 
acceptable toxicity (Budd et al., 1998). However, additional studies in vivo regarding the 
combinations of RA with the TAM metabolite EDX, which present higher cytostatic and 
antimigration effects, are required in order to provide more data concerning the efficacy and 
the possible toxic effects of these combinations. 
On the other hand, the fact that the synergistic decrease of melanoma cells 
proliferation induced by the combinations of RA with antiestrogens was not observed in 
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normal cells suggests that these compounds might target specific alterations of melanoma 
cells. Several studies have demonstrated the existence of an interaction between retinoid and 
estrogen signaling in breast cancer cells (Rousseau et al., 2003; Hua et al., 2009; Ross-Innes 
et al., 2010). In fact, RARα is a component of the ERα transcriptional complex in breast 
cancer cells, where it acts as a cofactor, playing an important role in the regulation of 
estrogen-mediated gene expression (Ross-Innes et al., 2010). The mechanism underlying the 
synergistic effects of RA in combination with antiestrogens on the inhibition of proliferation 
of melanoma cells is a matter deserving future investigation. 
In conclusion, this work reports that the combination of RA with the TAM active 
metabolite EDX enhances the inhibition of melanoma cell proliferation induced by the 
compounds individually and that this combination can also impair the migration potential of 
these cells. Moreover, the combinations studied are not toxic for endothelial cells or for rat 
liver mitochondrial bioenergetic function. Considering that the available therapies for 
malignant melanoma rely on very aggressive strategies that offer unsatisfactory clinical 
responses with high toxicity, the combinations of RA with EDX may offer a powerful 
strategy for the treatment of malignant melanoma, possibly with less toxic effects than the 
currently available treatments. 
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CHAPTER V 
 
 
 
THE GLUTAMATE RECEPTOR ANTAGONIST MK-801 ACTS 
SYNERGISTICALLY WITH TAMOXIFEN AND ITS ACTIVE 
METABOLITES TO DECREASE THE PROLIFERATION OF 
MELANOMA CELLS 
 
 
 
 
 
[Ribeiro, M.P., Nunes-Correia, I., Santos, A.E. and Custódio, J.B. (2013) 
The glutamate receptor antagonist MK-801 acts synergistically with 
tamoxifen and its active metabolites to decrease the proliferation of 
melanoma cells. Submitted for publication in Exp. Dermatol.] 
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Abstract  
 
Recent reports suggest that N-methyl-D-aspartate receptor (NMDAR) blockade by 
MK-801 decreases tumor growth and migration. Thus, we investigated whether other 
ionotropic glutamate receptor (iGluR) antagonists were also able to modulate the 
proliferation of melanoma cells. On the other hand, the antiestrogen tamoxifen (TAM) 
decreases the proliferation and migration of melanoma cells, and has been included in 
combined therapies for malignant melanoma. As the efficacy of TAM is limited by its 
metabolism, we investigated the effects of the NMDAR antagonist MK-801 in combination 
with TAM and its active metabolites, 4-hydroxytamoxifen (OHTAM) and endoxifen (EDX). 
The sulforhodamine B, the trypan blue dye exclusion, the lactate dehydrogenase and the 
BrdU incorporation assays, as well as the cell cycle analysis by flow cytometry, were 
performed. The NMDAR blockers MK-801 and memantine decreased melanoma cell 
biomass due to diminished cell proliferation as both compounds decreased cell number and 
DNA synthesis without increasing cell death. In contrast, the NMDAR competitive 
antagonist D-2-amino-5-phosphonovaleric acid (APV) and the α-amino-3-hydroxy-5-
methyl-4-isoxazole-propionate (AMPA) and the kainate receptor antagonist 2,3-dihydroxy-
6-nitro-7-sulfamoylbenzo[f]quinoxaline (NBQX) did not affect the proliferation of 
melanoma cells, suggesting that among the iGluR antagonists only the NMDAR channel 
blockers inhibit melanoma cell proliferation. The combination of MK-801 with the 
antiestrogens TAM, OHTAM and EDX synergistically enhanced the antitumoral effects 
induced by the compounds individually due to a decrease in cell proliferation, with the 
combinations including TAM metabolites promoting blockade of cell cycle progression in 
G1. Therefore, the data obtained indicate that these drugs in association may be useful in 
malignant melanoma therapy although further studies of clinical implications are warranted. 
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5.1 - Introduction 
 
Emerging evidence indicates that melanoma is a very heterogenous malignancy, 
with several variants and with multiple signaling pathways contributing to cell proliferation 
constitutively activated (Herlyn, 2009). Therefore, in order to target such diversity, we need 
to develop combinations of drugs with specific and complementary mechanisms of action 
(Herlyn, 2009; Ko and Fisher, 2011). 
Glutamate, the major excitatory neurotransmitter of the mammalian central nervous 
system, activates two classes of glutamate receptors (GluRs), the ionotropic (iGluRs) and 
metabotropic (mGluRs) receptors. The iGluRs form ion channels, while the mGluRs belong 
to the superfamily of G protein-coupled receptors (Teh and Chen, 2012). The iGluRs are 
divided into three groups based on structural and pharmacological similarities, and are 
named N-methyl-D-aspartate (NMDA), -amino-3-hydroxy-5-methyl-4-isoxazole-
propionate (AMPA) and kainate (KA) receptors, according to the type of synthetic agonist 
that activates them. So far, eight members of mGluRs have been identified, which are 
grouped in three classes based on sequence homology and downstream signaling pathways. 
The fact that both neuronal embryonic progenitor cells and tumor cells have 
propensity to proliferate and migrate led to the investigation of the role of glutamate and its 
receptors on the proliferation and migration of cancer cells. It has been reported that GluR 
subunits are differentially expressed in a variety of tumor cell lines (Stepulak et al., 2009; 
Brocke et al., 2010; North et al., 2010a, b; Stepulak et al., 2011) and in samples of human 
tumor tissues (North et al., 2010a, b). The knockdown of selected GluR subunits has also 
been shown to modulate cancer cell proliferation and invasive behavior (de Groot et al., 
2008; Luksch et al., 2011). Moreover, NMDA receptor (NMDAR) and AMPA receptor 
(AMPAR) antagonists inhibit the proliferation and migration of tumor cells and enhance the 
effects of cytostatic drugs, such as cyclophosphamide and thiotepa, in vitro and in vivo 
(Stepulak et al., 2005, 2007; North et al., 2010a, b; Rzeski et al., 2011; Stepulak et al., 2011). 
Beyond the role played by mGluR signaling in melanoma cells (Marín et al., 2006; 
Namkoong et al., 2007; Abdel-Daim et al., 2010; Lee et al., 2011), recent reports also suggest 
a role for iGluRs, since functional NMDARs are expressed in this type of cells and the 
NMDAR antagonist MK-801 was shown to inhibit the migration and proliferation of 
melanoma cells and to decrease their growth in vivo (Song et al., 2012). In addition, the 
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AMPAR antagonist CFM-2, as well as the NMDAR antagonists memantine and MK-801 
have been shown to alter melanocyte morphology, indicating that glutamate signaling may 
be relevant in melanocyte regulation (Hoogduijn et al., 2006).  
On the other hand, it has been reported that tamoxifen (TAM), a selective estrogen 
receptor (ER) modulator widely used in the treatment and prevention of breast cancer, also 
decreases the growth and migration of melanoma cells (Kanter-Lewensohn et al., 2000; 
Matsuoka et al., 2009; Ribeiro et al., 2013a) and sensitizes melanoma cells to other 
chemotherapeutic agents (Flaherty et al., 1996; McClay et al., 1997). The biological activity 
of TAM is mediated by two active metabolites, 4-hydroxytamoxifen (OHTAM) and 
endoxifen (EDX), generated via cytochrome P450 (CYP) enzymes, namely CYP3A4 and 
CYP2D6 (Kiyotani et al., 2012). Recent studies point to an association between CYP2D6 
polymorphisms and the clinical outcome in women treated with TAM (Schroth et al., 2009; 
Lammers et al., 2010). Furthermore, it was shown that the coadministration of CYP2D6-
inhibiting medication can limit the efficacy of TAM therapy (Kelly et al., 2010). Therefore, 
the use of TAM active metabolites may present strong advantages relatively to the utilization 
of the prodrug, as it would avoid the variability related with TAM metabolism, leading to a 
more reliable therapeutic outcome.  
Based on these findings, we investigated the effects of iGluR antagonists on the 
proliferation of a highly invasive melanoma cell line (K1735-M2). Additionally, since the 
combination of drugs with complementary mechanisms of action can provide superior 
therapeutic efficacy using lower concentrations, with the advantage of reducing the side 
effects of chemotherapy, we evaluated the effects of MK-801 in combination with 
antiestrogens on cell proliferation as well. We show that the NMDAR channel pore blockers, 
MK-801 and memantine, decrease melanoma cell proliferation due to decreased cell 
division. Moreover, the combined treatment of MK-801 with antiestrogens, and particularly 
with TAM metabolites, strongly enhances the antiproliferative effects induced by the 
compounds individually, supporting the view that these drugs in association may be useful 
in malignant melanoma therapy. 
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5.2 - Materials and Methods 
 
Reagents 
MK-801, Memantine TAM, OHTAM and EDX were obtained from SIGMA-
Aldrich (St Louis, MO, USA). 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline 
(NBQX) was purchased from Tocris. D-2-amino-5-phosphonovaleric acid (APV), 
Dulbecco’s modified Eagle’s medium (DMEM) and antibiotic/antimycotic solution (10 000 
units penicillin, 10 mg streptomycin, 25 µg amphotericin B per mL) were purchased from 
SIGMA-Aldrich (St Louis, MO, USA), Fetal Bovine Serum (FBS) and trypsin were obtained 
from Gibco, Invitrogen Life Technologies (Carlsbad, California, USA). All of the other 
chemicals were purchased from SIGMA-Aldrich (St Louis, MO, USA) and were of the 
highest grade of purity commercially available. GluR antagonists were kept in aqueous 
stocks. TAM and OHTAM stock solutions were prepared in absolute ethanol while EDX 
was prepared in dimethyl sulfoxide (DMSO). 
 
Cell culture 
K1735-M2 mouse melanoma cells (kindly offered by Dr. Paulo Oliveira, Center for 
Neurosciences and Cell Biology, Department of Zoology, University of Coimbra, Portugal) 
were cultured in DMEM, supplemented with 10 % heat-inactivated FBS and 1 % 
antibiotic/antimycotic solution, and kept in a humidified atmosphere with 5 % CO2/95 % air, 
at 37 ºC.  
Cells were plated with a density of 6.1×104 cells/cm2 and 24 h after plating, the 
GluR antagonists and/or the antiestrogens were added to the cultures from diluted stocks, 
except in the control condition where the vehicle was added.  
 
Sulforhodamine B (SRB) assay 
The cytotoxic effects induced by the drugs on melanoma cell cultures were 
determined using the SRB assay, which is based on the binding of SRB to the basic amino 
acids of cellular proteins (Holy et al., 2006). At selected time points, the cell culture was 
fixed with absolute methanol containing 1 % acetic acid, and stored at −20 ºC overnight. The 
methanol was then decanted and the plate air-dried. The SRB solution (0.5 % in 1 % acetic 
acid) was added to each well, and the plate incubated at 37 °C for 1 h. The cells were rinsed 
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with 1 % acetic acid, air-dried, and the bound dye eluted with 10 mM Tris buffer, pH 10. 
The absorbance was measured in a Synergy HT plate reader at 540 nm, providing an estimate 
of the total protein mass (biomass) which is related to the cell number. The absorbance 
obtained in control cultures was considered 100 %. Experiments were performed in 
triplicates for each independent experiment. 
 
Cell viability assessment by trypan blue dye exclusion 
Cell viability was investigated by staining cells with trypan blue (Houben et al., 
2009). At designated time points, adherent cells were trypsinized, centrifuged at 1 000 rpm 
for 5 min and treated with 0.4 % trypan blue for 2-3 min and then counted in a 
hemocytometer under a transmitted light microscope. Cells presenting a blue stained 
cytoplasm were considered as dead cells; cells excluding the dye were considered as viable. 
The number of independent experiments is indicated in figure legends. 
 
Lactate dehydrogenase (LDH) assay 
LDH is a cytosolic enzyme that is released into the extracellular medium following 
the loss of cell membrane integrity (Vieira et al., 2010). Thus, we investigated the ability of 
the compounds used in this study to induce melanoma cell death by determining the LDH 
activity in the cell medium. The culture medium was collected 72 h after incubation with the 
drugs and centrifuged at 14 000 rpm for 10 min at 4 ºC. An aliquot of supernatant (100 µL) 
was incubated with a substrate mixture containing 40 µM lactate in perchloric acid 3 %, and 
3.6 mM nicotinamide adenine dinucleotide (NAD+) in tris-hidrazine buffer [80 mM tris, 400 
mM hydrazine, 5 mM ethylenediaminetetraacetic acid (EDTA), pH 9.5]. LDH activity was 
determined by an enzymatic reaction whereby the NAD+ is reduced to NADH by oxidation 
of lactate to pyruvate. Thus, the amount of NADH is directly related to LDH activity in the 
supernatant. Absorption of NADH was measured at 340 nm. The LDH activity is expressed 
as the ratio between the LDH activity in the extracellular medium and the total LDH activity 
obtained from the supernatant of cells lysed with Triton X-100, which was considered as 
100 %. Experiments were performed in duplicates for each independent experiment.  
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5-bromo-2'-deoxyuridine (BrdU) incorporation assay 
Melanoma cell proliferation was monitored through the evaluation of BrdU 
incorporation during DNA synthesis in proliferating cells. For this purpose, the Cell 
Proliferation ELISA, BrdU, colorimetric kit (Roche) was used according to the 
manufacturer’s protocol. After 48 h of incubation with the drugs, cultured cells were placed 
in BrdU-labeling solution for 90 min. Afterwards the cells were fixed and the DNA 
denaturated with the FixDenat solution, provided with the kit, and then incubated with a 
monoclonal antibody conjugated with peroxidase (anti-BrdU-POD) to bind BrdU in the 
newly synthesized DNA. The immune complexes were detected using the 3,3’,5,5’-
tetramethylbenzidine (TMB) substrate and the absorbance was measured in a Synergy HT 
plate reader at 370 nm. The absorbance values correlate to the amount of DNA synthesis 
and, therefore, to the number of proliferating cells. The experiments were carried out in 
triplicate for each independent experiment and the absorbance obtained in control cultures 
was considered as 100 %. 
 
Cell cycle analysis by flow cytometry 
The effects of the drugs on cell cycle were monitored by flow cytometry (Carmo et 
al., 2011). Cells were plated in 6-multiwell plates and incubated with MK-801, TAM, 
OHTAM and EDX for 48 h. At the end of the incubation period, cells were trypsinized and 
centrifuged at 1 500 rpm for 10 min, the culture medium was discarded and the pellet was 
fixed overnight at 4 ºC with a solution of cold 70 % ethanol. The cells were then centrifuged 
at 1 500 rpm for 10 min, the pellet was resuspended in a solution of phosphate-buffered 
saline (PBS) containing RNAse and, after 45 min, propidium iodide was added and cells 
were further incubated for 1 h in the dark, at room temperature (the final concentrations of 
RNase and propidium iodide were 10 µg/mL and 20 μg/mL, respectively). The propidium 
iodide fluorescence was measured on a FACSCalibur flow cytometer (BD Biosciences, San 
Jose, CA) equipped with a 488 nm argon-ion laser. For aggregate/debris discrimination, in 
addition to propidium iodide fluorescence signal heights, areas and widths were also 
measured. Measurements for at least 20 000 events were collected per sample. Data were 
analyzed using the ModFit LT 3.0. software. The experiments were carried out in duplicate 
for each independent experiment and the results are expressed as % of total cells. 
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Statistical analysis 
Results are presented as the mean ± S.E.M. of the indicated number of independent 
experiments. Statistical significance between the different assays was determined using the 
one-way analysis of variance (ANOVA), followed by the Tukey post-test, for multiple 
comparisons. A p value <0.05 was considered statistically significant. These statistical 
analyses were performed using the software package GraphPad Prism 4. 
 
5.3 - Results 
 
In order to establish the most effective GluR antagonists to pursue our work, we 
initially studied the cytotoxic effects of the NMDAR channel blockers MK-801 and 
memantine, and the selective NMDAR competitive antagonist APV, as well as the AMPAR 
antagonist NBQX, on melanoma cell biomass by using the SRB assay which correlates with 
cell number (Fig. 5.1). After 72 and 96 h of incubation in the presence of MK-801 and 
memantine, the cell biomass was decreased and significant effects were detected at 500 µM 
of MK-801 and at 300 µM of memantine. In contrast, the cell biomass was unaffected by 
500 µM of APV or NBQX after 96 h of drug incubation (Fig. 5.1). Therefore, in the 
following experiments we used the NMDAR channel blockers MK-801 and memantine. 
To elucidate the mechanism underlying the cytotoxic effects of the NMDAR 
channel blockers MK-801 and memantine, we assayed cell viability after 72 h of incubation 
with the drugs by using the trypan blue dye exclusion assay (Fig. 5.2). In agreement with the 
results obtained with SRB assay, NMDAR channel blockers induced a decrease in the 
number of viable cells, which was significant at 500 µM of MK-801 and 300 µM of 
memantine (Fig. 5.2A). Moreover, at these concentrations MK-801 and memantine did not 
increase the number of dead cells during the course of 72 h (Fig. 5.2B).  
The absence of an increase in the number of dead cells within 72 h of treatment 
with the drugs was confirmed by the LDH assay which, as the trypan blue assay, is a 
cytotoxicity test based on cell membrane integrity. The LDH activity did not increase in the 
supernatant of cells grown in the presence of MK-801 or memantine (Fig. 5.3A). Therefore, 
we investigated whether the cytotoxic effect of the NMDAR antagonists could be due to the 
inhibition of melanoma cell proliferation by means of BrdU incorporation in the DNA  
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Fig. 5.1 - Effects of GluR antagonists on melanoma cell biomass. Cells were incubated in 
the absence (control) or in the presence of MK-801 (100-500 µM), memantine (100-500 
µM), APV (500 µM) and NBQX (500 µM). At 72 and 96 h, melanoma cell biomass was 
evaluated by the SRB assay. For that purpose, the cells were fixed with absolute methanol 
containing 1 % acetic acid and incubated with SRB solution at 37 °C for 1 h. Afterwards, 
the plates were rinsed and the bound dye eluted with Tris buffer and the absorbance was 
measured at 540 nm. Bars represent the mean ± S.E.M. of four independent experiments 
performed in triplicates. *** p<0.001 vs the respective time point control, One-way ANOVA 
followed by Tukey post-test. 
 
 
 
 
 
 _________________________ Effects on Endoxifen and Glutamate Receptor antagonists on melanoma cells 
163 
 
 
 
 
 
 
 
Fig. 5.2 - Cell viability of melanoma cells treated with the NMDAR channel blockers MK-
801 and memantine. Cells were grown in the absence (0) or in the presence of 100-500 µM 
of MK-801 or memantine for 72 h and the number of viable and dead cells was determined 
by the trypan blue dye exclusion assay. After the incubation period, cells were trypsinized, 
centrifuged, treated with 0.4 % trypan blue and counted in a hemocytometer under a 
transmitted light microscope. The number of trypan blue-negative (viable) cells and trypan 
blue-positive (dead) cells is presented in the graphs A and B, respectively. Data represent 
the mean ± S.E.M. of four independent experiments. *** p<0.001, * p<0.05 vs control. 
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synthesis after a 48 h treatment with MK-801 or memantine (100-500 µM). This earlier time 
point was selected as the number of cells in control condition at 72 h is substantially high 
and could lead to absorbance values beyond the acceptable measuring range. As shown in 
figure 5.3B, both compounds significantly reduced BrdU incorporation at 300 μM. Taken 
together, our results indicate that the toxic effects of the NMDAR channel blockers MK-801 
and memantine on melanoma cells might be due to a decrease in cell proliferation. 
To investigate the effect of drug combinations on cell proliferation, MK-801 was 
the compound of choice to study in association with antiestrogenic compounds, since it has 
been shown to be effective and safe in several animal models of cancer (Stepulak et al., 2005; 
North et al., 2010a, b; Song et al., 2012), whereas exposure to memantine at the 
concentrations used in this study compromises mitochondrial function (McAllister et al., 
2008), which can lead to drug-induced tissue injury (Labbe et al., 2008).  
The dose-dependent cytotoxic effects of antiestrogens on melanoma cells were 
initially evaluated by the SRB assay during a time-course experiment. The TAM active 
metabolite concentration of 5 µM was the lowest that induced a significant decrease in cell 
biomass (data not shown). Therefore, 5 µM was the selected concentration to pursue the 
studies aiming to assess the possible co-operative effects of a combination of antiestrogens 
with NMDAR antagonists on melanoma cells proliferation (Fig. 5.4). 
Thus, melanoma cells were subjected to treatment with MK-801 (100 µM) and 
antiestrogens (5 µM), alone or in combination, over 72 h (Fig. 5.4). At this concentration, 
the antiestrogen TAM did not significantly decrease melanoma cell biomass, whereas TAM 
active metabolite EDX significantly reduced cell biomass to about 82 % of control, in 
agreement with our previous studies (Ribeiro et al., 2013a). The other TAM active 
metabolite, OHTAM, significantly decreased cell biomass to approximately 66 % (Fig. 5.4). 
The combination of MK-801 with the antiestrogens TAM, OHTAM and EDX diminished 
cell biomass to approximately 46 %, 33 % and 38 % of control, respectively, which is a 
much stronger cytotoxic effect in comparison with that induced by the compounds 
individually. Noteworthy, MK-801 at a concentration that did not induce cytotoxicity, when 
applied individually, co-operated with the antiestrogens to potentiate their cytotoxic effects 
(Fig. 5.4). The effects of the combinations of MK-801 (100 µM) with antiestrogens (5 µM) 
on cell viability were then quantitated at selected time points through the trypan blue dye  
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Fig. 5.3 - The NMDAR channel blockers MK-801 and memantine do not induce cell death 
(A) and decrease cell proliferation (B). (A) Melanoma cells were grown in the absence 
(control) or in the presence of 100-500 µM of MK-801 or memantine. Cell death was 
assessed by measuring LDH activity in the supernatant of damaged cells after 72 h in culture. 
Bars represent the mean ± S.E.M. of three independent experiments performed in duplicates. 
The statistical analysis was performed by One-way ANOVA followed by Tukey post-test. 
(B) Cells were grown for 48 h in the absence (control) or in the presence of 100-500 µM 
MK-801 or memantine and then cell proliferation was assessed by the BrdU incorporation 
assay as described in the Materials and methods section. Bars represent the mean ± S.E.M. 
of four independent experiments performed in triplicates. *** p<0.001, ** p<0.01, One-way 
ANOVA followed by Tukey post-test. 
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Fig. 5.4 - The combined treatment of MK-801 with antiestrogens synergistically decreases 
the melanoma cell biomass. Melanoma cells were grown in the absence (control) or in the 
presence of 100 µM of MK-801, 5 µM of the antiestrogens TAM, OHTAM and EDX, alone 
or in combination. The melanoma cell biomass was evaluated by the SRB assay after 72 h 
of incubation. Bars represent the mean ± S.E.M. of six independent experiments performed 
in triplicates. *** p<0.001, ** p<0.01, * p<0.05 vs control. +++ p<0.001 vs MK-801. ### 
p<0.001, # p<0.05 vs antiestrogen, One-way ANOVA followed by Tukey post-test. 
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exclusion assay (Fig. 5.5). As shown in figure 5.5A, MK-801 and TAM did not alter the 
number of viable cells at 72 h, in agreement with the results obtained in SRB assays (Fig.5.4). 
However, a decrease in the number of viable cells was already observed at 48h when cells 
were treated with OHTAM (Fig. 5.5B), whereas the EDX metabolite only significantly 
decreased the number of viable cells at 72 h of incubation with the drug (Fig. 5.5C). The 
combination of any of the three antiestrogens with MK-801 induced a significantly larger 
decrease of viable cells already observed at 48 h of incubation when compared to the 
compounds applied individually (Figs. 5.5A-5.5C). On the other hand, the number of dead 
cells after exposure to MK-801 and to the three antiestrogens, alone or in combination, did 
not significantly increase during the course of 72 h (Figs. 5.5D-5.5F).  
The absence of an increase in the number of dead cells within 72 h of treatment 
with the drugs was confirmed by the LDH assay (Fig. 5.6). Neither the compounds 
individually nor their combinations increased the LDH activity in the extracellular medium, 
in accordance with the results obtained with the trypan blue dye exclusion assay (Fig. 5.5). 
The results obtained thus suggest that the toxic effects induced by the combined treatment 
of MK-801 and antiestrogens on melanoma cells may be related to a decrease in cell 
proliferation. Therefore, the inhibition of cell growth induced by MK-801 in association with 
the antiestrogens was also investigated by means of the BrdU incorporation assay (Fig. 5.7). 
While 100 µM of MK-801 by itself did not affect the BrdU incorporation in melanoma cells, 
5 µM of TAM, OHTAM and EDX significantly decreased the incorporation of BrdU to 80 
%, 52 % and 59 % of control, respectively. Noteworthy, the combination of MK-801 at 100 
µM with the three antiestrogens TAM, OHTAM and EDX significantly decreased BrdU 
incorporation to 35 %, 9 % and 17 % of control, respectively, which is a much stronger effect 
relatively to that of the compounds individually (Fig. 5.7). Thus, our results showed the 
combinations of MK-801 and the antiestrogens might have a cytostatic effect on melanoma 
cells, which is more prominent when MK-801 is combined with the TAM metabolites than 
with the prodrug. 
To confirm our hypothesis that the rate of proliferation of melanoma cells was in 
fact affected by the combination of MK-801 with antiestrogens, and that the reduction in 
BrdU signal was not a consequence of the decrease in cell number, the effect of the drugs on 
the cell cycle was analyzed by flow cytometry (Fig. 5.8). Untreated cells (control) were  
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Fig. 5.5 - Cell viability of melanoma cells treated with MK-801 and the antiestrogens. 
Melanoma cells were grown in the absence (control) or in the presence of 100 µM of MK-
801 and 5 µM of the antiestrogens TAM (A, D), OHTAM (B, E) and EDX (C, F), alone or 
in combination, and cell viability was assessed by the trypan blue dye exclusion assay as 
described in the Materials and methods section at 24 h, 48 h and 72 h. The graphs present 
the number of viable (A, B, C) and dead (D, E, F) cells. Data represent the mean ± S.E.M. 
of six independent experiments. *** p<0.001, ** p<0.01, * p<0.05 vs the respective time 
point control. +++ p<0.001, ++ p<0.01 vs MK-801 at the respective time point. ### p<0.001, 
## p<0.01, # p<0.05 vs the antiestrogen at the respective time point, One-way ANOVA 
followed by Tukey post-test. 
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Fig. 5.6 - The combination of MK-801 with the antiestrogens does not induce melanoma 
cell death. Melanoma cells were grown in the absence (control) or in the presence of 100 
µM of MK-801, 5 µM of the antiestrogens TAM, OHTAM and EDX, alone or in 
combination. Cell death was assessed by measuring LDH release from damaged cells, after 
72 h in culture. Bars represent the mean ± S.E.M. of four independent experiments performed 
in duplicates. 
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Fig. 5.7 - Melanoma cell treatment with the combination of MK-801 and the antiestrogens 
reduces cell proliferation. Cells were grown in the absence (control) or in the presence of 
100 µM of MK-801, 5 µM of the antiestrogens TAM, OHTAM and EDX, alone or in 
combination, for 48 h, and then cell proliferation was assessed by the BrdU incorporation 
assay as described in the Materials and methods section. Bars represent the mean ± S.E.M. 
of four independent experiments performed in triplicates. *** p<0.001, * p<0.05 vs control. 
+++ p<0.001 vs MK-801. ### p<0.001, ## p<0.01 vs antiestrogen, One-way ANOVA 
followed by Tukey post-test. 
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characterized by a long and well defined G1 peak, a slightly prominent S phase, a least 
prominent G2 peak and a relatively low G0/G1 fraction, which was considered as the 
apoptotic fraction (Fig. 5.8). Forty-eight hours after incubation with 100 µM of MK-801 or 
5 M of antiestrogens, the population of cells in each cell cycle phase relatively to the control 
condition was not changed (Fig. 5.8). The combination of MK-801 with the TAM active 
metabolites, OHTAM or EDX, significantly increased the percentage of cells in G1 while 
decreasing the population of cells in the S phase, thus arresting the cell cycle in the G1 phase 
(Fig. 5.8). 
 
5.4 - Discussion 
 
Recent studies have demonstrated that melanoma cells express NMDARs and that 
MK-801 inhibits their migration and proliferation (Song et al., 2012). In addition, it was 
reported that NMDAR and AMPAR antagonists enhance the effects of cytostatic drugs on 
human neuroblastoma and human rhabdomyosarcoma/medulloblastoma cell lines (Rzeski et 
al., 2001). Thus, we investigated whether other iGluR antagonists could also affect the 
proliferation of melanoma cells and the possible co-operative effects of MK-801 in 
combination with antiestrogenic compounds, which also decrease the growth and migration 
of melanoma cells (Kanter-Lewensohn et al., 2000; Matsuoka et al., 2009; Ribeiro et al., 
2013a). Our results show, for the first time, that the combined treatment of MK-801 with 
antiestrogens, and particularly with TAM active metabolites, enhances the antiproliferative 
action induced by the compounds individually. 
The cytotoxic effects of GluR antagonists on melanoma cells were assessed by the 
SRB assay which showed that MK-801 and memantine reduce melanoma cell biomass (Fig. 
5.1). On the contrary, the AMPAR and KAR antagonist NBQX, and the selective NMDAR 
competitive antagonist APV, which binds on the extracellular domain of the NMDAR, did 
not exhibit antiproliferative effects on melanoma cells even at high concentrations (Fig. 5.1). 
Although MK-801 and memantine have been traditionally considered to target the NMDAR 
channel, these compounds might act on other cellular targets. In fact, there is evidence that 
the 5-hydroxytryptamine receptor 3, the α7 and/or α4β2 nicotinic receptors and the dopamine 
receptors may also be involved in the biological activity of memantine (Rammes et al., 2008;  
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Fig. 5.8 - Melanoma cell treatment with MK-801 and TAM metabolites blocks cell cycle 
progression in G1. Cells were grown in the absence (control) or in the presence of MK-801 
(100 µM), 5 µM of the antiestrogens TAM, OHTAM and EDX, alone or in combination, for 
48 h. Cell cycle distribution was evaluated by flow cytometry analysis of the DNA content 
labeled with propidium iodide. Data are the mean ± S.E.M. of three independent experiments 
performed in duplicates. A total of 20 000 events were analyzed for each experiment. ** 
p<0.01, * p<0.05 vs control. + p<0.05 vs MK-801. ## p<0.01, # p<0.05 vs the antiestrogen, 
One-way ANOVA followed by Tukey post-test. 
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Seeman et al., 2008). In addition, acute and chronic exposure to memantine has NMDAR- 
independent effects on the mitochondrial function, by affecting complex I and complex IV 
activities (McAllister et al., 2008). Likewise, MK-801 might act on the α7 and α4β2 nicotinic 
receptors (Briggs et al., 1996; Buisson and Bertrand, 1998) and can also modulate 
thedopaminergic and serotonergic system (Rao et al., 1990; Clarke and Reuben, 1995; 
Iravani et al., 1999). Additionally, MK-801 was shown to inhibit protein synthesis, an effect 
that does not appear to be related with NMDAR inhibition (Charriaut-Marlangue et al., 
1994). Thus, considering that MK-801 and memantine might interact with multiple targets, 
it remains unclear whether the effects on melanoma cells are mediated by NMDAR 
inhibition, in particular due to the lack of effect of APV. On the other hand, the absence of 
a cytotoxic effect of NBQX suggests that AMPAR and KAR inhibition possibly does not 
affect melanoma cell viability. 
The cell viability assay with trypan blue staining revealed that MK-801 and 
memantine decrease the number of viable cells, without inducing cell death (Fig. 5.2). 
Moreover, the evaluation of LDH activity in the supernatant of melanoma cells (Fig. 5.3A) 
and the BrdU incorporation assay pointed out that MK-801 and memantine do not induce 
cancer cell death, but instead they inhibit cell proliferation (Fig. 5.3B). Our results correlate 
with a recent study that has demonstrated that MK-801 inhibits the proliferation of the 
human metastatic melanoma cell line WM451, and that it can also reduce melanoma cell 
motility and invasion (Song et al., 2012). As metastatic malignant melanoma is largely 
refractory to existing therapies and has a very poor prognosis, the combined cytostatic and 
antimigration activity of MK-801 may suggest that it is a promising drug for melanoma 
treatment. Moreover, MK-801 was shown to inhibit the cell growth of other tumor cell lines 
and to have an antitumoral effect on animal models of melanoma (Song et al., 2012), 
neuroblastoma and rhabdomyosarcoma (Stepulak et al., 2005), lung (Stepulak et al., 2005; 
North et al., 2010b) and breast cancer (North et al., 2010a).  
Considering the complex machinery involved in the onset and progression of 
malignant melanoma, the use of combination of drugs may provide an effective strategy to 
increase the therapeutic benefit (Herlyn, 2009; Ko and Fisher, 2011). Therefore, the effects 
of MK-801 were also investigated in combination with the antiestrogens TAM, OHTAM 
and EDX. Our results show, for the first time, that melanoma cell treatment with the 
NMDAR antagonist MK-801 combined with antiestrogens strongly reduces melanoma cell 
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biomass in a co-operative manner when compared with the effect induced by the compounds 
individually (Fig. 5.4). Likewise, the assessment of cell viability with trypan blue staining 
revealed that the combined treatment of MK-801 with antiestrogens induces a larger 
decrease in the number of viable cells, without increasing the number of dead cells (Fig. 
5.5), suggesting that the observed cytotoxic effect of the combinations of MK-801 with 
antiestrogens are due to decreased cell proliferation. Indeed, the evaluation of LDH activity 
in the supernatant of melanoma cells confirmed that the decrease in viable cells is not due to 
increased cell death (Fig. 5.6), whereas the BrdU incorporation assay pointed out that MK-
801 and the antiestrogens inhibit cell proliferation with maximal efficacy when the drugs are 
used in combination (Fig. 5.7). Moreover, the analysis of the cell cycle revealed that the 
combination of MK-801 with TAM metabolites, OHTAM or EDX, induce cell cycle arrest 
in G1 (Fig. 5.8). These results are in line with other studies that have shown that GluR 
antagonists co-operate with other cytostatic drugs, such as cyclophosphamide, thiotepa 
(Rzeski et al., 2001) and docetaxel (Haas et al., 2007) enhancing the antiproliferative action. 
According to our previous studies (Ribeiro et al., 2013a), TAM active metabolites 
were more effective than TAM in the inhibition of the proliferation of melanoma cells, either 
individually or in combination. As recent studies established that the CYP2D6 phenotype is 
an important predictor of treatment outcome (Lammers et al., 2010) and that the 
coadministration of CYP2D6-inhibiting medication diminishes the treatment effect of TAM 
(Kelly et al., 2010), the use of TAM metabolites instead of the prodrug may increase the 
therapeutic benefit. Importantly, the use of MK-801 in a combined therapy might allow 
achieving an antitumoral effect with a lower dose than that necessary if the compound would 
be used in a monotherapy regimen, thus increasing the possibility of using MK-801 in a 
chronic treatment, without major side effects. In fact, in vivo studies have revealed that doses 
of MK-801 that were able to slow breast (two daily doses of 0.3 mg/kg), melanoma (0.6 
mg/kg every three days) and lung (up to 0.3 mg/kg) cancer progression were devoid of 
significant side effects (Stepulak et al., 2005; North et al., 2010a, b; Song et al., 2012). 
Noteworthy, the chronic exposure to MK-801 at concentrations up to 1.0 mg/kg was well 
tolerated by juvenile rhesus monkeys (Popke et al., 2002), suggesting that MK-801 might be 
suitable as a drug for cancer therapy. Nevertheless, others have found that these doses might 
influence rodents behavior (Gilbert, 1988; Tricklebank, 1989; Kawabe et al., 1998) and thus, 
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the MK-801 dose and the duration of treatment necessary to achieve a maximal effect on 
cancer proliferation without major side effects has yet to be determined.  
In conclusion, we report that the NMDAR channel blocker MK-801 decreases 
melanoma cell proliferation and that its therapeutic potential is greatly enhanced when used 
in combination with antiestrogenic compounds, particularly with the active metabolites of 
TAM. Altogether, these data suggest that the NMDAR antagonist MK-801 may have 
therapeutic potential as an anticancer agent, particularly in therapeutic association. 
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Abstract 
 
The activation of the G protein-coupled receptor 30 (GPR30) (also termed G 
protein-coupled estrogen receptor 1) by its specific agonist G-1 inhibits prostate cancer and 
17β-estradiol-stimulated breast cancer cell proliferation. In addition to 17β-estradiol and G-
1, the antiestrogen tamoxifen (TAM) and one of its active metabolites 4-hydroxytamoxifen 
(OHTAM), are also known to activate the GPR30. TAM decreases melanoma cell 
proliferation and migration, but its mechanism of action in this malignancy and its inclusion 
in melanoma therapeutic regimens remains controversial. Therefore, we investigated the 
expression of GPR30 in K1735-M2 melanoma cells and the effects of G-1 and the 
antiestrogens TAM, OHTAM, as well as the other key metabolite of TAM, endoxifen 
(EDX), on melanoma cell proliferation to clarify the role of GPR30 in the antiproliferative 
activity of antiestrogens in melanoma. Our data demonstrate that melanoma cells expressed 
GPR30 and that the selective agonist G-1 markedly reduced melanoma cell biomass and the 
number of viable cells without increasing cell death. Rather, G-1 decreased cell division, as 
shown by the decrease in DNA synthesis and by the cell cycle arrest in G2 phase. Likewise, 
the antiestrogens TAM, OHTAM and EDX exhibited an antiproliferative activity in 
melanoma cells due to decreased cell division. Moreover, G-1 and the antiestrogens showed 
a trend to decrease the levels of phosphorylated extracellular signal-regulated kinases (ERK) 
1/2 after 1 h treatment, but only EDX induced significant effects. Thus, our results identify 
the GPR30 as a possible new target for the antiestrogens in melanoma and considering that 
the activation of the GPR30 inhibits the proliferation of melanoma cells, targeting the 
GPR30 may be an innovative strategy for the clinical management of melanoma. 
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6.1 - Introduction 
 
Emerging evidences suggest that the G-protein-coupled receptors (GPCRs) play a 
central role in cancer development and progression (Lee et al., 2008). In fact, several GPCRs 
are overexpressed in diverse types of cancer tissues (Li et al., 2005) and the interference with 
GPCRs and their downstream targets thus represents an attractive strategy for cancer 
treatment. Similarly, some GPCRs have been shown to be involved in tumorigenesis and 
metastatic progression of melanoma (Lee et al., 2008). 
The G protein-coupled receptor 30 (GPR30), also designated G protein-coupled 
estrogen receptor 1 (GPER1), was identified between 1996-1998 by four different 
laboratories as a new 17β-estradiol-binding protein structurally distinct from the classical 
estrogen receptors (ER) (Wang et al., 2010). It was demonstrated that the GPR30 mediates 
the proliferative effects of estrogen on some cancer cells (Vivacqua et al., 2006a; Albanito 
et al., 2007) and that its cellular activation involves the transactivation of epidermal growth 
factor receptor via a G protein-dependent pathway as well as the activation of adenylate 
cyclase, the mitogen activated protein kinase (MAPK) and phosphoinositide-3-kinase 
(PI3K) signaling pathways (Filardo et al., 2000, 2002; Ge et al., 2013). The identification of 
G-1, the first GPR30-selective agonist (Bologa et al., 2006), with no notable activity towards 
ERα and on 25 other important GPCRs (Prossnitz and Barton, 2011), provided an important 
tool for studying the GPR30-mediated signaling. It was reported that G-1 decreases 
endothelial and urothelial cells proliferation (Teng et al., 2008; Holm et al., 2011). Moreover, 
G-1 inhibits the proliferation of prostate cancer (Chan et al., 2010) and 17β-estradiol-
stimulated breast cancer cells (Ariazi et al., 2010). The expression of GPR30 was also 
reported in ovarian, endometrial and thyroid cancer cells, but its activation has been shown 
to increase cell proliferation (Vivacqua et al., 2006a; Fujiwara et al., 2012; Du et al., 2012), 
suggesting that the effects resulting from the activation of the GPR30 may vary according 
to the cell type. 
Besides the specific agonist G-1 and 17β-estradiol, the selective ER modulators 
tamoxifen (TAM) and 4-hydroxytamoxifen (OHTAM) have also been shown to behave as 
agonists for GPR30 (Maggiolini et al., 2004; Thomas et al., 2005; Vivacqua et al., 2006a; 
Pandey et al., 2009). TAM inhibits melanoma cell proliferation (Gill et al., 1984; Piantelli 
et al., 1995; Lama et al., 1998; Kanter-Lewensohn et al., 2000), invasion and metastasis 
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(Matsuoka et al., 2009) and it has been used in the clinical management of melanoma as a 
single agent or, more often, in combination with other chemotherapeutic agents (Cocconi et 
al., 1992; McClay et al., 1993). However, the mechanisms underlying the antitumor activity 
of TAM in melanoma are poorly understood and the clinical trials performed to clarify the 
benefit of TAM in therapeutic regimens for advanced and metastatic melanoma have 
produced contradictory results (Lens, 2003; Beguerie et al., 2010).  
Based on these findings, we investigated the expression of GPR30 and the effects 
of GPR30 ligands on the proliferation of a highly invasive melanoma cell line (K1735-M2) 
and the signaling pathways involved. We show, for the first time, that K1735-M2 cells 
express GPR30 and that G-1 decreases melanoma cell proliferation due to decreased cell 
division, similarly to TAM and its active metabolites, OHTAM and endoxifen (EDX). 
Noteworthy, the TAM active metabolites are more potent that the prodrug in the inhibition 
of proliferation of melanoma cells and EDX was the most powerful compound regarding the 
decrease in extracellular signal-regulated kinases (ERK) 1/2 activation. Therefore, our 
results support the view that the targeting of GPR30 may be an innovative and powerful 
strategy in malignant melanoma therapy and lay the foundation for future development of 
GPR30-based therapies for melanoma.  
 
6.2 - Materials and Methods  
 
Reagents 
G-1, TAM, OHTAM and EDX were obtained from SIGMA-Aldrich (St Louis, MO, 
USA). Dulbecco’s modified Eagle’s medium (DMEM) and antibiotic/antimycotic solution 
(10 000 units penicillin, 10 mg streptomycin, 25 µg amphotericin B per mL) were purchased 
from SIGMA-Aldrich (St Louis, MO, USA), Fetal Bovine Serum (FBS) and trypsin were 
obtained from Gibco, Invitrogen Life Technologies (Carlsbad, California, USA). All of the 
other chemicals were purchased from SIGMA-Aldrich (St Louis, MO, USA) and were of 
the highest grade of purity commercially available. TAM and OHTAM stock solutions were 
prepared in absolute ethanol. G-1 and EDX were kept in dimethyl sulfoxide (DMSO). 
Primary specific rabbit polyclonal antibody to GPR30 and anti-mouse and anti-rabbit IgG 
secondary antibodies were obtained from Abcam (Cambridge, UK); primary specific rabbit 
polyclonal antibodies to phospho-Akt, total-Akt and phospho-ERK 1/2 were obtained from 
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Cell Signaling Techonology (MA, USA); primary specific rabbit polyclonal antibody to 
total-ERK 1/2 was purchased from Millipore (MA, USA); mouse monoclonal antibody to β-
actin was purchased from SIGMA-Aldrich (St Louis, MO, USA). 
 
Cell culture 
K1735-M2 mouse melanoma cells (kindly offered by Dr. Paulo Oliveira, Center for 
Neurosciences and Cell Biology, Department of Zoology, University of Coimbra, Coimbra, 
Portugal) were cultured in DMEM, supplemented with 10 % heat-inactivated FBS and 1 % 
antibiotic/antimycotic solution, and kept in a humidified incubator with 5 % CO2/95 % air, 
at 37 ºC. Cells were plated 6.1×104 cells/cm2. The drugs were added to cells 24 h after 
plating. The volumes added did not exceed 0.5 % (v/v). Vehicle controls were performed.  
 
Western-blot (WB) analysis 
Protein expression was evaluated by WB analysis. For the preparation of total cell 
extracts, cells were washed twice with ice-cold phosphate-buffered saline (PBS) and placed 
on lysis buffer, containing 50 mM 4-(2-hydroxymethyl)-1-piperazineethanesulfonic acid 
(HEPES), 150 mM NaCl, 1 % Triton X-100, 0.1 % sodium dodecyl sulfate (SDS), 2 mM 
ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’-tetra-acetic acid (EGTA), 2 mM 
ethylenediaminetetraacetic acid (EDTA), 50 mM NaF, 2 mM Na3VO4, 1 mM dithiothreitol 
(DTT), pH 7.4, supplemented with 1 mM phenylmethanesulphonyl fluoride (PMSF) and a 
cocktail of protease inhibitors (P8340, Sigma). Extracts were submitted to three freeze/thaw 
cycles and centrifuged at 14 000 rpm for 15 min at 4 ºC. Supernatants were recovered and 
the protein quantified by the bicinchoninic acid (BCA) assay kit (Pierce, as part of Thermo 
Fisher Scientific, IL, USA). Equal amounts of protein from total cell extracts were separated 
by SDS-polyacrylamide gel electrophoresis (PAGE) using polyacrylamide gels of 10 % and 
then transferred into a polyvinyldiene fluoride (PVDF) membrane. The membranes were 
blocked with tris-buffered saline (TBS)-T (20 mM Tris-HCl, 150 mM NaCl, 0.1 % Tween) 
with 5 % nonfat milk, for 1 h at room temperature, and then incubated overnight at 4 ºC with 
the primary antibody in TBS-T with 5 % nonfat milk. After extensive washing, membranes 
were incubated with the secondary antibody conjugated with alkaline phosphatase for 1 h at 
room temperature. After additional washes, the membranes were developed using the 
enhanced chemifluorescence (ECF) substrate, and scanned on the Typhoon 9000 scanner 
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(Amersham Biosciences). Appropriate controls were used to ensure equal protein loading as 
indicated in the figure legends. The bands were analyzed using the ImageQuant TM software 
from Amersham Biosciences. For subsequent reprobing, the membranes were stripped of 
antibody with 0.2 M NaOH, blocked again and incubated with the appropriate antibodies. 
 
Sulforhodamine B (SRB) assay 
The cytotoxic effects induced by the drugs on melanoma cells were assessed by the 
SRB assay (Holy et al., 2006). At designated time points, the cultures were fixed with 
absolute methanol containing 1 % acetic acid, and stored at −20 ºC overnight. The methanol 
was decanted and the plate air-dried. The labeling solution, containing 0.5 % SRB in 1 % 
acetic acid, was added to each well and the plate incubated for 1 h, at 37 °C. Plates were 
rinsed with 1 % acetic acid, air-dried, and the bound dye eluted with 10 mM Tris buffer, pH 
10. The absorbance was measured in a Synergy HT plate reader at 540 nm. As SRB binds to 
basic amino acid of proteins of adherent cells, the absorbance at 540 nm provides an estimate 
of total protein mass (biomass), which is related to cell number. The absorbance obtained in 
control cultures was considered 100 %. The number of independent experiments is indicated 
in figure legends. 
 
Cell viability assessment by trypan blue dye exclusion 
The effect of drugs on cell viability was investigated by staining cell suspensions 
with trypan blue, based on the principle that viable cells with an intact membrane exclude 
the dye, while dead cells present a blue stained cytoplasm (Houben et al., 2009). After 72 h 
of incubation with the drugs, cells were trypsinized, centrifuged and the pellet ressuspended 
in 0.4 % trypan blue for 2-3 min and then cells were counted in a hemocytometer under a 
transmitted light microscope. The experiments were carried out in duplicate for each 
independent experiment. 
 
Lactate dehydrogenase (LDH) assay 
The LDH assay allows to determine the cytotoxic effects of drugs based on the 
release of this cytosolic enzyme into the extracellular medium following the loss of cellular 
membrane integrity (Vieira et al., 2010). The culture medium was collected after 72 h of 
incubation with the drugs and centrifuged at 14 000 rpm for 10 min at 4 ºC. An aliquot of 
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supernatant (100 µL) was collected and incubated with substrate mixture, containing 40 µM 
lactate in perchloric acid 3 %, and 3.6 mM nicotinamide adenine dinucleotide (NAD+), in 
tris-hidrazine buffer (80 mM tris, 400 mM hydrazine, 5 mM EDTA, pH 9.5). The enzymatic 
reaction that occurs leads to the reduction of NAD+ to NADH by oxidation of lactate to 
pyruvate. Thus, the amount of NADH is directly related to LDH activity in the supernatant 
and can be evaluated by measuring the absorbance of NADH at 340 nm. The LDH activity 
is expressed as the ratio between the LDH activity in the extracellular medium and the total 
LDH activity obtained from the supernatant of cells lysed with Triton X-100, which was 
considered 100 %. Experiments were performed in duplicates for each independent 
experiment.  
 
5-bromo-2'-deoxyuridine (BrdU) incorporation assay 
K1735-M2 cell proliferation was evaluated by measuring BrdU incorporation 
during DNA synthesis in proliferating cells, using the Cell Proliferation ELISA, BrdU, 
colorimetric kit (Roche). After 48 h of incubation with the drugs, cultured cells were placed 
in BrdU-labeling solution for 90 min. Afterwards the cells were fixed and the DNA 
denaturated with the FixDenat solution provided with the kit and then incubated with a 
monoclonal antibody conjugated with peroxidase (anti-BrdU-POD), which binds to the 
BrdU in the newly synthesized DNA. The complexes formed were detected by using the 
3,3’,5,5’-tetramethylbenzidine (TMB) substrate and quantified by measuring the absorbance 
in a Synergy HT plate reader at 370 nm. The absorbance values directly correlate to the 
amount of DNA synthesis and, therefore, to the number of proliferating cells. The 
experiments were carried out in triplicate for each independent experiment and the 
absorbance obtained in control cultures was considered 100 %. 
 
Cell cycle analysis by flow cytometry 
The effects of G-1 and the antiestrogens on cell cycle were monitored by flow 
cytometry (Carmo et al., 2011). Cells were plated in 6-multiwell plates and, after 48 h of 
incubation with the drugs, cells were trypsinized and centrifuged at 1 500 rpm for 10 min. 
Afterwards, the culture medium was discarded and the pellet was fixed overnight at 4 ºC 
with a solution of cold 70 % ethanol. The cells were then centrifuged at 1 500 rpm for 10 
min, the pellet was resuspended in a solution of PBS containing RNAse and, after 45 min, 
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propidium iodide was added and cells were further incubated for 1 h in the dark, at room 
temperature (the final concentrations of RNase and propidium iodide were 10 µg/mL and 20 
μg/mL, respectively). The propidium iodide fluorescence was measured on a FACSCalibur 
flow cytometer (BD Biosciences, San Jose, CA) equipped with a 488 nm argon-ion laser. 
For aggregate/debris discrimination, in addition to propidium iodide fluorescence signal 
heights, areas and widths were also measured. Measurements for at least 20 000 events were 
collected per sample. Data were analyzed using the ModFit LT 3.0. software. The 
experiments were carried out in duplicate for each independent experiment and the results 
are expressed as % of total cells. 
 
Statistical analysis 
Results are presented as the mean ± S.E.M. of the indicated number of independent 
experiments. Statistical significance between the different assays was determined using the 
one-way analysis of variance (ANOVA), followed by the Tukey post-test, for multiple 
comparisons. A p value <0.05 was considered statistically significant. These statistical 
analyses were performed using the software package GraphPad Prism 5. 
 
6.3 - Results 
 
In order to investigate the presence of GPR30 in melanoma cells, we have 
determined the GPR30 protein expression by means of WB analysis. As shown in figure 6.1, 
K1735-M2 cell line express GPR30. For positive control, MCF-7 cells, which are known to 
express the receptor (Filardo et al., 2000; Ariazi et al., 2010), were used (Fig. 6.1). β-actin 
antibody was used to ensure equal amount of protein loading. 
To examine the effects of GPR30 activation in melanoma, K1735-M2 cells were 
treated for 72 h with G-1, a specific agonist for GPR30, and cell biomass was determined by 
using the SRB assay during a time-course experiment (Fig. 6.2A). After 24 h of incubation, 
the cell biomass was not significantly changed by G-1 up to 1 µM, but above 2.5 µM a 
significant decreased was observed (Fig. 6.2A). When cells were grown in the presence of 
G-1 for 48 and 72 h, the cell biomass was significantly decreased in the presence of 1 µM; 
for G-1 concentrations of 2.5 µM to 20 µM the effects were more pronounced but  
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Fig. 6.1 - GPR30 is expressed in melanoma cells. 80 µg of total protein were used for 
immunoblot analysis with an anti-GPR30 antibody. The membrane was reprobed with a β-
actin antibody to confirm an equal amount of protein loading in each gel lane. MCF-7 cell 
lysate was used as positive control. The experiments were performed in 3 independent 
preparations. 
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concentration-independent (Fig. 6.2A). These results indicate that the activation of GPR30 
may mediate an inhibitory effect on melanoma cells proliferation. Thus, the effects of 
antiestrogenic compounds, TAM and OHTAM, which bind to GPR30 (Wang et al., 2010), 
were also monitored on melanoma cells (Figs. 6.2B and 6.2C). After 24, 48 and 72 h of 
incubation, TAM below 7.5 µM did not affect cell biomass, but at concentrations ≥ 7.5 µM 
a significant decrease was observed in comparison with the control condition (Fig. 6.2B). 
The treatment of melanoma cells with OHTAM up to 5 µM for 24 h did not change cell 
biomass, and at 7.5 and 10 µM significant cytotoxicity was observed; after 48 and 72 h of 
incubation, OHTAM at concentrations ≥ 5 µM significantly decreased cell biomass (Fig. 
6.2C). Additionally, considering that EDX plays a key role in the antitumor activity of TAM 
in breast cancer, its possible cytotoxic effects on melanoma cells were also investigated (Fig. 
6.2D). The cell biomass was unaffected by treatment with EDX up to 5 µM within 48 h, 
however, after 72 h of incubation a significant decrease in the cell biomass was observed; 
EDX above 7.5 µM induced a significant reduction in the cell biomass at each time point 
(Fig. 6.2D). Since 5 µM was the lowest concentration of TAM active metabolites that 
induced a significant decrease in melanoma cell biomass, that was the selected concentration 
to pursue our work and for further comparisons with the selective agonist G-1. 
To elucidate the mechanism underlying the cytotoxic effects of G-1 and the 
antiestrogens TAM, OHTAM and EDX, we assayed cell viability after 72 h of incubation 
with the drugs at 5 μM by using the trypan blue dye exclusion assay (Fig. 6.3). G-1 at 5 μM 
significantly decreased the number of viable cells (Fig. 6.3). The number of viable cells was 
not significantly affected by TAM, whereas a significant decrease was observed after 
incubation with either OHTAM or EDX (Fig. 6. 3), in agreement with the results obtained 
with the SRB assay (Figs. 6.2B-6.2D). Moreover, at this concentration, the compounds 
tested did not increase the number of dead cells during the course of 72 h (Fig. 6.3).  
The absence of an increase in cell death within 72 h of treatment with the drugs was 
confirmed by the LDH assay (Fig. 6.4) which, as the trypan blue assay, is a cytotoxicity test 
based on cell membrane integrity. Neither G-1 nor the antiestrogens TAM, OHTAM and 
EDX at 5 µM increased the activity of LDH in the extracellular medium of melanoma cells 
(Fig. 6.4). Thus, our results indicate that the cytotoxic effects of G-1 and of the antiestrogens 
on melanoma cells are not related with increased cell death. 
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Fig. 6.2 – G-1 and the antiestrogens decrease melanoma cell biomass. Cells were incubated 
in the absence (0) or in the presence of G-1 (A), and the antiestrogens TAM (B), OHTAM 
(C) and EDX (D). At the selected time points, melanoma cell biomass was evaluated by the 
SRB assay as described in the Materials and methods section. Bars represent the mean ± 
S.E.M. of three independent experiments performed in triplicates. *** p<0.001, ** p<0.01 
vs the respective time point control, One-way ANOVA followed by Tukey post-test. 
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Fig. 6.3 - Cell viability of melanoma cells treated with G-1 and the antiestrogens. Melanoma 
cells were grown for 72 h in the absence (control) or in the presence of 5 µM of G-1, TAM, 
OHTAM or EDX and after the incubation period the melanoma cell viability was determined 
by the trypan blue dye exclusion assay. The number of trypan blue-negative (viable) cells 
and trypan blue-positive (dead) cells is presented. Data represent the mean ± S.E.M. of three 
independent experiments performed in duplicates. *** p<0.001, ** p<0.01, * p<0.05 vs 
control, One-way ANOVA followed by Tukey post-test. 
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Fig. 6.4 – The GPR30 selective agonist G-1 and the antiestrogens do not induce melanoma 
cell death. Melanoma cells were grown in the absence (control) or in the presence of 5 µM 
of G-1, TAM, OHTAM or EDX. Cell death was assessed by measuring LDH release from 
damaged cells after 72 h in culture. Bars represent the mean ± S.E.M. of three independent 
experiments performed in duplicates. 
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The effects of the drugs on melanoma cell proliferation were then investigated by 
means of the BrdU incorporation in DNA synthesis after a 48 h treatment with 5 µM of G-1 
or with 5 µM of the antiestrogenic compounds TAM, OHTAM and EDX (Fig. 6.5). This 
earlier time point was selected as the number of cells in control condition at 72 h is 
substantially high and could lead to absorbance values beyond the acceptable measuring 
range. As shown in figure 6.5, G-1 at 5 µM significantly diminished BrdU incorporation to 
about 42 % relative to control, whereas OHTAM and EDX diminished it to approximately 
52 % and 59 %, respectively (Fig. 6.5). On the contrary, TAM at 5 µM decreased BrdU 
incorporation to about 80 %, which was not significant in comparison with control (Fig. 6.5). 
Thus, our results indicate that the cytotoxic effects induced by this concentration of G-1 and 
TAM metabolites on melanoma cells might be due to a decrease in cell proliferation. 
Therefore, we analyzed the effect of the drugs on the cell cycle by flow cytometry 
(Fig. 6.6). The cell cycle of untreated cells (control) was characterized by a long and sharp 
G1 peak, a slightly prominent S phase, a least prominent G2 peak and a low apoptotic 
fraction (Fig. 6.6). The cells incubated with 5 µM of G-1 had a markedly diminished 
percentage of cells in the S phase, whereas a significant increase in G2 was observed (Fig. 
6.6). In contrast, at this time point the antiestrogens at 5 µM did not significantly affect the 
cell cycle (Fig. 6.6). 
Given that the MAPK and the PI3K pathways are major pathways implicated in 
melanoma cell proliferation and survival (Ko and Fisher, 2011), which can be activated 
downstream of GPR30 (Maggiolini and Picard, 2010), the effects of 5 µM of G-1, TAM and 
EDX on the phosphorylation of ERK 1/2 and Akt after 1 h of drug addition were evaluated 
(Fig. 6.7). The compounds decreased the phosphorylation of ERK, but only the effects of 
EDX were significant at this early time point (Figs. 6.7A and 6.7B). In contrast, no 
significant effects on the phosphorylation of Akt were detected at this time point (Figs. 6.7A 
and 6.7C). 
 
6.4 - Discussion 
 
The expression of GPR30 was demonstrated in human tumor tissues or cancer cell 
lines, including human seminoma (Chevalier et al., 2012), lung (Jala et al., 2012),  
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Fig. 6.5 – G-1 and the antiestrogens decrease melanoma cell proliferation. Melanoma cells 
were grown in the absence (control) or in the presence of 5 µM of G-1, TAM, OHTAM or 
EDX. After 48 h, cell proliferation was assessed by the BrdU incorporation assay as 
described in the Materials and methods section. Bars represent the mean ± S.E.M. of four 
independent experiments performed in triplicates. *** p<0.001 vs control, One-way 
ANOVA followed by Tukey post-test.  
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Fig. 6.6 - G-1 blocks cell cycle progression in G2. Melanoma cells were grown in the 
absence (control) or in the presence of 5 µM of G-1, TAM, OHTAM and EDX. Cell cycle 
distribution was evaluated by flow cytometry analysis of the DNA content labeled with 
propidium iodide after 48 h. A total of 20 000 events were analyzed for each experiment. 
Data represent the mean ± S.E.M. of three independent experiments performed in duplicates. 
*** p<0.001 vs control, One-way ANOVA followed by Tukey post-test. 
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Fig. 6.7 - Effects of G-1 and the antiestrogens on ERK 1/2 and Akt phosphorylation. 
Melanoma cells were incubated for 1 h in the absence (control) or in the presence of G-1, 
TAM and EDX at 5 µM and total extracts were prepared. Sixty µg of total protein was used 
for immunoblot analysis with phospho-ERK 1/2 and phospho-Akt antibodies. The 
membrane was reprobed with total-ERK 1/2 and total-Akt antibodies. Representative blots 
(A) and relative densitometric values of ERK 1/2 phosphorylation (B) and Akt 
phosphorylation (C) are shown and were normalized to total-ERK 1/2 and total-Akt, 
respectively, and expressed as percentage of control. Values are the mean ± S.E.M. of nine 
experiments. * p<0.05 vs control, One-way ANOVA followed by Tukey post-test. 
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endometrial (Du et al., 2012), ovarian (Fujiwara et al., 2012) and breast cancer (Filardo et 
al., 2000, 2006). The GPR30 is also present in normal human skin fibroblast cells (Tsui et 
al., 2011), but whether melanoma cells express GPR30 or whether it has a role in this 
malignancy is not yet clarified.  
Our studies show, for the first time, that melanoma cells express GPR30 (Fig. 6.1) 
and that its activation by G-1, a selective agonist of GPR30 (Bologa et al., 2006), induces 
profound cytotoxic effects on melanoma cells, at concentrations as low as 1 µM, as shown 
by the SRB assay (Fig. 6.2A). Increasing the concentration of G-1 from 2.5 up to 20 µM did 
not enhance the cytotoxic effect, which is in agreement with the saturation of the receptor. 
The cell viability assay with trypan blue staining revealed that G-1 decreases the number of 
viable cells, without increasing the number of dead cells (Fig. 6.3). Accordingly, the 
evaluation of LDH activity in the supernatant of cells (Fig. 6.4) point out that G-1 does not 
induce melanoma cell death, but instead inhibits cell proliferation, as suggested by the BrdU 
incorporation assay (Fig. 6.5). The cell cycle analysis by flow cytometry supports these 
findings, as G-1 induces cell cycle arrest in G2 (Fig. 6.6). These results are in agreement 
with data from the literature showing that G-1 decreases endothelial cell proliferation by 
accumulating cells in the S and G2 phases of the cell cycle (Holm et al., 2011), and 
diminishes DNA synthesis in urothelial cells (Teng et al., 2008). G-1 also inhibits prostate 
cancer cells proliferation and induces cell-cycle arrest in G2 (Chan et al., 2010), whereas it 
promotes the blockade in G1 phase in 17β-estradiol-stimulated breast cancer cells (Ariazi et 
al., 2010).  
Therefore, our results suggest that the GPR30 is a new target in melanoma therapy 
and that the evaluation of GPR30 expression in human melanoma tissues will allow the 
identification of subgroups of patients who may benefit from a GPR30-based therapy. 
Noteworthy, the treatment with G-1 was found to have minimal or no effects on normal 
prostatic epithelial cells and on benign prostate epithelial cells (Chan et al., 2010) and in an 
animal model of multiple sclerosis, G-1 exerted beneficial effects without estradiol-
associated side effects (Wang et al., 2009), suggesting that GPR30-based therapies may be 
well tolerated and have little harmful effects on patients normal tissues.  
Importantly, like the selective agonist G-1, TAM and OHTAM, which bind to 
GPR30 (Wang et al., 2010), can also decrease melanoma cell biomass (Figs. 6.2B and 6.2C). 
In addition, our results show that EDX resembles OHTAM in the ability to decrease 
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melanoma cell biomass (Fig. 6.2D), suggesting that EDX might bind to GPR30 as well. 
Similarly to what was observed with G-1, the cytotoxic effects induced by TAM metabolites 
at 5 µM are not related with cell death, as demonstrated by the absence of an increase in the 
number of dead cells and in the LDH activity in the supernatant of cells (Figs. 6.3 and 6.4). 
Rather, and in agreement with our previous studies (Ribeiro et al., 2013a, c), TAM 
metabolites decrease BrdU incorporation (Fig. 6.5), indicating that TAM metabolites 
decrease cell division, similarly to G-1. These observations suggest that the activation of the 
GPR30 is a new mechanism that may contribute to the anticancer activity of antiestrogenic 
compounds in melanoma. 
In contrast, the activation of GPR30 in endometrial and thyroid cancer has been 
shown to stimulate cell proliferation (He el al., 2009; Vivacqua et al., 2006a) suggesting that 
the effects mediated by GPR30 may vary according to the cell type. These results parallel 
with the observation that TAM behaves as an antiestrogen in breast cancer cells, but has mild 
estrogenic effects in other tissues, such as the uterus and the bone, and the cardiovascular 
system (McDonnell, 1999). Therefore, the factors that modulate the GPR30-mediated 
signaling in different tissues are worthy of further investigation. 
Noteworthy, TAM active metabolites are more potent than the prodrug, inducing 
significant effects on cell proliferation at lower concentrations (Figs. 6.2, 6.3 and 6.5). These 
findings correlate with the reported superior anticancer activity of TAM metabolites in breast 
cancer (Lim et al., 2005; Wu et al., 2009) and suggest that the individual variability in TAM 
metabolism and the coadministration of CYP2D6-inhibiting medication may influence the 
efficacy of TAM in melanoma, as already demonstrated in breast cancer (Higgins and 
Stearns, 2010; Kelly et al., 2010; Lammers et al., 2010; Thompson et al., 2011). In fact, the 
many studies conducted until now with the goal of establishing the benefits of the inclusion 
of TAM in melanoma therapeutic regimens provided contradictory results (McClay et al., 
1989, 1992; Cocconi et al., 1992; Rusthoven et al., 1996). Previous studies performed in our 
laboratory have supported the view that EDX is an effective alternative to TAM, providing 
superior anticancer activity than the prodrug when used in combination with other agents 
(Ribeiro et al., 2013a, c). The impact of the variability in TAM metabolism in the melanoma 
treatment efficacy is unknown at the moment, but can contribute to explain the discrepant 
outcomes observed in melanoma patients taking TAM and should be taken into 
consideration in future trials. However, we can not exclude that a possible variability in 
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GPR30 expression in melanoma cells might contribute as well to the discrepant outcomes 
regarding TAM therapy, should this drug act through the activation of this receptor.  
To provide further insights on the antiproliferative mechanisms of the drugs under 
investigation, the effects of G-1, TAM and EDX on the phosphorylation of ERK 1/2 and 
Akt, which are key signaling pathways in melanoma, were also evaluated. ERK is 
constitutively activated in up to 90 % of melanomas (Russo et al., 2009), whereas 
phosphorylated Akt is detected in 49 % and 77 % of the biopsies of primary melanoma and 
melanoma metastases (Dai et al., 2005). The compounds decreased ERK 1/2 
phosphorylation, but after 1 h treatment, only EDX was able to provide a significant 
reduction of ERK 1/2 activation (Fig. 6.7B). Strikingly, G-1, which is the most potent 
compound regarding the inhibition of melanoma cell proliferation (Figs. 6.2, 6.3, 6.5 and 
6.6) is the least effective in the inhibition of  ERK 1/2 activation (Fig. 6.7B). As it was 
reported that TAM inhibits melanoma cell migration and invasion by suppressing the 
phosphorylation of ERK 1/2 and Akt through the inhibition of protein kinase C (PKC) 
phosphorylation (Matsuoka et al., 2009), these differences may be related with effects 
promoted by the antiestrogens on targets other than the GPR30. In fact, the mechanisms 
underlying the antitumor activity of TAM in melanoma are not entirely clarified, but both 
genomic and nongenomic mechanisms were proposed. Earlier investigations detected the 
presence of ERs (Fisher et al., 1976; Walker et al., 1987), but further studies using ER-
specific monoclonal antibodies have failed to support this hypothesis (Cohen et al., 1990; 
Lecavalier et al., 1990; Kanter-Lewensohn et al., 2000). More recently, methylated ERα 
were detected in the tumor tissues and sera of melanoma patients resulting in ERα gene 
silencing (Mori et al., 2006). On the other hand, the inactivation of the insulin-like growth 
factor-1 receptor (IGF-1R) was also reported as a possible mechanism of TAM-induced 
cytotoxicity in melanoma cells (Kanter-Lewensohn et al., 2000). The multiple actions 
promoted by the antiestrogens in melanoma cells may contribute to explain the absence of a 
significant effect on cell cycle at the time point selected, as these drugs induce effects on 
multiple targets rather than a single one, as occurs with the selective agonist G-1 (Fig. 6.6). 
No significant effects were detected on Akt activation (Figs. 6.7A and 6.7B), but further 
studies at different time points are needed. 
A great concern regarding melanoma therapy is the development of resistance, 
given the great plasticity of melanoma cells that can rewire their signaling circuitries, 
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allowing the adaptation of tumor cells to pharmacological challenges (Herlyn, 2009; 
Villanueva et al., 2010). The development of resistance can be surpassed by the combination 
with other agents (Villanueva et al., 2010) and our previous studies demonstrate that EDX 
acts synergistically with glutamate receptor antagonist MK-801 (Ribeiro et al., 2013c) or all-
trans-retinoic acid (Ribeiro et al., 2013a) to decrease melanoma cells proliferation. 
Moreover, the combination of EDX with all-trans-retinoic acid, which provides 
antiproliferative and antimigration effects on melanoma cells, was devoid of significant 
toxicity in non-neoplasic cells and in mitochondrial functions (Ribeiro et al., 2013a, d).  
In conclusion, our results suggest that the pharmacological activation of GPR30 
may be an appropriate therapy for melanoma treatment and opens up the opportunity for the 
development of new therapies targeting the GPR30. Indeed, it might have the advantage of 
exerting beneficial effects without overt side effects (Wang et al., 2009). Furthermore, our 
results suggest a new possible mechanism of action of antiestrogenic compounds in 
melanoma cells and can contribute to select patients who may benefit from the inclusion of 
antiestrogens in their therapeutic regimens against melanoma. As the prognosis for locally 
advanced and metastatic melanoma is poor and currently available therapies are unable to 
clearly alter the history of the disease (Ko and Fisher, 2011), the activation of GPR30 
represents an innovative strategy for the clinical management of malignant melanoma. 
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7.1 - General discussion 
 
Recently, a systematic review synthesized the safety data from clinical trials to 
elucidate the adverse events associated with several drugs used in advanced melanoma 
therapy, including interferon-α, dacarbazine, interleukin-2 and the newly approved 
ipilimumab and vemurafenib (Ma and Armstrong, 2013). It demonstrated that currently 
available therapies for the management of malignant melanoma are associated with the 
induction of severe side effects (Ma and Armstrong, 2013). Therefore, new therapeutic 
strategies with high efficacy and low toxic effects are required. 
As described in chapter II, our results show that EDX, at concentrations much 
higher than those reached in tissues (Lien et al., 1991; Borges et al., 2006), depresses the 
phosphorylation efficiency of mitochondria (Figs. 2.1 and 2.2) and promotes membrane 
permeabilization to protons, whereas TAM induces a much more potent proton leak (Fig. 
2.3), indicating that EDX, like OHTAM (Cardoso et al., 2002a), mildly affects membrane 
integrity, in comparison with TAM. The ability of TAM to unspecifically disrupt the 
structure of model and native membranes has been implicated in its side effects, including 
the hemolytic anemia (Cruz Silva et al., 2000). The fact that EDX only compromises 
membrane integrity at very high concentrations suggests that EDX would present less 
unspecific effects than the treatment with its prodrug. Such results are in accordance with 
the demonstration of the absence of significant alterations in hematologic and biochemical 
parameters, including the cholesterol and triglyceride levels, in individuals taking a daily 
oral dose of 4 mg of EDX, which provides a similar EDX steady-state concentration to that 
found in patients with normal CYP2D6 function who are administered 20 mg of TAM/day 
(Ahmad et al., 2010b). Altogether, our results suggest that EDX is less toxic than TAM to 
mitochondrial functions and therefore the use of EDX instead of TAM will minimize the 
adverse effects related with mitochondrial damage, membrane disruption and changes in 
lipid metabolism induced by TAM. 
Furthermore, EDX prevents the MPT induced by Ca2+ and phosphate (Figs. 2.4 and 
2.5). This protection was observed either when the drug was added before (Figs. 2.4A and 
2.5A) or after calcium loading during membrane depolarization (Fig. 2.4B and 2.5B), 
suggesting a direct interference with the proteins that form the MPT complex and excluding 
a possible effect on Ca2+ uptake across the uniport or other mitochondrial effects. Likewise, 
General Discussion and Conclusions _________________________________________________________  
202 
both TAM and OHTAM inhibit the MPT induced by several agents (Custódio et al., 1998; 
Cardoso et al., 2002b; Hernández-Esquivel et al., 2011a, b). The mechanisms underlying the 
inhibition of MPT by antiestrogens remain unclear. EDX at concentrations that inhibit the 
MPT does not compromise the active ANT content (Fig. 2.6) or phosphorylation efficiency 
(Figs. 2.1 and 2.2), suggesting that neither the ANT nor the phosphate carrier is related with 
the inhibition of MPT by EDX. The antiestrogen EDX significantly inhibits oxidative stress 
(Fig. 2.7), which may indicate that the MPT inhibition by EDX is related with its antioxidant 
properties, since the oxidation state of cysteine residues in the vicinity of the pore is a critical 
factor regulating MPT induction (Petronilli et al., 1994). Another possible explanation is the 
interference with membrane fluidity, as described for TAM and OHTAM, which leads to a 
configurational change of the ANT (Custódio et al., 1991, 1993a, b; Hernández-Esquivel et 
al., 2011a; Kazanci and Severcan, 2007). The interaction of EDX with CypD, inhibiting the 
pore assembly similarly to CyA (Zoratti and Szabo, 1995), is also conceivable. 
On the other hand, mitochondria, which play a central role in the cellular life or 
death, are thought to be involved in the pharmacological action of several drugs, including 
RA. It was reported that RA inhibits the proliferation of both primary and metastatic 
melanoma cells by reducing mitochondrial viability, which is followed by alterations of the 
cell cycle distribution and, at higher concentrations, apoptotic cell death (Zhang et al., 2003). 
A recent study conducted by Xun et al (2012) also proposed that the effects of RA on 
mitochondria may be beneficial in cancer therapy. It was shown that during RA-induced 
differentiation of neuroblastoma cells there is a dramatic increase in the oxygen consumption 
rate without changes in the number of mitochondria or in the composition of the electron 
transport chain (Xun et al., 2012). Through a mechanism yet to be determined, RA treatment 
enhances the metabolic activity of neuroblastoma cells and the energetic demands in the 
differentiated state; as the maintenance of differentiated cells takes precedence over tumor 
cell growth, the availability of nutrients for tumor cells is limited and the tumor growth is 
supressed (Xun et al., 2012). In addition, the induction of MPT has garnered significant 
attention as a possible strategy to trigger cancer cell death and retinoids are known inducers 
of MPT (Rigobello et al., 1999; Fulda et al., 2010). 
In spite of being a powerful anticancer agent, the utilization of RA in clinical 
practice is almost restricted to APL, as RA induces severe side effects (Zusi et al., 2002). 
Cases of hepatotoxicity were reported during dietary supplementation (Stickel et al., 2011) 
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or treatment of APL patients (de-Medeiros et al., 1998) with retinoids; hypertriglyceridemia 
is also common and it was shown to be mediated by RARs (Standeven et al., 1996). As 
mentioned previously, alterations in lipid metabolism and liver damage are closely related 
with mitochondrial dysfunction (Begriche et al., 2006; Labbe et al., 2008; Rolo et al., 2012). 
In fact, besides being an inducer of MPT (Rigobello et al., 1999), RA compromises 
mitochondrial bioenergetics as well, since it induces uncoupling of mitochondria (Stillwell 
et al., 1982; Stillwell and Nahmias, 1983). In vivo studies supported the view that 
mitochondria are a target of retinoid toxicity. In rats, vitamin A supplementation induced 
slight enlargement of mitochondria and a moderate decrease in cytochrome c oxidase 
activity (Leo et al., 1982). In the study conducted by de Oliveira et al (2009), short-term 
vitamin A supplementation of adult rats also induced hepatic oxidative insult and 
mitochondrial dysfunction. The combination of RA with other agents can possibly allow to 
achieve therapeutic efficacy with lower concentrations, this way minimizing the adverse 
effects of retinoid treatment. Indeed, the combinations of RA with TAM demonstrated a 
synergism of action in breast cancer cells (Wang et al., 2007; Searovic et al., 2009; Koay et 
al., 2010) and an interplay between retinoid and estrogen signaling was reported (Hua et al., 
2009; Ross-Innes et al., 2010), suggesting that these combinations may be useful in breast 
cancer treatment. However, the combination of RA with TAM, which presents overlapping 
toxicity pattern, may raise some concerns.  
Therefore, understanding the effects of RA on mitochondrial function can 
contribute to clarify either the pharmacological or the toxicological mechanisms of action of 
this agent. Furthermore, the evaluation of the effects of RA in combination with TAM on 
mitochondria can provide relevant mechanistic information regarding the potential toxicity 
of these combinations. As our results demonstrate that EDX promotes less deleterious effects 
on mitochondria than TAM (Ribeiro et al., 2013b), the effects of RA were evaluated in 
combination with EDX and OHTAM and compared to those promoted by TAM. 
The data shown in chapter III demonstrate that RA induces the MPT pore opening 
(Figs. 3.1 and 3.2), in accordance with previous reports (Rigobello et al., 1999; Notario et 
al., 2003). As observed with the MPT induced by Ca2+ and phosphate, EDX inhibits the MPT 
induced by RA by directly interfering with the proteins that form the MPT pore complex 
(Figs. 3.1 and 3.2). RA is considered an ANT modulator (Notario et al., 2003) and the ANT 
ligands ADP and ATP prevent the RA-induced MPT (Fig. 3.5). However, EDX at the 
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concentrations that inhibit the MPT does not affect the phosphorylation efficiency (Figs. 2.1 
and 2.2) and, therefore, neither the ANT nor the phosphate carrier seems to be related with 
the inhibition of RA-induced MPT by EDX. On the other hand, EDX enhances the 
antioxidant activity of RA (Figs. 3.3C and 3.3D), but the thiol protecting agents do not 
prevent the MPT induced by RA (Fig. 3.4), suggesting that other mechanisms may be 
involved. Therefore, the protection afforded by EDX against the MPT may rely on multiple 
effects exerted by this drug on mitochondria, including the effects on membrane fluidity or 
the interaction with CypD, as proposed for the MPT induced by Ca2+ and phosphate. 
MPT induction is often implicated in cell death and it is thought to play a role in 
the therapeutic efficacy of anticancer drugs (Fulda et al., 2010). However, the combination 
with antiestrogenic compounds, which prevent the onset of MPT, does not limit the 
anticancer activity of RA, according to our results in melanoma cells (Figs. 4.2-4.5) and to 
studies performed by others in breast cancer cells (Danforth, 2004; Wang et al., 2007; 
Searovic et al., 2009; Koay et al., 2010). In addition, although EGTA and CyA were able to 
inhibit the MPT induced by 13-cis RA, both agents did not prevent the release of cytochrome 
c from the IMS caused by the retinoid (Rigobello et al., 1999). Moreover, in MCF-7 cell 
line, CyA did not prevent the formation of fragmented nuclei characteristic from the 
apoptotic process or the changes in mitochondrial parameters induced by retinoids (Poot et 
al., 2002). Mitochondria isolated from vitamin A-treated rat liver were also more sensitive 
to calcium regarding the redox status, but the insult elicited by calcium was independent of 
the MPT, since it was not prevented by CyA (de Oliveira et al., 2009). These evidences 
support that MPT induction may not be critical for RA to exert its antitumoral activity. On 
the contrary, the protection afforded by the antiestrogens against RA-induced MPT may 
contribute to prevent or reduce the adverse effects promoted by RA, including the 
hepatotoxicity, as several inducers of MPT are hepatotoxic (Labbe et al., 2008; Nadanaciva 
and Will, 2009). 
RA decreases the phosphorylation efficiency in a concentration-dependent manner 
and at high concentrations induces the permeabilization of mitochondrial membrane to 
protons, which is possibly related with a proton leak through the Fo fraction of complex V 
(Figs. 3.6-3.8). As these effects promoted by RA are dose-dependent (Figs. 3.6 and 3.7), 
using a low dose of RA may avoid compromising mitochondrial bioenergetics and this way 
the toxicity of RA. The combinations of low concentrations of RA (5 nmol/mg protein) with 
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antiestrogens (10 nmol/mg protein) do not present significant effects on mitochondrial 
functions, except for the RCR, which is decreased in comparison with control, reflecting the 
effects on both state 3 and state 4 (Figs. 3.9 and 3.10). The combination of TAM with 5 
nmol/mg protein of RA significantly diminished the RCR relatively to RA, suggesting that 
the combination with TAM has more drastic effects on mitochondrial bioenergetics than the 
combinations with its active metabolites EDX or OHTAM (Fig. 3.10C). In contrast, the 
combination of high concentrations of RA (above 10 nmol/mg protein) with antiestrogens 
significantly affects mitochondrial bioenergetic functions (Figs. 3.9 and 3.10). Our results 
correlate with the study performed by Budd et al (1998) in patients with advanced breast 
cancer. RA presented dose-dependent toxicity and 190 mg/m2/day was established as the 
maximum tolerated dose; the combination with 20 mg of TAM/day did not enhance the 
toxicity of RA (Budd et al., 1998). On the contrary, the antitumor activity of this combination 
in breast cancer was not convincing, since in 7 patients with measurable disease, only 2 
presented partial responses; in 18 patients with evaluable nonmeasurable disease, only 7 
achieved disease stabilization for more than 6 months, but remarkably among these 7 
patients, 5 presented TAM-resistant disease (Budd et al., 1998). Considering our current 
knowledge, it is possible to speculate whether the results would have been the same if the 
the individual metabolism or the intake of CYP2D6-inhibiting medication were taken into 
consideration. However, this study of Budd et al (1998) reinforces the notion that RA and 
antiestrogens can be given together with acceptable toxicity, if the concentrations of RA are 
low. 
Based on the remarkable progress of research into the mechanisms of cancer 
pathogenesis, several mechanism-based therapies have been developed in the last years. 
Such therapies have been considered beneficial, as they can inhibit a specific molecular 
target, with less off-target effects, which in principle translates into less unspecific toxicity 
(Hanahan and Weinberg, 2011). However, these targeted therapies lead almost inevitably to 
relapses. There are two main reasons that explain the failure of such approach: the existence 
of redundant pathways, which allow some cancer cells to survive and adapt through 
mutations, epigenetic reprogramming or remodeling of the tumor microenvironment; on the 
other hand, tumor cells can shift their dependence from one hallmark capability to another 
(for instance, the inhibition of angiogenesis can be surpassed by increasing invasiveness and 
metastasis) (Hanahan and Weinberg, 2011). Therefore, mechanism-guided combinations 
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that can target several hallmark capabilites of cancer can provide more effective and durable 
therapeutic strategies (Hanahan and Weinberg, 2011). 
Considering that retinoids and TAM decrease the proliferation of melanoma cells 
individually, and the absence of significant toxic effects on mitochondrial functions when 
RA is used at low concentrations in combination with antiestrogens (Ribeiro et al., 2013d), 
the effects of RA in combination with TAM on melanoma cells were investigated. Moreover, 
the effects of RA combined with EDX were also studied, which is to our knowledge the first 
time that EDX is tested in melanoma cells, and compared to those promoted by the 
combinations with TAM. 
As shown in chapter IV, RA at concentrations as low as 0.5 µM has an 
antiproliferative effect on K1735-M2 melanoma cells (Fig. 4.1), which is not related with 
increased cell death, but is due to decreased cell division (Figs. 4.3-4.5). Similar findings 
were reported by Helige et al (1993) which showed that RA at 1 µM decreases K1735-M2 
melanoma cell number. Melanoma cell death after 72 h treatment with RA at 0.5 µM was 
not detected (Fig. 4.3), in agreement with previous studies in leukemia and in melanoma 
cells, which demonstrate that the induction of apoptosis by RA requires long exposure time 
(2 days or more) and high concentrations of drug (10 μM) (Hsu and Yung, 2000; Baroni et 
al., 2003; Zhang et al., 2003). The antiproliferative effect of RA in K1735-M2 melanoma 
cells is related with cell cycle arrest in the G1 phase (Fig. 4.5), as previously shown by others 
in B16 melanoma cells (Niles, 2003), or in human myeloid cell lines (Dimberg and Oberg, 
2003). It was reported that the induction of apoptosis and cell cycle arrest in melanoma cells 
by RA involves the down-regulation of the MAPK proteins and the up-regulation of p27 
(Zhang and Rosdahl, 2004), as well as an increase in p16 expression in a time- and dose-
dependent manner (Zhang and Rosdahl, 2005). 
The combination of RA with EDX significantly enhanced the antiproliferative 
activity of both compounds individually and was more effective than the combination with 
TAM, which was unable to potentiate the action of RA (Figs. 4.2, 4.3 and 4.5). The 
combination of RA with EDX did not increase cell death (Fig. 4.3), but decreased cell 
division, inducing cell cycle arrest in G1 (Fig. 4.5). The mechanism underlying this 
synergism of action in melanoma is not yet clarified. Like RA, which is known to down-
regulate the MAPK pathway (Zhang and Rosdahl, 2004), EDX also down-regulates this 
pathway in melanoma cells as shown for the first time by our results (Fig. 6.7). In addition, 
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it is known that TAM inhibits PKC activity in ER− cancer cells (Gundimeda et al., 1996; 
Gelmann, 1997; Luo et al., 1997), which further contributes to MAPK pathway suppression 
(Matsuoka et al., 2009). On the other hand, it was reported that the interaction between RA 
and PKCα decreases PKC activity at concentrations higher than those used in our 
experiments (Radominska-Pandya et al., 2000). Interestingly, the antitumor activity of RA 
in B16 melanoma cells involves an increase in PKCα expression, but as the inhibition of the 
enzyme activity does not inhibit RA action, it seems that the antitumor activity of RA does 
not require the phosphorylation activity of PKC (Niles, 2003). The effects of RA related 
with PKC involve other protein-protein interactions (Niles, 2003) and, therefore, the 
inhibition of PKC phosphorylation by the antiestrogens does not compromise the anticancer 
activity of RA, but possibly adds to it. 
One of the most important factors in the development of malignant melanoma are 
G1/S checkpoint abnormalities (Sauroja et al., 2000). The G1/S transition is regulated by the 
retinoblastoma protein (pRb) and p53 pathways, but while alterations in the pRb pathway 
are relatively common in melanomas, due to lower levels of p16 or pRb, mutations in the 
gene encoding the cyclin-dependent kinase (cdk) 4 or overexpression of cyclin D1, those in 
the p53 pathway are infrequent (Li et al., 2006). In addition, studies in melanoma cells 
demonstrate the increase of p27 expression in the cytoplasm and a simultaneous reduction 
of nuclear expression, which is the only form of p27 that functions as a cdk inhibitor 
(Denicourt et al., 2007). Thus, targeting the pRb pathway seems crucial in the suppression 
of melanoma development (Li et al., 2006). As most tumors show aberrant expression of 
more than one protein (Li et al., 2006), the use of combined strategies is more likely to target 
such a diversity and produce significant responses.  
An interplay between retinoid and estrogen signaling has already been 
demonstrated in a breast cancer ER+ cell line, and it was shown that retinoid and 
antiestrogen-mediated signaling converge at the cell cycle regulation level (Wilcken et al., 
1996). Both the antiestrogen and RA block cell cycle progression in G1 phase; whereas 
antiestrogen treatment caused a rapid inhibition of cyclin Dl gene expression, RA reduced 
cdk4 activity without reducing cyclin or cdk levels (Wilcken et al., 1996). However, 
following exposure to either RA or antiestrogen, there was a reduction in the amount of 
hyperphosphorylated pRb, indicating that the mechanisms of action of antiestrogens and 
retinoids are different but converge at pRb (Wilcken et al., 1996). Importantly, it was 
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demonstrated that OHTAM (but not TAM) and various retinoids up-regulate the expression 
of p27 in both ER+ and ER− human breast cancer cell lines, through different pathways (Eto, 
2010). This piece of information may be relevant as it also supports the existence of 
similarities between the modes of action of retinoids and antiestrogens. Considering that the 
MAPK pathway activation reduces the inhibitory activity of p27 (Donovan et al., 2001), 
melanoma cells treated with the combination with EDX possibly present higher p27 activity 
than those treated with TAM, in agreement with a more pronounced inhibition of the MAPK 
pathway promoted by EDX (Fig. 6.7), explaining the finding that the combinations with 
TAM do not enhance the effects induced by RA on cell cyle.  
On the other hand, it remains unknown the role played by classic ER in the 
synergism of action between retinoids and EDX in melanoma cells. It was shown that an 
interaction between ERα and RARα is necessary for effective transcriptional activity in 
breast cancer cells (Ross-Innes et al., 2010). Whether such interplay is also important in 
melanoma is not known. In addition, ER can also mediate nongenomic signaling which can 
interact with GPR30- and RA-mediated signaling. These are questions that should be 
addressed in future investigations. 
In melanoma, as in most peripheral cancers, metastatic disease is more important 
than local tumor growth as a determinant of mortality. Therefore, drugs that combine a 
cytostatic action and the ability to limit tumor metastasis can bring great therapeutic 
advantage. RA decreases melanoma cell migration through changes in cellular adhesion 
(Helige et al., 1993; Situ et al., 1993) and in the production of degradative enzymes that lead 
to host tissue degradation (Helige et al., 1993; Hendrix et al., 1990; Jacob et al., 1998), 
alterations in the actin cytoskeleton (Helige et al., 1993) and decreased motility (Helige et 
al., 1993). Several of these alterations were observed in K1735-M2 melanoma cells under 
treatment with RA (Helige et al., 1993). In our studies, RA up to 1 µM does not provide 
significant effects (Fig. 4.6), but as pointed by Helige et al (1993), the directional migration 
study was the one revealing the most modest activity of RA in K1735-M2 cells, whereas the 
adhesion capacity and the organization of the actin cytoskeleton were considerably affected 
(Helige et al., 1993).  
A recent investigation conducted by Matsuoka et al (2009) has provided new 
insights on the role of antiestrogens in the inhibition of melanoma cells migration and 
invasion. MMPs are key players in the invasive process and it was shown that melanoma 
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cells express MMP-1, MMP-2 and MMP-9 (Hofmann et al., 2000). TAM inhibits MMP 
expression through the suppression of the PKC/MEK/ERK and PKC/PI3K/Akt pathways in 
B16BL6 melanoma cells above 2.5 and 5 μM, respectively (Matuoka et al., 2009). 
Furthermore, mice injected with melanoma cells previously treated with TAM present less 
visible lung nodules, whereas the treatment with TAM after the injection of B16BL6 cells 
decreased metastasis, indicating that TAM inhibits either developing or clinically evident 
metastasis, although the latter requires higher doses (Matuoka et al., 2009). As TAM is able 
to inhibit developing metastasis in vivo at 1 mg/kg, the authors suggest that the metabolic 
activation that occurs in vivo may contribute to amplify the antimetastatic potential of TAM 
(Matsuoka et al., 2009). Although in our experimental setting neither TAM nor EDX 
decreases the migration of K1735-M2 cells, the combination with RA at 1 µM was able to 
significantly enhance the effects of EDX and decrease the number of migrating cells relative 
to control, suggesting that EDX may be a more powerful antimetastatic agent than TAM 
when combined with other agents (Fig. 4.6). As RA also regulates the expression of MMP-
1 (Jacob et al., 1998) and down-regulates the MAPK pathway in melanoma cells (Zhang and 
Rosdahl, 2004), it is possible that shared pathways can account for the antimigration activity 
of RA combined with EDX. Several studies established a good correlation between the 
invasive properties of tumor cells in vitro and their metastatic potential in vivo and, therefore, 
it is reasonable to expect that the combined treatment of RA with EDX, which inhibits 
melanoma cells migration in vitro, may provide similar effects in vivo. 
Most systemic chemotherapeutic regimens for cancer, either in the adjuvant setting 
or in the treatment of metastatic disease, use agents targeting the cell cycle, which also affect 
the proliferation of normal cells, resulting in marrow suppression (neutropenia), hair loss 
and gut toxicity (Rodriguez-Acebes et al., 2010). Therefore, to provide the first clues on the 
potential adverse effects of RA in combination with antiestrogens, the viability of normal 
cells after 72 h treatment was monitored. Our results demonstrate that neither the compounds 
nor their combinations affect the number of viable endothelial cells (Fig. 4.7). Importantly, 
the number of dead endothelial cells is also not increased by these combinations (Fig. 4.7). 
The effects of RA on BAEC were also investigated by Gaetano et al (2001) after 7 days of 
exposure using the same technique to assess cell viability. According to this study, RA at 1 
µM does not affect endothelial cell proliferation (Gaetano et al., 2001), in agreement with 
our findings. Moreover, EDX and RA at the concentrations used to decrease the proliferation 
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and migration of melanoma cells do not affect mitochondrial functions (Fig. 4.8). Given that 
the toxicity induced by treatment with RA remains the major obstacle to its clinical 
utilization as an anticancer agent, the use of low concentrations of RA in combination with 
EDX may be a suitable strategy to improve the outcomes with reduced toxicity. 
Accumulating evidence suggests that glutamate plays an important role in the 
regulation of tumor cells proliferation and migration. Accordingly, NMDAR and AMPAR 
antagonists limit the proliferation of several non-neuronal cancers (Rzeski et al., 2001; 
Abdul and Hoosein, 2005; North et al., 2010a, b), as well as their motility (Rzeski et al., 
2001). More recently, it was reported that melanoma cells WM451 express functional 
NMDAR and that the treatment with MK-801 alters melanoma cell morphology, motility 
and proliferation (Song et al., 2012), but this was the only study until now reporting the 
effects of an iGluR antagonist on melanoma. 
The results described in chapter V demonstrate that NMDAR channel blockers 
memantine and MK-801 decrease the proliferation of K1735-M2 melanoma cells (Figs. 5.1-
5.3), in agreement with the study conducted by Song et al (2012) that showed that MK-801 
decreases WM451 melanoma cells proliferation in vitro and decreases tumor volume and 
growth in mouse models inoculated with melanoma cells. Significant effects were achieved 
at 500 and 300 µM of MK-801 and memantine, respectively (Figs. 5.1 and 5.2), which is in 
the range of iGluR antagonists concentrations used by others to decrease cancer cell 
proliferation (Rzeski et al., 2001; Stepulak et al., 2005; North et al., 2010a, b). Interestingly, 
memantine is more effective than MK-801 in the decrease of melanoma cells proliferation 
(Figs. 5.1 and 5.2), in spite of having a lower binding affinity towards NMDAR than the 
latter. Similar findings were reported by other groups (Rzeski et al., 2001; Stepulak et al., 
2005; North et al., 2010a, b) and may suggest the existence of mechanisms of action other 
than the blockade of NMDAR.  
As the concentrations of NMDAR antagonists necessary to block tumor cell 
proliferation are relatively high, some concerns about the toxic effects of treatment with 
NMDAR antagonists may be raised. Indeed, these concentrations might influence rodents 
behavior (Gilbert, 1988; Tricklebank, 1989; Kawabe et al., 1998). On the other hand, MK-
801 and memantine do not induce cytotoxicity in melanocytes at 100 µM, but memantine 
promotes a larger increase in apoptosis (Hoogduijn et al., 2006). Moreover, treatment of 
human skin fibroblasts and bone marrow stromal cells with MK-801 up to 250 µM for 96 h 
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did not affect non-malignant cells viability (Rzeski et al., 2001). The absence of significant 
effects on non-neoplasic cells may predict that the treatment with NMDAR channel blocker 
MK-801 is devoid of significant toxicity. These observations were corroborated by studies 
using in vivo models of melanoma (Song et al., 2012), breast (North et al., 2010a) and lung 
(Stepulak et al., 2005; North et al., 2010b) cancers, which required doses of MK-801 much 
lower than expected based on the corresponding in vitro studies. However, for the treatment 
of peripheral cancers, it was proposed that the use of NMDAR antagonists that do not cross 
the blood-brain barrier could minimize the possible adverse effects. 
Memantine at the concentrations used in our study affects mitochondrial function 
(McAllister et al., 2008) and induces a larger increase in apoptosis of melanocytes than MK-
801 (Hoogduijn et al., 2006), and therefore MK-801 was the drug of choice to study in 
combination with antiestrogens. The antiestrogens are able to act synergistically with MK-
801 to decrease melanoma cell proliferation (Figs. 5.4, 5.5 and 5.7), and the combinations 
with EDX or OHTAM were more effective than the combinations with TAM, inducing cell 
cycle arrest in G1 phase (Fig. 5.8). The effects of MK-801, at concentrations that do not 
induce significant effects individually, are greatly potentiated by the antiestrogens, 
indicating that through the combination with other agents, the doses of MK-801 used can be 
significantly reduced, this way minimizing the possible adverse effects. Likewise, MK-801 
enhanced the antiproliferative effect of cyclophosphamide and thiotepa in 
rhabdomyosarcoma/medulloblastoma, neuroblastoma, lung carcinoma and astrocytoma 
cells (Rzeski et al., 2001), supporting that the NMDAR antagonists possess anticancer 
potential that can add to the existing therapies of cancer. The mechanisms underlying the 
interaction between NMDAR antagonists and antiestrogens are not yet clarified. However, 
the activation of NMDAR in neurons results in the phosphorylation of ERK 1/2 (Kemp and 
McKernan, 2002; Hardingham and Bading, 2003). Accordingly, MK-801 at 250 µM 
decreases ERK 1/2 phosphorylation in laryngeal cancer cells (Stepulak et al., 2011) and in 
lung cancer cells, which results in decreased CREB phosphorylation (Stepulak et al., 2005). 
In addition, after 24 h of exposure to 250 µM of MK-801 cyclin D1 was down-regulated, 
whereas p53 and p21 were up-regulated, providing a link to the cell cycle machinery and 
explaining the lung cancer cell cycle arrest in G1 (Stepulak et al., 2005). Although MK-801 
at 100 µM does not affect the cell cycle of melanoma cells individually, the combination 
with EDX and OHTAM enhanced the effects induced by the compounds individually, 
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promoting cell cycle arrest in G1 phase. As it seems that the MAPK pathway plays a pivotal 
role in NMDAR signaling in different types of cancer cells and EDX decreases ERK 1/2 
phosphorylation in K1735-M2 cells (Fig. 6.7), it is possible that the synergism of action 
observed in melanoma cells involves this common pathway and a convergence of cell cycle 
regulation mechanisms. 
Talampanel is a recently developed noncompetitive antagonist of the AMPAR that 
has provided encouraging results for the use of GluRs antagonists in cancer therapy. In 
patients diagnosed with recurrent glioblastoma, monotherapy with talampanel has not 
demonstrated useful activity, but it was well tolerated (Iwamoto et. al., 2010). However, in 
a second larger phase II study performed in newly diagnosed glioblastoma patients, the 
combination of talampanel with radiation therapy plus temozolomide, demonstrated 
improved survival and talampanel did not increase the toxicity of temozolomide (Grossman 
et. al., 2009). These data support the view that GluR antagonists may be useful agents in 
therapeutic association, without adding significant toxicity to the treatment. 
Our results demonstrate that EDX has a more powerful cytostatic action in 
melanoma cells than TAM and its benefits are greatly enhanced when used in therapeutic 
association. Moreover, EDX is less toxic to mitochondrial functions than TAM, allowing 
the reduction of the possible side effects related with mitochondrial damage, and avoids the 
variability in TAM metabolism, as well as drug interactions. Thus, EDX is an advantageous 
therapeutic alternative to TAM in the management of malignant melanoma, which is a new 
indication for this drug that is already being tested in humans. However, the mechanisms of 
action of antiestrogens in melanoma remain poorly defined. The understanding of the 
mechanisms involved and the explanation for the superior cytostatic activity of EDX over 
TAM in melanoma can contribute to clarify the contradictory results obtained so far, as it is 
possible that certain patients, according to the specific traits of their lesions, can benefit from 
the treatment with antiestrogens, while others do not. The identification of the GPR30 as a 
new ER, which can be activated by TAM and OHTAM, led us to investigate the expression 
and the role played by GPR30 in melanoma cells. 
The results described in chapter VI show, for the first time, that melanoma cells 
express GPR30 (Fig. 6.1) and that its activation by low concentrations of G-1, a selective 
agonist of GPR30 (Bologa et al., 2006), induces profound cytostatic effects on melanoma 
cells (Figs. 6.2, 6.3, 6.5 and 6.6). Similar findings were reported in prostate cancer cells 
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(Chan et al., 2010). Thus, our results suggest that targeting the GPR30 is a new strategy in 
melanoma therapy and the evaluation of GPR30 expression in samples obtained from 
melanoma biopsies, and the comparison with the expression in normal skin, are required to 
support these findings.  
The ability of G-1 to decrease melanoma cell proliferation, by decreasing cell 
division without enhancing cell death, resembles the effects promoted by the antiestrogens 
(Figs. 6.2-6.5). Since both TAM and OHTAM bind to GPR30 (Wang et al., 2010) it is 
possible that the antiproliferative effect on melanoma cells induced by these antiestrogens, 
and also by EDX, is at least in part mediated by this receptor. However, some differences 
should be noted. Whereas the three antiestrogens decrease the cell biomass in a 
concentration-dependent manner (Fig. 6.2B-6.2D), increasing the concentration of G-1 from 
2.5 up to 20 µM does not enhance the decrease in cell biomass, which is in agreement with 
the saturation of the receptor (Fig. 6.2A). Moreover, after a 48 h treatment, G-1 induced cell 
cycle arrest in G2 phase, but none of the antiestrogens was able to induce significant effects 
at this time point (Fig. 6.6). Nevertheless, TAM metabolites were able to enhance the effects 
on cell cyle promoted by RA (Fig. 4.5) or MK-801 (Fig. 5.8). The differences observed are 
likely to reflect the multiple mechanisms by which antiestrogens exert their anticancer 
activity (de Médina et al., 2004), in contrast to G-1, which is a selective agonist, without 
significant activity on classic ER or on other GPCRs (Bologa et al., 2006). The effects 
promoted by the antiestrogens on targets other than the GPR30 may account for the fact that, 
although G-1 and TAM decrease ERK 1/2 phosphorylation, at the time point selected, only 
EDX provides a significant reduction (Fig. 6.7). However, this finding is highly relevant, as 
it provides the first mechanistic information that explains the superior efficacy of EDX in 
comparison with TAM in the reduction of melanoma cell proliferation, either individually 
or in combination with RA or MK-801, which also target the MAPK pathway, as discussed 
above. Since melanoma cells respond to chronic inhibition of specific targets by re-wiring 
their signaling circuitries, allowing the tumor cells to adapt to pharmacological challenges, 
combination strategies targeting key oncogenic pathways should be developed for successful 
therapy (Villanueva et al., 2010). Therefore, the signaling pathways modulated by 
antiestrogens, retinoids or MK-801 should be addressed in future experiments. Studies using 
RNA interference are also underway in order to confirm the involvement of GPR30 in the 
antiproliferative action of antiestrogens in melanoma. If this is the case, the study of a 
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possible association between the expression of GPR30, the steady-state levels of EDX and 
the clinical outcome of melanoma patients treated with TAM would be the next step. 
The fact that antiestrogens can act through different mechanisms would have been 
considered pernicious some time ago. However, it is emerging the view that in a very 
heterogeneous and plastic malignancy, such as melanoma, targeting a single alteration will 
not be sufficient to kill all tumor cells, as learned from vemurafenib. In contrast, drugs that 
target several alterations in cancer cells can be beneficial, if devoid of significant toxicity in 
normal tissues. The possible off-target effects can be minimized through the use of low 
concentrations of drugs in combination with other agents, according to the genetic signature 
of lesions of each patient (Herlyn, 2009). Therefore, the future of EDX in melanoma therapy 
will inevitably involve its association with other chemotherapeutic agents.  
 
 
7.2 - Conclusions 
 
Our results demonstrate that EDX, at the concentrations reached in tissues, slightly 
affects mitochondrial bioenergetic functions in comparison with the damaging effects 
promoted by TAM. Therefore, the administration of EDX instead of TAM may decrease the 
adverse effects related with mitochondrial dysfunction, such as the liver injury commonly 
observed in patients taking TAM. Similarly to TAM, EDX inhibits the MPT pore opening 
induced by calcium and phosphate or by RA, which can contribute to decrease the toxicity 
of the retinoid. As the utilization of RA has been limited by its toxicity, the combination 
with EDX can contribute to turn RA into a more suitable agent for clinical practice. 
On the other hand, EDX presents stronger cytostatic activity in melanoma cells than 
TAM, which may be due to a more pronounced inhibition of the MAPK pathway. In 
addition, the therapeutic benefit obtained from the administration of EDX is not limited by 
metabolic intervariability or by the intake of drugs that can limit the extent of TAM 
metabolism. The antiproliferative activity of EDX in melanoma is greatly enhanced when 
used in combination of with RA or MK-801, blocking cell cycle progression in G1. 
Noteworthy, the combinations of RA with EDX, in addition to the antiproliferative effect, 
also decrease the migration of melanoma cells at concentrations that do not affect the 
proliferation of normal cells. These findings, together with the inhibition of RA-induced 
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MPT by EDX, suggest that the combination of RA with EDX is an effective strategy for 
melanoma, without prohibitory side effects. 
Our results also show, for the first time, that K1735-M2 melanoma cells express 
GPR30 and that the activation of the receptor decreases the proliferation of melanoma cells. 
Therefore, GPR30 is a new target in melanoma therapy that is possibly involved in the 
antiproliferative activity of antiestrogens, paving the way for future investigations. 
Altogether, the results obtained support that EDX is a less toxic alternative to TAM 
in cancer therapy and a promising drug for the clinical management of malignant melanoma. 
The mechanisms underlying the anticancer activity of EDX in melanoma have just begun to 
be elucidated. However, given the complexity of melanoma and the multiple mechanisms 
involved in the pharmacological action of antiestrogenic compounds, it will be a long way 
to run, but hopefully it will worth the effort. 
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